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ABSTRACT 
 
 
Aliskiren is an antihypertensive drug approved for clinical use in 2007. It acts by 
inhibiting renin, the first enzyme in the renin-angiotensin-aldosterone system. Marked 
interindividual variability exists in the pharmacokinetics of aliskiren. Interestingly, the 
pharmacokinetic properties of aliskiren suggest an important role for drug transporters 
in its pharmacokinetics. Aliskiren is poorly absorbed, and therefore, its oral 
bioavailability is only 2-3%. The elimination of aliskiren occurs mainly as an 
unchanged drug by biliary and renal excretion, and only a small proportion is 
metabolized by cytochrome P450 (CYP) 3A4. Organic anion-transporting polypeptide 
2B1 (OATP2B1) influx transporter is thought to facilitate the intestinal absorption and 
hepatic uptake of aliskiren. Based on a more recent finding, OATP1A2 may also 
contribute to aliskiren absorption. Moreover, aliskiren is a substrate of P-glycoprotein 
(P-gp) efflux transporter, which can reduce the intestinal absorption of its substrates and 
enhance their elimination into bile, urine, and intestine. Furthermore, P-gp limits the 
passage of its substrates across many blood-tissue barriers such as the blood-brain 
barrier. In previous studies, cyclosporine (an inhibitor of P-gp, OATP2B1, and 
CYP3A4) as well as ketoconazole and atorvastatin (inhibitors of P-gp and CYP3A4) 
have raised the area under the plasma aliskiren concentration-time curve (AUC) 5-fold, 
1.8-fold, and 1.5-fold, respectively. Considering the interindividual differences in 
aliskiren pharmacokinetics, information on related pharmacokinetic interactions and 
genetic variations may improve the safety of aliskiren therapy. 
 
This thesis comprises four randomized, placebo-controlled, cross-over pharmacokinetic 
interaction studies and two prospective genotype panel studies in healthy volunteers to 
assess the potential pharmacokinetic interactions and genetic variations affecting the 
pharmacokinetics and pharmacodynamics of aliskiren. The effects of induction and 
inhibition of P-gp and CYP3A4 were investigated by using rifampicin and itraconazole 
as a model inducer and inhibitor, respectively. Furthermore, the effects of grapefruit 
juice, orange juice, and apple juice, all of which have inhibited OATP1A2 and 
OATP2B1 in vitro, were also examined. Genetic variations of P-gp and OATP2B1 for 
the pharmacogenetic studies were selected on the basis of previous studies reporting 
their associations with altered plasma concentrations of the substrates of respective drug 
transporters, and on the basis of their frequencies in the Finnish population. Therefore, 
the effects of common haplotypes of the ABCB1 gene encoding P-gp, c.1236C-
c.2677G-c.3435C and c.1236T-c.2677T-c.3435T, as well as the effects of c.935G>A 
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single-nucleotide polymorphism (SNP) in the SLCO2B1 gene encoding OATP2B1 were 
evaluated. In all studies, aliskiren was administered as a single dose. Furthermore, in 
pharmacokinetic interaction studies, the potentially interacting substances were 
administered according to relevant dosing schemes. Blood and urine samples were 
collected for the determination of drug concentrations and plasma renin activity, in 
addition to which blood pressure was measured. 
 
Rifampicin, grapefruit juice, orange juice, and apple juice markedly reduced the plasma 
concentrations of aliskiren, and the reductions in the AUC values of aliskiren were 56%, 
61%, 62%, and 63%, respectively (P < 0.001). In addition, the reduced exposure to 
aliskiren by rifampicin, orange juice, and apple juice led to the attenuation of the renin-
inhibiting effect of aliskiren. During the rifampicin, orange juice, and apple juice phases 
plasma renin activity 24 hours after aliskiren ingestion was 61% (P = 0.008), 87%       
(P = 0.037), and 67% (P = 0.036) higher, respectively, than during the placebo or water 
phases. Itraconazole raised the AUC of aliskiren considerably, 6.5-fold (P < 0.001), and 
also enhanced the renin-inhibiting effect of aliskiren. Plasma renin activity 24 hours 
after aliskiren ingestion was 68% lower during the itraconazole phase, than during the 
placebo phase (P = 0.011). The ABCB1 c.1236C-c.2677G-c.3435C and c.1236T-
c.2677T-c.3435T haplotypes and the SLCO2B1 c.935G>A SNP were not significantly 
associated with the pharmacokinetics or pharmacodynamics of aliskiren. 
 
In conclusion, aliskiren was found to be susceptible to transporter-mediated 
pharmacokinetic interactions of clinical significance. The interactions of rifampicin and 
itraconazole with aliskiren probably resulted from induction and inhibition of P-gp in 
the small intestine, respectively, with a minor contribution from a parallel effect on 
CYP3A4. Grapefruit, orange, and apple juices reduced the absorption of aliskiren from 
the gastrointestinal tract, possibly by inhibiting intestinal OATP transporters. The 
genetic variations of P-gp and OATP2B1 examined did not explain the large 
interindividual differences in aliskiren pharmacokinetics. Clinicians should be aware of 
the possibility that rifampicin may reduce the antihypertensive efficacy of aliskiren. 
Itraconazole can markedly raise the plasma concentrations of aliskiren and enhance its 
renin-inhibiting efficacy, and thus, should not be used with aliskiren. In addition, the 
inhibition of P-gp by itraconazole may alter the tissue distribution of aliskiren and 
potentially produce adverse reactions not observed with higher doses of aliskiren alone. 
Moreover, the concomitant use of aliskiren with grapefruit, orange, or apple juices is 
best avoided because of the risk of therapeutic failure due to reduced aliskiren exposure. 
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INTRODUCTION 
 
 
Hypertension is a major healthcare issue worldwide due to its high frequency and the 
concomitant risk of cardiovascular diseases (Kearney et al. 2005). When the cut-off 
values of 140 mmHg and 90 mmHg are used, about half of the Finnish men aged 25-64 
years and one-third of the women in the same age group have hypertension (Kastarinen 
et al. 2009). Lifestyle modification is the first-line treatment of hypertension, but drug 
therapy is also often necessary to achieve treatment goals (Mancia et al. 2007; Mancia 
et al. 2009). The treatment of hypertension according to Finnish Current Care 
Guidelines is considered cost-effective (Booth et al. 2007). In 2010, over 500 000 
patients received the special reimbursement for antihypertensive drugs from the Social 
Insurance Institution of Finland (KELA 2011). 
 
Patients with essential hypertension differ markedly in their response to different 
antihypertensive drugs (Materson et al. 1993; Dickerson et al. 1999). Such variability 
may partly be accounted for by interindividual differences in pharmacokinetics due to 
genetic variation in drug transporters and metabolizing enzymes or due to 
pharmacokinetic interactions (Wilkinson 2005; Eichelbaum et al. 2006). Knowledge of 
the crucial role of cytochrome P450 (CYP) enzymes in drug metabolism and 
interactions has improved enormously during the past two decades, whereas the 
significance of the various drug transporters in drug pharmacokinetics has not been 
recognized until more recently. Identification of unrecognized interactions and genetic 
factors affecting drug pharmacokinetics will improve the safety and predictability of 
drug therapies and are important steps towards personalized medicine. 
 
Aliskiren is a renin-inhibiting antihypertensive drug with considerable interindividual 
variability in its pharmacokinetics (Wood et al. 2003; Vaidyanathan et al. 2008c). 
Interestingly, drug transporters appear to be important determinants of its absorption 
and disposition. Aliskiren has a low oral bioavailability and passive membrane 
permeability, and it is only slightly metabolized by CYP3A4 (FDA 2007; Waldmeier et 
al. 2007; Vaidyanathan et al. 2008c). The absorption of aliskiren from the small 
intestine is thought to be facilitated by organic-anion transporting polypeptide 2B1 
(OATP2B1) influx transporter, and, based on a more recent finding, also by OATP1A2 
(Vaidyanathan et al. 2008b; Rebello et al. 2011c). P-glycoprotein (P-gp) efflux 
transporter transports aliskiren back into the intestinal lumen and mediates its biliary 
and renal excretion (Vaidyanathan et al. 2008b). 
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Given the pharmacokinetic properties of aliskiren, we decided to investigate its 
susceptibility to transporter-mediated interactions in more detail. In previous studies, P-
gp, OATP2B1, and CYP3A4 inhibitor cyclosporine raised exposure to aliskiren 5-fold 
(Rebello et al. 2011a), and the P-gp and CYP3A4 inhibitors ketoconazole and 
atorvastatin 1.8-fold and 1.5-fold, respectively (Vaidyanathan et al. 2008b). The effects 
of inducers of P-gp and CYP3A4 on aliskiren pharmacokinetics have not been reported. 
In this thesis work, the effects of induction and inhibition of P-gp and CYP3A4 on 
aliskiren pharmacokinetics and pharmacodynamics were investigated by using 
rifampicin and itraconazole, respectively. 
 
To date, no published studies have demonstrated clinically significant OATP2B1-
mediated drug interactions. However, certain constituents of grapefruit, orange, and 
apple juice have been found to inhibit OATP1A2 and OATP2B1 in vitro (Dresser et al. 
2002a; Satoh et al. 2005; Fuchikami et al. 2006; Bailey et al. 2007; Mandery et al. 2010; 
Imanaga et al. 2011), and these juices have also reduced the exposure to orally 
administered substrates of these transporters, such as fexofenadine (Dresser et al. 2002a; 
Bailey 2010). Grapefruit, orange, and apple juices were thus interesting substances for 
interaction studies with the intestinal OATP-substrate aliskiren. Moreover, grapefruit 
juice is a mechanism-based inhibitor of intestinal CYP3A4 that enhances the oral 
bioavailabilities of many CYP3A4 substrates (Bailey et al. 1991; Lown et al. 1997; 
Schmiedlin-Ren et al. 1997; Bailey and Dresser 2004), complicating prediction of its 
effects on aliskiren pharmacokinetics. By contrast, orange and apple juices have not 
been reported to affect CYP3A4 activity (Bailey et al. 1991; Yee et al. 1995; Edwards et 
al. 1996; Kakar et al. 2004; Imanaga et al. 2011). 
 
Considering the marked interindividual variability in aliskiren pharmacokinetics, the 
impact of the common genetic variations of P-gp and OATP2B1 on aliskiren 
pharmacokinetics was examined. The common single-nucleotide polymorphisms 
(SNPs) in the ABCB1 gene encoding P-gp, c.1236C>T (synonymous), c.2677G>T/A 
(p.Ala893Ser/Thr), and c.3435C>T (synonymous), have been variably associated with 
altered expression and function of P-gp in vitro and plasma concentrations of P-gp 
substrate drugs in vivo, especially when occurring as the c.1236T-c.2677T-c.3435T 
(TTT) and c.1236C-c.2677G-c.3435C (CGC) haplotypes (Hoffmeyer et al. 2000; Kim 
et al. 2001; Kroetz et al. 2003; Kimchi-Sarfaty et al. 2007; Keskitalo et al. 2008). For 
instance, the ABCB1 TTT haplotype has been associated with increased plasma 
concentrations of and enhanced lipid-lowering response to simvastatin (acid) and 
atorvastatin, compared with the ABCB1 CGC haplotype (Kajinami et al. 2004; 
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Fiegenbaum et al. 2005; Keskitalo et al. 2008). In the Finnish population, the 
frequencies of the ABCB1 TTT and CGC haplotypes are 42.7% and 34.4%, 
respectively, and the corresponding frequencies of the TTT/TTT and CGC/CGC 
genotypes are 17.6% and 12.4% (Keskitalo et al. 2008). Moreover, a non-synonymous 
SNP in the SLCO2B1 gene encoding OATP2B1, c.935G>A (p.Arg312Gln), has been 
associated with reduced plasma concentrations of and impaired response to the 
leukotriene receptor antagonist montelukast in patients with asthma (Mougey et al. 
2009). In the Finnish population, the frequency of the c.935A variant allele is 13.6%, 
and the frequencies of the c.935GA and c.935AA genotypes 23.6% and 1.8%, 
respectively (Laitinen and Niemi 2011). 
 
To summarize, the purpose of this thesis was to investigate the effects of rifampicin and 
itraconazole as well as of grapefruit, orange, and apple juices on the pharmacokinetics 
and pharmacodynamics of the antihypertensive drug aliskiren in healthy volunteers. 
Furthermore, the roles of the ABCB1 c.1236T-c.2677T-c.3435T and c.1236C-c.2677G-
c.3435C haplotypes and the SLCO2B1 c.935G>A SNP in the pharmacokinetics of 
aliskiren were evaluated in prospective genotype panel studies. 
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REVIEW OF THE LITERATURE 
 
 
1 Aliskiren 
 
Aliskiren is an antihypertensive drug that acts by inhibiting renin, the first enzyme in 
the renin-angiotensin-aldosterone system (RAAS) (Skeggs et al. 1957; Wood et al. 
2003; Vaidyanathan et al. 2008c). It was approved by the European Medicines Agency 
(EMA) and the U.S. Food and Drug Administration (FDA) in 2007 and is the first direct 
renin inhibitor in clinical use (FDA 2007; EMA 2012). 
 
 
1.1 Physicochemical properties 
 
Aliskiren has a molecular formula of C30H53N3O6 and a molecular mass of 551.8 g/mol 
as its free base (609.8 g/mol as hemi-fumarate salt) (Figure 1) (Wood et al. 2003). It is a 
rather hydrophilic molecule (logarithm of the octanol/water partition coefficient is 2.45 
and solubility in water >350 mg/ml at pH 7.4), and, as a base with pKa of 9.49, it is 
mostly ionized at physiological pH. Aliskiren has a low passive permeability through 
biological membranes due to its physicochemical properties (FDA 2007). 
 
 
 
 
Figure 1. Chemical structure of aliskiren (IUPAC name (2S,4S,5S,7S)-5-amino-N-(2-
carbamoyl-2,2-dimethylethyl)-4-hydroxy-7-{[4-methoxy-3-(3-methoxypropoxy-)-
phenyl]methyl}-8-methyl-2-(propan-2-yl)nonanamide). 
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1.2 Pharmacokinetics 
 
Aliskiren has a low oral bioavailability of 2-3% (Waldmeier et al. 2007), meaning that 
only a small fraction of the drug administered orally reaches the systemic circulation. 
The peak plasma concentration (Cmax) is reached within 1-3 hours (Vaidyanathan et al. 
2008c). Aliskiren is moderately bound to plasma proteins (47-51%), and the volume of 
distribution (Vd) averages 1.9 l/kg. The elimination occurs primarily as an unchanged 
drug by biliary excretion, and enterohepatic circulation ensues (Waldmeier et al. 2007). 
A small amount of aliskiren is also excreted unchanged into urine (0.4% of the oral 
dose). About 1.4% of the oral dose undergoes oxidative biotransformation, principally 
via the CYP3A4 enzyme. Minor amounts of nine different metabolites have been 
identified in plasma, urine, and faeces. At the time of the Cmax, the most abundant 
metabolites in plasma have been M3 (alcohol, O-demethylated; 1-5% of aliskiren Cmax), 
M2 (carboxylic acid, oxidized side chain; ≤1% of aliskiren Cmax), and M1 (phenol,      
O-demethylated; trace amounts). The M3 metabolite (<1% of the dose) and trace 
amounts of M2, M4 (phenol, O-dealkylated), M6 (O-glucuronide conjugate of M4), and 
M9 (lactone) have been detected in urine. In addition, faecal extracts have contained M3 
(0.6% of the dose), M2 (0.5% of the dose), M1 (0.1% of the dose), M4 (trace amounts), 
and M9 (trace amounts) metabolites, as well as M12 (N-acetylated), M13, and M14 
metabolites (structural isomers containing an additional C3H4O2 moiety), which have 
not been found elsewhere (M12, M13, and M14 have together accounted for 1% of the 
dose). Aliskiren has a low hepatic extraction ratio of 0.10 (Azizi et al. 2006). The 
elimination half-life (t½) is approximately 30-40 hours (Vaidyanathan et al. 2008c). 
According to the Biopharmaceutics Classification System, based on its high solubility 
and low permeability, aliskiren is categorized as a class three compound with typical 
pharmacokinetic characteristics, with metabolism having a minor role and drug 
transporters having a large impact on aliskiren absorption and disposition (FDA 2007; 
Shugarts and Benet 2009). 
 
Aliskiren is a substrate of P-gp, with a Michaelis-Menten kinetic constant (Km) of     
2.1-3 μmol/l, but not of breast cancer resistance protein (BCRP), multidrug resistance-
associated protein 2 (MRP2), OATP1B1, or OATP1B3 (Vaidyanathan et al. 2008b). In 
the initial studies, aliskiren was also shown to be transported by OATP2B1 in human 
embryonic kidney 293 (HEK293) cells, with a Km of 72 μmol/l (Vaidyanathan et al. 
2008b). Aliskiren has no inhibitory effect on CYP enzymes or P-gp, but it has inhibited 
OATP2B1, with an inhibitor concentration producing 50% inhibition (IC50) of 95 
μmol/l. Subsequently, in a study in HEK293 cells, aliskiren was found to be a substrate 
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of OATP1A2 (Km value could not be estimated in the concentration range of 0.8-50 
μmol/l), and transport by OATP2B1 could not be demonstrated (Rebello et al. 2011c). 
 
The pharmacokinetics of aliskiren is non-linear (Vaidyanathan et al. 2008c). In the 
range of 75-600 mg as a single oral dose, a 2-fold increase in dose has resulted in about 
2.6- and 2.3-fold increases in the Cmax and the area under the plasma concentration-time 
curve (AUC), respectively. Mechanisms responsible for non-linearity have not been 
identified. A possible mechanism is saturation of transporters at the absorption site or in 
the hepatobiliary clearance route. A high degree of interindividual variability has been 
reported in the pharmacokinetics of aliskiren, and the between-subjects coefficients of 
variation (CV) have ranged between 50% and 100% for the Cmax and between 30% and 
70% for the AUC (Vaidyanathan et al. 2006a; Vaidyanathan et al. 2007b; Waldmeier et 
al. 2007). The AUC of aliskiren has been shown to negatively correlate with body 
weight, and the Cmax and AUC of aliskiren to be 24% and 22% lower in men than in 
women, attributable to differences in body weight (Jarugula et al. 2010). 
 
 
1.3 Pharmacokinetic interactions 
 
Cyclosporine is a potent inhibitor of P-gp, OATP2B1, and CYP3A4 (Rao and 
Scarborough 1994; Kajosaari et al. 2005b; Ho et al. 2006b), and it has raised the Cmax 
and AUC of aliskiren 2.5-fold and 5-fold, respectively, when single oral doses of 
cyclosporine 600 mg and aliskiren 75 mg have been taken concomitantly (Rebello et al. 
2011a). Accordingly, the concomitant use of aliskiren with potent P-gp inhibitors, such 
as cyclosporine or quinidine, has been contraindicated by EMA (EMA 2012). The 
exposure to aliskiren has also been increased by the dual inhibitors of CYP3A4 and P-
gp verapamil (2-fold increases in Cmax and AUC of aliskiren) (Lemma et al. 2006; 
Rebello et al. 2011b), ketoconazole (Cmax and AUC of aliskiren increased by 81% and 
76%, respectively) (Jurima-Romet et al. 1994; Olkkola et al. 1994; Wang et al. 2002; 
Vaidyanathan et al. 2008b), and atorvastatin (Cmax and AUC of aliskiren increased by 
50% and 47%, respectively) (Neuvonen et al. 2006; Vaidyanathan et al. 2008b). High-
fat meals have substantially decreased the absorption of aliskiren (Cmax and AUC of 
aliskiren decreased by 85% and 71%, respectively) (Vaidyanathan et al. 2008c). 
 
Co-administration of aliskiren with the following drugs has resulted in 20-30% changes 
in the AUC of aliskiren: amlodipine (aliskiren AUC increased by 29%) (Vaidyanathan 
et al. 2006b), metformin (aliskiren AUC decreased by 27%) (Vaidyanathan et al. 
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2008d), cimetidine (aliskiren AUC increased by 20%) (Dieterle et al. 2005; 
Ayalasomayajula et al. 2008), and valsartan (aliskiren AUC decreased by 26%) 
(Vaidyanathan et al. 2006b). In addition, irbesartan has reduced the Cmax of aliskiren by 
50% (Vaidyanathan et al. 2007a). Aliskiren has reduced the Cmax and AUC of 
furosemide by 49% and 28%, respectively (Vaidyanathan et al. 2008a). No clinically 
relevant interactions have been found between aliskiren and acenocoumarol, 
allopurinol, atenolol, celecoxib, digoxin, fenofibrate, hydrochlorothiazide, isosorbide-5-
mononitrate, lovastatin, pioglitazone, ramipril, or single-dose warfarin (Dieterle et al. 
2004; Dieterle et al. 2005; Vaidyanathan et al. 2006b; Ayalasomayajula et al. 2008; 
Huang et al. 2008; Vaidyanathan et al. 2008a; Vaidyanathan et al. 2008b; Vaidyanathan 
et al. 2008d). 
 
 
1.4 Renin-angiotensin-aldosterone system and pharmacodynamics of aliskiren 
 
The history of the discovery of the renin-angiotensin-aldosterone system (RAAS) began 
in 1898, when the Finnish physiologist Robert Tigerstedt and his Swedish student Per 
Bergman demonstrated that an extract from the renal cortex of rabbits (later named 
renin) increased blood pressure when injected intravenously (Tigerstedt and Bergman 
1898). Nowadays, RAAS is known to have an important role in the regulation of blood 
pressure, fluid volume, and vascular response to injury and inflammation (Figure 2) 
(Peach 1977; Fyhrquist and Saijonmaa 2008; Ma et al. 2010; Ruggenenti et al. 2010). 
 
The RAAS cascade begins with the release of renin from the juxtaglomerular cells of 
the kidneys in response to reduction in blood pressure, blood volume, renal perfusion, 
or plasma sodium levels, or when the β-adrenergic receptors are stimulated (Peach 
1977; Fyhrquist and Saijonmaa 2008; Ma et al. 2010). The excretion of renin is further 
reduced by negative feedback action of angiotensin II. Renin catalyses the first and the 
rate-limiting step of the cascade where angiotensinogen, mainly produced by the liver, 
is converted to biologically inactive angiotensin I. Angiotensin I is further activated in 
the circulation and tissues by angiotensin-converting enzyme (ACE) to form 
angiotensin II, the main effector of the system. Angiotensin II may also be formed by 
non-ACE pathways involving chymases. 
 
Angiotensin II has a number of rapid effects, including vasoconstriction, increased 
aldosterone secretion, increased thirst and release of antidiuretic hormone, increased 
myocardial contractility, and increased activity of the sympathetic nervous system, 
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which are all intended to increase the effective circulating volume (Fyhrquist and 
Saijonmaa 2008; Ma et al. 2010; Ruggenenti et al. 2010). However, in the long run, 
angiotensin II can cause remodelling of the cardiovascular system, characterized by 
hypertrophy and fibrosis. Angiotensin II exerts its actions via AT1 and AT2 receptors, 
and the foregoing effects are mainly consequences of the activation of AT1 receptor. By 
contrast, AT2 receptor mediates in principle the opposite actions, such as vasodilatation 
and inhibition of growth, although it may also contribute to some potentially harmful 
effects of angiotensin II. The inappropriate activation of RAAS may result in 
hypertension. The drugs affecting RAAS include ACE inhibitors, angiotensin II type 1 
receptor blockers, aldosterone antagonists, and direct renin inhibitors. 
 
 
 
 
 
 
Figure 2. Renin-angiotensin-aldosterone system. Adapted from Fyhrquist and Saijonmaa 2008, 
Ma et al. 2010, and Ruggenenti et al. 2010. 
ACE, angiotensin-converting enzyme. 
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Aliskiren is a competitive inhibitor of human renin with an IC50 of 0.6 nmol/l (Wood et 
al. 2003). In clinical trials, aliskiren has reduced plasma renin activity by 50-80% (FDA 
2007; EMA 2012). The renin-inhibiting effect of aliskiren is detectable already 30 
minutes after the first aliskiren dose (Nussberger et al. 2002), but the maximal blood 
pressure-lowering effect is not achieved until about two weeks (EMA 2012; Novartis 
2012). Aliskiren has had no effect on blood pressure or heart rate in healthy volunteers 
in dosages up to 640 mg once daily for eight days (Nussberger et al. 2002). In a pooled 
analysis of placebo-controlled trials, including altogether 7045 patients with mild to 
moderate hypertension and treatment durations of 6-8 weeks, aliskiren has reduced 
mean sitting systolic/diastolic blood pressures from baseline by 8.6-12.1/7.2-10.3 
mmHg (75 mg), 8.7-13.0/7.8-10.3 mmHg (150 mg), 14.1-15.8/10.3-12.3 mmHg (300 
mg), and 15.7-15.8/11.5-12.5 mmHg (600 mg), compared with 2.9-10.0/3.3-8.6 mmHg 
for placebo (Weir et al. 2007). In clinical studies ranging in duration from four to 52 
weeks, the antihypertensive efficacy of aliskiren has been essentially similar to that of 
the diuretic hydrochlorothiazide, beta blocker atenolol, calcium-channel blocker 
amlodipine, ACE inhibitor ramipril, and angiotensin-receptor blockers irbesartan, 
losartan, and valsartan (Stanton et al. 2003; Gradman et al. 2005; Oparil et al. 2007; 
Dietz et al. 2008; Schmieder et al. 2009; Brown et al. 2011). The efficacy of aliskiren in 
the prevention of hypertension-related end-organ damage, such as left ventricular 
hypertrophy or kidney failure, or in the reduction of cardiovascular morbidity and 
mortality has not been proven. Instead, at the end of 2011, the independent Data 
Monitoring Committee recommended early termination of the ALTITUDE study 
(Aliskiren trial in type 2 diabetes using cardio-renal disease endpoints), in which 
aliskiren was used in addition to an ACE inhibitor or angiotensin-receptor blocker in 
high-risk patients with diabetes and renal impairment (EMA 2012). Patients treated with 
aliskiren experienced a significantly higher number of cardiovascular and renal 
problems than patients given placebo. 
 
 
1.5 Clinical use and adverse effects 
 
At the moment, the role of aliskiren in the treatment of hypertension has not been 
established. Aliskiren is approved for the treatment of essential hypertension at once-
daily doses of 150 mg and 300 mg as monotherapy or in combination with other 
antihypertensive agents (FDA 2007; EMA 2012). However, the combination of 
aliskiren with ACE inhibitors or angiotensin-receptor blockers is not recommended in 
any patient groups and contraindicated in patients with diabetes or moderate or severe 
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kidney impairment because of the risk of adverse outcomes such as hyperkalaemia, 
hypotension, stroke, or kidney complications (EMA 2012). As high-fat meals reduce 
aliskiren absorption (Vaidyanathan et al. 2008c), aliskiren is recommended to be taken 
with a light meal or in a routine pattern with regard to meals (FDA 2007; EMA 2012). 
 
The most common adverse effect with aliskiren is diarrhoea (FDA 2007; Parving et al. 
2008; EMA 2012; Novartis 2012). Other adverse reactions include rash, arthralgia, 
cough, small decreases in haemoglobin and haematocrit, hyperkalaemia, and an increase 
in blood creatinine. In addition, rare cases of hypersensitivity reactions, severe 
cutaneous adverse reactions, angioedema, and renal failure have been reported. 
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2. Individual differences in drug response 
 
Substantial differences in response to drugs commonly exist among patients (Wilkinson 
2005; Eichelbaum et al. 2006). Such variability arises from differences in both intrinsic 
and extrinsic factors, which further affect the pharmacokinetics and pharmacodynamics 
of drugs (Figure 3). 
 
 
 
Figure 3. Factors modifying drug response. 
 
 
2.1 Pharmacokinetic aspects 
 
Pharmacokinetics is defined as quantification of the time course of a drug and its 
metabolites in the body (Rowland and Tozer 2011). The concentration of the drug in 
plasma and peripheral tissues depends on the extent of its absorption, distribution, and 
elimination (i.e. metabolism and excretion). Drugs may pass through biological 
membranes by either a paracellular or transcellular pathway, the latter comprising 
passive diffusion and passage involving facilitated mechanisms, such as channels and 
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drug transporters. Important factors affecting transmembrane passage of drugs are 
physicochemical properties of the drug (molecular size, charge, and lipophilicity), 
membrane characteristics (thickness, surface area, existence of tight junctions or 
fenestrations), and activity of drug transporters. 
 
Pharmacokinetic drug interactions (i.e. the delivery of a drug to its site of action is 
altered) are important causes of variability in drug response, having consequences 
ranging from lack of efficacy to toxicity (Pirmohamed et al. 2004; Wilkinson 2005). 
The main mechanisms of these interactions are physicochemical interactions, plasma 
protein binding-related interactions, and interactions affecting the activity of drug 
transporters and metabolizing enzymes (Bjornsson et al. 2003; Neuvonen 2012). In 
general, changes in plasma drug concentrations of 2-fold or more are considered 
potentially relevant clinically (Dresser et al. 2000). However, less pronounced 
pharmacokinetic interactions may be clinically important, especially for drugs with a 
narrow therapeutic index. Coefficient of variation (CV) is commonly used to express 
the variability in pharmacokinetics (Rowland and Tozer 2011). In general, a CV of 10% 
or less is considered low variability, 25% moderate variability, and above 40% high 
variability. 
 
 
2.2 Pharmacodynamic aspects 
 
By definition, pharmacodynamics is a study of the mechanisms of drug action and the 
relationship between the effects produced and the systemic exposure to the drug over 
time (Rowland and Tozer 2011). Most drugs interact with biological molecules, such as 
receptors, ion channels, enzymes, transporters, or deoxyribonucleic acid (DNA), to 
produce a response by blocking or triggering biochemical and physiological events 
(Mager et al. 2003). Pharmacodynamic drug interactions may be caused by a large 
variety of mechanisms, which may lead to antagonistic, synergistic, or additive effects 
(Danhof et al. 2007). 
 
 
2.3 Pharmacogenetic aspects 
 
By definition, pharmacogenomics is a study of variations of DNA and ribonucleic acid 
(RNA) characteristics as related to drug response (EMA 2007). Pharmacogenetics, its 
subset, is defined as the study of variations in DNA sequence as related to drug 
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response. Nucleotide sequence variation (polymorphism) in drug transporters, drug 
metabolizing enzymes, and drug targets can significantly contribute to interindividual 
variability in drug response (Eichelbaum et al. 2006). Polymorphisms include 
nucleotide substitutions (single-nucleotide polymorphism, SNP), insertions, deletions, 
and duplications of one or more nucleotides, short sequence repeats, and gene copy-
number variations (Nebert and Vesell 2004; Eichelbaum et al. 2006; Ingelman-
Sundberg et al. 2007). 
 
Polymorphisms can cause phenotypic variation by many mechanisms (Sadée and Dai 
2005; Pastinen et al. 2006; Cheung and Spielman 2009). Polymorphisms in the coding 
regions of the gene may alter the amino acid sequence of the translated protein (non-
synonymous variants), thus affecting protein structure and function. Moreover, both 
synonymous and non-synonymous coding region variants can alter the secondary 
structure of mRNA, causing differences in mRNA stability or translation efficiency and 
altered protein expression levels. In addition, polymorphisms in splice sites or splicing 
regulatory sites can alter RNA splicing, altering the mRNA produced. Polymorphisms 
in the gene regulatory regions can influence gene expression, and consequently, the 
amount of protein. Cis-acting polymorphisms are found close to the target genes, 
whereas trans-acting polymorphisms are located far from the target genes, often on 
another chromosome. 
 
Phenotypes are not solely determined by genotypes, but are also influenced by 
environmental factors. Pharmacoepigenetics is a study of heritable changes in gene 
expression or phenotype caused by mechanisms other than variations in underlying 
DNA sequence, such as DNA methylation or histone modification (Ivanov et al. 2012). 
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3. Drug transporters 
 
Drug transporters are important determinants of absorption, tissue distribution, and 
elimination of drugs (Giacomini et al. 2010). They may be classified as influx (uptake 
into the cell) or efflux (out of the cell) transporters, which typically are localized in 
either the apical or basolateral membrane of polarized cells. Different drug transporters 
can be expressed in the same cell, share the same substrates, and act in concert with 
each other and with drug-metabolizing enzymes (Wacher et al. 1995; Glaeser et al. 
2007; Giacomini et al. 2010). It is thus this complex interplay that ultimately determines 
the absorption and disposition as well as the clinical effects of the drug (Giacomini et al. 
2010). Drug transporters also have important physiological functions, as they transport 
many endogenous substrates, including amino acids, lipids, sugars, bile acids, and 
hormones (Ho and Kim 2005). 
 
The genetic variability in genes encoding drug transporters can partly explain the 
interindividual variability in drug pharmacokinetics and drug response (Giacomini et al. 
2010). It has also become evident that clinically significant drug interactions can result 
from the inhibition or induction of drug transporters (Müller and Fromm 2011). For 
instance, inhibition of intestinal influx or efflux transporters can lead to decreased or 
increased systemic exposure to the parent compound. Modification of the activity of 
drug transporters can also affect the distribution of drugs into organs where these 
transporters are expressed (e.g. liver, central nervous system) as well as alter the 
transporter-mediated excretion of drugs and metabolites. Altered activity of drug 
transporters may also contribute to adverse drug reactions (Zolk and Fromm 2011). The 
estimation of the role of a single transporter in drug pharmacokinetics and 
pharmacokinetic interactions is challenging because drugs are usually substrates of 
several drug transporters and often subject to metabolism by CYP enzymes. The human 
genome contains numerous genes encoding membrane transporters; the two major 
superfamilies, adenosine triphosphate (ATP)-binding cassette (ABC) and solute carrier 
(SLC), alone comprise more than 400 members (Giacomini et al. 2010). The 
International Transporter Consortium has compiled a list of drug transporters that have 
evidence from published studies demonstrating their role in pharmacokinetics and 
pharmacokinetic interactions (Figure 4, Tables 1 and 2). 
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Figure 4. Selected human transporters for drugs and endogenous compounds, expressed in the 
apical or basolateral membrane of intestinal enterocyte (A), hepatocyte (B), renal proximal 
tubular cell (C), or brain capillary endothelial cell (D). 
 
 
3.1 Influx transporters 
 
3.1.1 Organic-anion transporting polypeptides 
 
Organic anion-transporting polypeptides (OATPs) are membrane influx transporters 
that regulate the cellular uptake of a number of endogenous compounds and therapeutic 
drugs in various tissues important for pharmacokinetics (Niemi 2007). They are 
encoded by genes of the solute carrier organic anion transporter (SLCO) superfamily 
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(Hagenbuch and Meier 2004). OATPs are classified based on amino acid sequence 
homology into families designated by Arabic numbering (≥ 40% amino acid sequence 
identity), e.g. OATP1, subfamilies designated by letters (≥ 60% amino acid sequence 
identity), e.g. OATP1A, and individual proteins designated by additional continuous 
Arabic numbering based on the chronology of identification, e.g. OATP1A2. Since the 
first Oatp, rat Oatp1a1, was identified and isolated by expression cloning in 1994 from 
rat liver (Jacquemin et al. 1994), 12 OATPs have been identified in humans: OATP1A2, 
OATP1B1, OATP1B3, OATP1B7, OATP1C1, OATP2A1, OATP2B1, OATP3A1, 
OATP4A1, OATP4C1, OATP5A1, and OATP6A1 (Hagenbuch and Meier 2004; NCBI 
2012). 
 
The general predicted OATP structure consists of glycoproteins with 12 transmembrane 
domains with 643-722 amino acids and apparent molecular masses between 70 and 90 
kDa (Hagenbuch and Gui 2008). Transport has been suggested to occur through a 
central positively charged pore in a so-called rocker-switch type of mechanism (Meier-
Abt et al. 2005). This mechanism consists of anion exchange, in which the cellular 
uptake of substrate is coupled with the efflux of endogenous intracellular substances, 
such as bicarbonate, glutathione, or glutathione-S-conjugates, in a process that seems to 
be electroneutral, but may be driven by the pH gradient (Satlin et al. 1997; Li et al. 
1998; Li et al. 2000; Kobayashi et al. 2003; Leuthold et al. 2009). 
 
OATP1A2, the first cloned human OATP, facilitates the absorption of its substrates in 
the small intestine, in addition to which it probably mediates the influx across the blood-
brain barrier (Kullak-Ublick et al. 1995; Gao et al. 2000; Steckelbroeck et al. 2004; Lee 
et al. 2005; Glaeser et al. 2007). The transporter is also found in several other tissues, 
including cholangiocytes in the liver and the apical membrane of cells in distal nephrons 
in the kidney (Kullak-Ublick et al. 1995; Lee et al. 2005). OATP1A2 transports a wide 
range of endogenous as well as exogenous substrates, including bile acids, steroid 
hormones and their conjugates, thyroid hormones, and numerous drugs, such as beta 
blockers and fexofenadine (Cvetkovic et al. 1999; Maeda et al. 2007; Kalliokoski and 
Niemi 2009; Kato et al. 2009; Shirasaka et al. 2010). Rifampicin, certain fruit juices, 
and some flavonoids have been shown to inhibit OATP1A2 in vitro (Dresser et al. 
2002a; Vavricka et al. 2002; Bailey et al. 2007; Mandery et al. 2010; Rebello et al. 
2011c). Grapefruit juice, orange juice, and apple juice have also reduced the oral 
bioavailabilities of some OATP1A2 substrate drugs in vivo (Dresser et al. 2002a; Bailey 
2010; Jeon et al. 2012). Several SNPs in the SLCO1A2 gene have been found of which 
the c.516A>C (p.Glu172Asp), c.382A>T (p.Asn128Tyr), c.404A>T (p.Asn135Ile), and 
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c.2003C>G (p.Thr668Ser) SNPs have been associated with decreased OATP1A2 
transport activity in vitro (Lee et al. 2005; Eechoute et al. 2011). However, they have 
not affected the pharmacokinetics of imatinib in patients with cancer (Eechoute et al. 
2011). The SLCO1A2 g.-1105G>A, g.-1032G>A, and g.-361G>A SNPs in the promoter 
region have been suggested to affect the clearance of imatinib (Yamakawa et al. 2011). 
 
OATP1B1 is localized to the sinusoidal membrane of hepatocytes, where it participates 
in the hepatic uptake of a broad range of compounds from the portal venous blood (Abe 
et al. 1999; Hsiang et al. 1999; König et al. 2000a; König et al. 2000b; Niemi et al. 
2011). At the mRNA level, OATP1B1 has also been found in small intestinal 
enterocytes (Glaeser et al. 2007). OATP1B1 transports bile acids, unconjugated and 
conjugated bilirubin, eicosanoids, steroid conjugates, thyroid hormones, and many 
drugs, including 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase 
inhibitors (statins) (Niemi et al. 2011). A common variant of the SLCO1B1 gene, the 
c.521T>C (p.Val174Ala) SNP, has been associated with a reduced transport activity of 
OATP1B1 in vitro and markedly increased plasma concentrations of OATP1B1 
substrate drugs in vivo (Niemi et al. 2011). In individuals homozygous for the 
SLCO1B1 c.521T>C SNP, the hepatic influx of active simvastatin acid has been shown 
to be severely impaired, resulting in a more than 3-fold increased plasma simvastatin 
acid exposure (Pasanen et al. 2006b), and consequently, a markedly increased risk of 
simvastatin-induced myopathy, as compared with individuals with the c.521TT 
genotype (Link et al. 2008). The same variant has also been found to affect the plasma 
concentrations of other statins, such as atorvastatin (2.4-fold increase in AUC), 
pravastatin (1.9-fold increase in AUC), and rosuvastatin (1.7-fold increase in AUC), but 
not fluvastatin (Niemi et al. 2006b; Pasanen et al. 2007). In the Finnish population, the 
frequency of the SLCO1B1 c.521CC genotype is approximately 4.3% (Pasanen et al. 
2006a). Many drugs have been identified as inhibitors of OATP1B1 in vitro, potentially 
causing important pharmacokinetic interactions in vivo (Niemi et al. 2011). For 
example, inhibition of OATP1B1 has had a major role in pharmacokinetic interactions 
in which cyclosporine and gemfibrozil have increased the systemic exposure to many 
statins (Neuvonen et al. 2006). 
 
OATP1B3 shares 80% amino acid identity with OATP1B1 (König et al. 2000a). It is 
also localized to the sinusoidal membrane of hepatocytes, but unlike OATP1B1, which 
shows a uniform expression pattern throughout the liver lobe, OATP1B3 is highly 
expressed in perivenous regions (König et al. 2000a; Abe et al. 2001). The substrate 
specificity of OATP1B3 is very similar to that of OATP1B1 and includes bile acids, 
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bilirubin, eicosanoids, steroid conjugates, thyroid hormones, and numerous drugs 
(Hagenbuch and Gui 2008; Kalliokoski and Niemi 2009). In addition, OATP1B3 has 
drug substrates, such as docetaxel and paclitaxel, that are not transported by OATP1B1 
(Smith et al. 2005). Many inhibitors of OATP1B1 also inhibit OATP1B3 (Kalliokoski 
and Niemi 2009; Niemi et al. 2011). 
 
OATP2B1 is expressed widely in human tissues, including the intestine, liver, brain, 
heart, pancreas, platelets, skeletal muscle, skin, testis, mammary gland, and placenta 
(Tamai et al. 2000; Kullak-Ublick et al. 2001; St-Pierre et al. 2002; Kobayashi et al. 
2003; Pizzagalli et al. 2003; Schiffer et al. 2003; Steckelbroeck et al. 2004; Englund et 
al. 2006; Grube et al. 2006; Grube et al. 2007; Niessen et al. 2009; Knauer et al. 2010). 
At the cellular level, OATP2B1 is localized to the luminal membrane of small intestinal 
enterocytes, to the sinusoidal membrane of hepatocytes, to the apical membrane of brain 
endothelial cells, to the vascular endothelium of the heart, to the basal (foetal-facing) 
membrane of syncytiotrophoblasts, and to the basolateral membrane of the non-
pigmented epithelium in the ciliary body (Kullak-Ublick et al. 2001; St-Pierre et al. 
2002; Kobayashi et al. 2003; Bronger et al. 2005; Gao et al. 2005; Grube et al. 2006). In 
the transcription analysis of the SLCO2B1 gene, five transcriptional variants differing in 
length and transcription start sites have been found, suggesting that the gene is 
differently expressed in different tissues (Pomari et al. 2009). 
 
OATP2B1 transports bile acids, steroid conjugates, and such drugs as some statins and 
montelukast (Kalliokoski and Niemi 2009; Mougey et al. 2009). Grapefruit juice and 
orange juice have been shown to inhibit OATP2B1 in vitro, and it has been 
hypothesized that they may reduce the absorption of OATP2B1 substrate drugs (Satoh 
et al. 2005). However, grapefruit juice has not significantly affected the 
pharmacokinetics of glibenclamide, an OATP2B1 substrate, in humans (Lilja et al. 
2007). Cyclosporine and gemfibrozil have also been found to inhibit OATP2B1 in vitro 
(Ho et al. 2006b). 
 
Various sequence variants have been described in the SLCO2B1 gene encoding the 
OATP2B1 influx transporter, but their clinical relevance has not been clarified (Nozawa 
et al. 2002; Ho et al. 2006a; Aoki et al. 2009; Mougey et al. 2009). A non-synonymous 
SNP in the SLCO2B1 gene, c.935G>A (p.Arg312Gln), has been associated with 
reduced plasma concentrations of and impaired response to montelukast in patients with 
asthma (Mougey et al. 2009). By contrast, no relationship has been found between the 
c.935G>A SNP and the pharmacokinetics of celiprolol (Ieiri et al. 2012). In the Finnish 
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population, the c.935A variant allele has been reported to have a frequency of 13.6%, 
and the c.935GA and c.935AA genotypes frequencies of 23.6%, and 1.8%, respectively 
(Laitinen and Niemi 2011). 
 
Of other sequence variants of SLCO2B1, the c.43C>T (p.Pro15Ser), c.601G>A 
(p.Val201Met), and c.1175C>T (p.Thr392Ile) SNPs as well as the p.Glu26_Thr28del 
deletion variant have been associated with reduced transport activity, and the SLCO2B1 
c.1457C>T (p.Ser486Phe) SNP with both reduced and increased transport activity of the 
protein in vitro (Nozawa et al. 2002; Ho et al. 2006a). In addition, the SLCO2B1         
g.-282G>A SNP in the promoter region has been associated with increased protein 
expression level in the human liver (Aoki et al. 2009). The SLCO2B1 c.1457C>T SNP 
has been associated with reduced plasma concentrations of celiprolol and fexofenadine 
in healthy volunteers (Imanaga et al. 2011; Ieiri et al. 2012). Furthermore, the extent of 
the interaction between apple juice and fexofenadine has been smaller in individuals 
carrying the c.1457C>T SNP than in individuals with the c.1457CC genotype (Imanaga 
et al. 2011). 
 
OATP4C1 is considered to be a kidney-specific transporter. It is localized to the 
basolateral membrane of renal proximal tubular cells, where it possibly mediates the 
uptake of its substrates from the blood into the kidney (Mikkaichi et al. 2004). Among 
the substrates of OATP4C1 are thyroid hormones, digoxin, methotrexate, and sitagliptin 
(Mikkaichi et al. 2004; Chu et al. 2007). 
 
 
3.1.2 Other influx transporters 
 
Organic anion transporters (OATs) 1 and 3 are anion-exchangers expressed mainly in 
the basolateral membrane of the renal proximal tubular cells, where they may mediate 
the renal uptake of their substrates from blood (Hosoyamada et al. 1999; Cha et al. 
2001; Klaassen and Aleksunes 2010). These substrates include endogenous compounds 
such as urate, as well as many drugs, including antimicrobial agents, non-steroidal anti-
inflammatory drugs (NSAIDs), and diuretics (Rizwan and Burckhardt 2007; Klaassen 
and Aleksunes 2010). A classic example of a pharmacokinetic drug interaction is the 
reduction in renal excretion of benzylpenicillin, an OAT3 substrate, caused by 
probenecid, the inhibitor of OAT1 and OAT3 (Gibaldi and Schwartz 1968). Probenecid 
and many NSAIDs may also reduce the renal excretion of methotrexate by inhibiting 
OATs (Takeda et al. 2002). It has been suggested that OAT1 is involved in 
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nephrotoxicity caused by antiviral drugs adefovir and cidofovir (Ho et al. 2000a; Uwai 
et al. 2007), and that probenecid could be used to overcome this effect (Zolk and 
Fromm 2011). 
 
Organic cation transporters (OCTs) 1 and 2 are uniporters that mediate the facilitated 
diffusion of a variety of low molecular mass organic cations in either direction, driven 
by the electrochemical potential (Gorboulev et al. 1997; Koepsell et al. 2007). OCT1 is 
primarily expressed in the sinusoidal membrane of hepatocytes, where it mediates the 
exit from portal venous blood (Gorboulev et al. 1997), but is also found in other tissues, 
such as the apical membrane of renal proximal and distal tubular cells (Koepsell et al. 
2007; Tzvetkov et al. 2009). OCT2 is principally expressed in the basolateral membrane 
of renal proximal tubular cells (Gorboulev et al. 1997), but is also found in neurons, and 
its endogenous substrates include many neurotransmitters (Koepsell et al. 2007). 
 
A prototypic drug substrate of both of these OCT transporters is metformin (Dresser et 
al. 2002b; Kimura et al. 2005). Metformin is primarily excreted into urine by a 
mechanism involving a functional interplay between OCT2-mediated metformin uptake 
and efflux by multidrug and toxin extrusion protein 1 (MATE1) in the renal proximal 
tubular cell (Meyer zu Schwabedissen et al. 2010; König et al. 2011). In the liver, i.e. 
the site of metformin action, the drug transport into and out of the hepatocyte is 
mediated by OCT1 and MATE1, respectively (König et al. 2011). Certain low-activity 
genotypes of the SLC22A1 gene encoding OCT1 have been associated with reduced 
metformin efficacy, probably as a result of decreased hepatic uptake and increased renal 
excretion of metformin (Shu et al. 2007; Shu et al. 2008; Tzvetkov et al. 2009). Genetic 
variation in the SLC22A2 gene encoding OCT2 may also have a role in the differences 
in the excretion of metformin (Leabman et al. 2002; Song et al. 2008; Wang et al. 2008; 
Chen et al. 2009). Moreover, OCT1 transports imatinib into mononuclear cells in 
chronic myeloid leukaemia, and the functional activity of OCT1 has been shown to be 
positively associated with the degree to which patients respond to imatinib (White et al. 
2006; White et al. 2007; White et al. 2010). 
 
OCTs may contribute to clinical pharmacokinetic interactions (Fahrmayr et al. 2010; 
Giacomini et al. 2010). Inhibitors of OCT1 and OCT2 include cimetidine and quinidine 
(Urakami et al. 1998; Zolk et al. 2009), in addition to which, for example, some 
antiviral drugs and oral antidiabetic drugs have been shown to inhibit OCT1 
(Bachmakov et al. 2008; Jung et al. 2008), and some beta blockers OCT2 (Bachmakov 
et al. 2009; Zolk et al. 2009). Cimetidine has also inhibited the OCT2-mediated renal 
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excretion of metformin in vivo (AUC of metformin increased by 50%) (Somogyi et al. 
1987; Wang et al. 2008). Moreover, OCT2 probably plays an important role in the 
development of nephro- and ototoxicity caused by cisplatin, and OCT2 inhibitors have 
been suggested as an option to reduce these adverse effects (Ciarimboli et al. 2005; 
Ciarimboli et al. 2010; Zolk and Fromm 2011). 
 
The peptide transporters (PEPTs) 1 and 2 are proton-coupled symporters responsible 
for the cellular uptake of physiologically occurring peptides and structurally related 
drugs, such as β-lactam antibacterials (Ganapathy and Leibach 1983; Fei et al. 1994; 
Liu et al. 1995; Brandsch 2009). PEPT1 is primarily expressed in the luminal membrane 
of intestinal enterocytes, where it mediates the absorption of di- and tripeptides 
originating from protein digestion (Groneberg et al. 2001; Ziegler et al. 2002). In the 
renal proximal tubular cells, PEPT2 is responsible for the re-uptake of peptides from the 
glomerular filtrate, probably accompanied by PEPT1 (Liu et al. 1995; Brandsch 2009). 
 
 
3.2 Efflux transporters 
 
3.2.1 P-glycoprotein 
 
The multidrug resistance transporter 1 P-glycoprotein (MDR1, P-gp) belongs to the 
adenosine triphosphate (ATP)-binding cassette (ABC) superfamily and is encoded by 
the ABCB1 gene (Fairchild et al. 1987). P-gp was first characterized in tumour cells, 
where it produced resistance to multiple anticancer agents (Biedler and Riehm 1970; 
Juliano and Ling 1976; Kartner et al. 1983). Subsequently, it was shown to have 
important physiological functions. P-gp is an efflux pump located in the luminal 
membrane of enterocytes in the small intestine, in the apical membrane of excretory 
cells such as hepatocytes and renal proximal tubular cells, and in the apical membrane 
of endothelial cells that comprise many blood-tissue barriers such as the blood-brain, 
blood-testes, and blood-placenta barriers (Thiebaut et al. 1987; Cordon-Cardo et al. 
1990; Fromm 2004). Energy provided by ATP hydrolysis enables P-gp to work against 
considerable concentration gradients (Senior and Gadsby 1997). In the small intestine, 
P-gp prevents the entry of foreign compounds into the systemic circulation by 
transporting molecules from enterocytes back into the intestinal lumen (Watkins 1997). 
This protective function is shared with CYP3A4, and many compounds have been 
identified as substrates of both P-gp and CYP3A4 (Schuetz et al. 1996; Watkins 1997; 
Kivistö et al. 2004). P-gp also enhances the elimination of its substrates and their 
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metabolites by facilitating their removal by excretion into bile, urine, and the intestine 
(Wetterich et al. 1996; Fromm 2004). In addition, P-gp has an important role in drug 
distribution by limiting entry of various drugs into sensitive tissues such the central 
nervous system, foetal circulation, testis, and lymphocytes (Fromm 2004). 
 
P-gp comprises approximately 1280 amino acids and has a molecular mass of 170 kDa. 
An x-ray crystallographic structure of the mouse P-gp, which has 87% sequence identity 
to human P-gp, was described in 2009 (Aller et al. 2009). It revealed that in the initial 
state of the transport cycle, P-gp has an inward-facing conformation formed from two 
halves, each containing six transmembrane helices and an intracellular nucleotide-
binding domain. These two halves form a large internal cavity open both to the inner 
leaflet of the cell membrane and to the cytoplasm and contain distinct binding sites for 
drugs. During the catalytic cycle the binding of a substrate stimulates further the 
binding of ATP, which likely causes dimerization of the nucleotide-binding domains. 
This produces large structural changes, resulting in an outward-facing conformation. 
Substrates may be released either as a result of ATP hydrolysis or as a consequence of 
decreased binding affinity. ATP hydrolysis likely resets the system back to inward 
facing. 
 
P-gp transports a broad variety of structurally diverse molecules, ranging in size from 
less than 200 Da to almost 1900 Da (Schinkel and Jonker 2003). Most P-gp substrates 
are quite hydrophobic and can therefore insert into the inner leaflet of the cell 
membrane to be transported by P-gp (Aller et al. 2009). The substrates of P-gp include 
antibacterial, anticancer, and antiviral agents, beta blockers, calcium-channel blockers, 
glucocorticoids, statins, immunosuppressants, and aliskiren (Fromm 2004; 
Vaidyanathan et al. 2008b). Digoxin is recommended by regulatory authorities as a 
probe drug in vivo in pharmacokinetic interaction studies with new molecules that are 
inhibitors of P-gp (EMA 2010b; Giacomini et al. 2010; FDA 2012). The advantage of 
digoxin is its negligible metabolism (Iisalo 1977). However, digoxin has a narrow 
therapeutic index and a high oral bioavailability (60-80%), and it is not entirely safe or 
very sensitive as a probe drug. 
 
The level of expression and functionality of P-gp can be modulated by induction and 
inhibition, and P-gp is thus involved in many clinically significant pharmacokinetic 
interactions (Müller and Fromm 2011). The transcription of ABCB1 is regulated by 
nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor 
(CAR) (Geick et al. 2001; Burk et al. 2005). Rifampicin induces P-gp via PXR and is 
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recommended as an inducer in drug interaction studies involving P-gp substrates 
(Schuetz et al. 1996; Greiner et al. 1999; Geick et al. 2001; FDA 2012). St. John’s wort 
is another known inducer of P-gp (Johne et al. 1999). In addition, thyroid hormones 
have been found to induce the expression of ABCB1 mRNA in the intestine and kidney 
cell lines (Burk et al. 2010). Among the inhibitors of P-gp are cyclosporine, 
itraconazole, ketoconazole, and verapamil (Naito and Tsuruo 1989; Rao and 
Scarborough 1994; Wang et al. 2002; Marzolini et al. 2004). 
 
Because of the localization at important blood-tissue barriers, inhibition of P-gp may 
have a larger effect on tissue drug exposure than on plasma exposure (Eyal et al. 2009). 
In a study with knockout mice, digoxin concentration in the brain after intravenous 
administration was about 27-fold higher in mice lacking mdr1-type P-gp transporters, 
compared with wild-type mice, whereas no significant difference was found in plasma 
digoxin concentrations (Schinkel et al. 1997). However, prediction of human 
transporter-mediated drug interactions based on preclinical animal data is challenging 
(Giacomini et al. 2010). 
 
Many sequence variations have been described in the ABCB1 gene (Hoffmeyer et al. 
2000; Fromm 2002; Chinn and Kroetz 2007). However, findings regarding the effect of 
ABCB1 polymorphisms on P-gp substrates have not been consistently reproduced, and 
therefore, further studies with larger numbers of samples may be needed to clarify the 
clinical impact of ABCB1 polymorphisms (Chinn and Kroetz 2007; Giacomini et al. 
2010). The most studied sequence variant is a common synonymous ABCB1 c.3435C>T 
SNP, which has been variably associated with reduced expression and function of P-gp 
in vitro and increased plasma concentrations of P-gp substrate drugs in vivo (Hoffmeyer 
et al. 2000; Kimchi-Sarfaty et al. 2007; Keskitalo et al. 2008). This SNP has been 
suggested to affect ABCB1 mRNA stability (Wang et al. 2005). On the other hand, the 
associations may also be explained by linkage disequilibrium between c.3435C>T and a 
functional sequence variation. The ABCB1 c.3435C>T SNP has been found to be in 
strong linkage disequilibrium with the c.1236C>T (synonymous) and c.2677G>T/A 
(p.Ala893Ser/Thr) SNPs in the same gene (Kim et al. 2001; Kroetz et al. 2003; 
Keskitalo et al. 2008). Alternatively, c.3435C>T and sequence variations in linkage 
disequilibrium with it may form a haplotype conferring altered P-gp activity (Kim et al. 
2001; Kimchi-Sarfaty et al. 2007). The variant alleles c.1236T, c.2677T, and c.3435T 
are common in Europeans and European Americans, with reported frequency ranges of 
39-46%, 39-47%, and 54-60%, respectively (Cascorbi et al. 2001; Kim et al. 2001; 
Kroetz et al. 2003; Leschziner et al. 2007; Keskitalo et al. 2008). In the Finnish 
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population, the two most common haplotypes are c.1236T-c.2677T-c.3435T (TTT) and 
c.1236C-c.2377G-c.3435C (CGC), with frequencies of 42.7% and 34.4%, respectively 
(Keskitalo et al. 2008). The ABCB1 TTT haplotype has been associated with, for 
example, increased plasma concentrations of and enhanced lipid-lowering response to 
simvastatin (acid) (AUC increased by 60% in individuals with the ABCB1 TTT/TTT 
genotype, compared with individuals with the CGC/CGC genotype) and atorvastatin 
(AUC increased by 55%) (Kajinami et al. 2004; Fiegenbaum et al. 2005; Keskitalo et al. 
2008). Studies investigating the effects of the ABCB1 c.3435C>T SNP on the 
pharmacokinetics of digoxin have revealed conflicting results, with a meta-analysis 
suggesting that the ABCB1 c.3435C>T SNP does not affect digoxin pharmacokinetics 
(Greiner et al. 1999; Hoffmeyer et al. 2000; Sakaeda et al. 2001; Johne et al. 2002; 
Verstuyft et al. 2003; Chowbay et al. 2005). It has been suggested that the ABCB1 
c.3435C>T SNP, or its combination with the c.1236C>T or c.2677G>T/A SNP, may 
alter the substrate specificity of P-gp, and therefore, the effect of the ABCB1 genotype 
on the pharmacokinetics of different P-gp substrates may vary (Kimchi-Sarfaty et al. 
2007). 
 
 
3.2.2 Other efflux transporters 
 
Breast cancer resistance protein (BCRP), also known as ATP-binding cassette G2 
protein encoded by the ABCG2 gene, was first cloned based on its overexpression in a 
multidrug-resistant Michigan Cancer Foundation (MCF-7) breast cancer cell line (Doyle 
et al. 1998). BCRP mediates the efflux of its substrates in the physiological barriers and 
excreting organs, such as the luminal membrane of enterocytes, canalicular membrane 
of hepatocytes, apical membrane of brain capillary endothelial cells, and maternal side 
of placental syncytiotrophoblasts (Maliepaard et al. 2001; Schinkel and Jonker 2003; 
Leslie et al. 2005). The physiological functions of BCRP include the transport of 
oestrogen conjugates, the extrusion of porphyrins from haematopoietic cells and 
hepatocytes, as well as the secretion of vitamin B2 and possibly other vitamins, such as 
biotin and vitamin K, into breast milk (Choudhuri and Klaassen 2006; Giacomini et al. 
2010). Among the drug substrates of BCRP are anticancer agents, such as topotecan and 
methotrexate, antibacterial drugs, and statins (Choudhuri and Klaassen 2006). 
Cyclosporine is an inhibitor of BCRP (Xia et al. 2007). The sequence variant of BCRP, 
ABCG2 c.421C>A (p.Gln141Lys) SNP, has been associated with reduced BCRP 
transport activity in vitro (Imai et al. 2002; Kondo et al. 2004; Mizuarai et al. 2004) and 
increased plasma concentrations of drugs, such as topotecan, sulphasalazine, 
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rosuvastatin, atorvastatin, fluvastatin, and simvastatin lactone, in vivo (Sparreboom et 
al. 2005; Urquhart et al. 2008; Yamasaki et al. 2008; Keskitalo et al. 2009a; Keskitalo et 
al. 2009b). 
 
Bile salt export pump (BSEP), encoded by ABCB11, is expressed in the canalicular 
membrane of hepatocytes, where it is involved in the secretion of bile salts (Childs et al. 
1995; Gerloff et al. 1998). A reduced function of BSEP, caused by inherited mutations 
or acquired factors, may lead to progressive intrahepatic cholestasis and severe liver 
disease (Lang et al. 2007; Stieger 2010). BSEP-inhibiting factors include drugs, such as 
cyclosporine and rifampicin, as well as other xenobiotics, aberrant bile salt metabolites, 
and pregnancy. Pravastatin is a known drug substrate of BSEP. 
 
Multidrug and toxin extrusion proteins (MATE) are antiporters first identified in 
bacteria (Morita et al. 1998; Brown et al. 1999). MATE1 transports cationic compounds 
across the canalicular membrane of hepatocytes into the bile and across the apical 
membrane of renal proximal tubular cells into urine, but it is also expressed in other 
tissues such as skeletal muscle (Otsuka et al. 2005; Klaassen and Aleksunes 2010). 
MATE2-K appears to be specific to the kidney, where it mediates the efflux of organic 
cations across the apical membrane of proximal tubular cells (Masuda et al. 2006). 
Metformin is a prototypic substrate of MATE1 and MATE2-K (Tanihara et al. 2007), 
and cimetidine has been shown to inhibit MATE1 (Matsushima et al. 2009). MATE1 
has been demonstrated to act in concert with the OCT1 and OCT2 influx transporters in 
the liver and kidneys, respectively (Terada and Inui 2008; Meyer zu Schwabedissen et 
al. 2010; König et al. 2011). A non-coding SNP (rs2289669 G>A) in the SLC47A1 gene 
encoding MATE1 has been associated with an increased glucose-lowering efficacy of 
metformin in individuals homozygous for the non-coding SNP (rs622342 A>C) in the 
SLC22A1 gene encoding OCT1 (Becker et al. 2009; Becker et al. 2010). 
 
Multidrug resistance-associated proteins (MRP) 2, 3, and 4 are ATP-binding cassette 
efflux transporters encoded by the ABCC2, ABCC3, and ABCC4 genes, respectively 
(Klaassen and Aleksunes 2010). MRP2 is expressed in the canalicular membrane of 
hepatocytes, in the luminal membrane of enterocytes, in the apical membrane of renal 
proximal tubular cells, and in the maternal side of placental syncytiotrophoblasts 
(Mayer et al. 1995; Paulusma et al. 1996; Paulusma et al. 1997; Schaub et al. 1999; 
Fromm et al. 2000; St-Pierre et al. 2000). It transports glutathione, glucuronide, and 
sulphate conjugates, but also some unconjugated drugs, e.g. many anticancer drugs 
(Leslie et al. 2005; Choudhuri and Klaassen 2006). Some antiretroviral drugs have been 
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shown to inhibit MRP2 (Weiss et al. 2007). Several mutations in the ABCC2 gene, 
resulting in a lack of functional MRP2 transporter, have been identified to cause the 
Dubin-Johnson syndrome, which is characterized by conjugated hyperbilirubinaemia 
and dark pigment deposition in the liver (Dubin and Johnson 1954; Mayer et al. 1995; 
Paulusma et al. 1996; Paulusma et al. 1997; Tsujii et al. 1999). In addition, loss-of-
function mutations in the ABCC2 gene have been suggested to be associated with 
impaired renal elimination of methotrexate and consequently increased risk of toxicity 
(Hulot et al. 2005; Zolk and Fromm 2011). The synonymous ABCC2 c.1446C>G SNP 
has been associated with reduced systemic exposure to pravastatin as a consequence of 
increased MRP2 expression (Kivistö et al. 2005; Niemi et al. 2006a). 
 
MRP3 mediates the basolateral efflux of its substrates in the liver and intestine (Kool et 
al. 1997; Uchiumi et al. 1998; Scheffer et al. 2000). These substrates include 
glucuronide conjugates, such as estradiol-17β-glucuronide, unconjugated and 
conjugated bile acids, and anticancer drugs (Kool et al. 1999; Choudhuri and Klaassen 
2006). MRP3 has been shown to be inhibited by some antiretroviral drugs (Weiss et al. 
2007). 
 
MRP4 is expressed in many tissues, including the apical membrane of the renal 
proximal tubular cells, the luminal membrane of the capillary endothelial cells in the 
brain, and in the basolateral membrane of hepatocytes (Kool et al. 1997; van Aubel et 
al. 2002; Rius et al. 2003; Nies et al. 2004; Klaassen and Aleksunes 2010). The 
transporter contributes to resistance against nucleoside analogue antiviral drugs such as 
adefovir (Schuetz et al. 1999). Among the substrates of MRP4 are also many anticancer 
drugs as well as endogenous compounds, including bile acids, urate, prostaglandins, 
leukotrienes, steroid conjugates, folate, glutathione, and cyclic nucleotides (van Aubel 
et al. 2002; Reid et al. 2003; Rius et al. 2003; Choudhuri and Klaassen 2006; Klaassen 
and Aleksunes 2010). Many NSAIDs have been shown to inhibit MRP4 (Reid et al. 
2003). 
 
Multidrug resistance protein 3 (MDR3), encoded by the ABCB4 gene, is a 
phospholipid translocator expressed in the canalicular membrane of hepatocytes (Van 
der Bliek et al. 1987; Schinkel et al. 1991; van Helvoort et al. 1996). Translocation of 
phospholipids from the inner to the outer leaflet of the hepatocyte cell membrane is 
required for the actual secretion process driven by bile acids (Klaassen and Aleksunes 
2010). Phospholipids protect the biliary tree from injury by forming micelles with bile 
acids. Variants of ABCB4 gene have been associated with the progressive familial 
 37 
intrahepatic cholestasis, the severe form of cholestasis in pregnancy, rare cases of 
juvenile cholesterol gallstones, and drug-induced hepatocellular and cholestatic injury 
(Deleuze et al. 1996; de Vree et al. 1998; Jacquemin et al. 1999; Lang et al. 2007; 
Nakken et al. 2009; Klaassen and Aleksunes 2010). MDR3 also participates in the 
efflux of drugs into bile and can be inhibited by cyclosporine and verapamil (Smith et 
al. 2000). 
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Table 1. Selected influx transporters, their tissue distribution, and examples of their 
drug substrates and inhibitors. 
Transporter 
(Gene) 
Tissue 
distribution 
Examples of substrates Examples of 
inhibitors 
Important roles 
OATP1A2 
(SLCO1A2) 
Intestine, 
brain, liver, 
kidney 
Acebutolol, 
aliskiren, 
atenolol, 
celiprolol, 
ciprofloxacin, 
erythromycin, 
fexofenadine, 
imatinib, 
levofloxacin, 
methotrexate, 
pitavastatin, 
rocuronium, 
rosuvastatin, 
saquinavir, 
talinolol, 
thyroxine 
Apple juice, 
grapefruit 
juice,      
orange juice, 
rifampicin, 
verapamil 
Intestinal 
absorption,  
central nervous 
system 
distribution, 
pharmacokinetic 
interactions 
OATP1B1 
(SLCO1B1) 
Liver Atorvastatin, 
atrasentan, 
benzyl-
penicillin, 
bosentan, 
caspofungin, 
cerivastatin, 
darunavir, 
enalapril, 
fexofenadine, 
fluvastatin, 
lopinavir, 
methotrexate, 
olmesartan, 
pitavastatin, 
pravastatin, 
repaglinide, 
rifampicin, 
rosuvastatin, 
saquinavir, 
simvastatin, 
SN-38, 
temocapril, 
valsartan 
Atazanavir, 
cyclosporine, 
gemfibrozil, 
lopinavir, 
rifampicin, 
ritonavir, 
saquinavir 
Hepatic uptake, 
clinically 
important 
polymorphisms, 
pharmacokinetic 
interactions 
OATP1B3 
(SLCO1B3) 
Liver Atrasentan, 
bosentan, 
digoxin, 
docetaxel, 
enalapril, 
erythromycin, 
fexofenadine, 
fluvastatin, 
imatinib, 
methotrexate, 
olmesartan, 
paclitaxel, 
pitavastatin, 
rifampicin, 
rosuvastatin, 
SN-38, 
telmisartan, 
thyroxine, 
valsartan 
Cyclosporine, 
rifampicin 
Hepatic uptake 
OATP2B1 
(SLCO2B1) 
Intestine, 
liver, brain, 
heart, pancre-
as, platelets, 
skeletal 
muscle, skin, 
testis, mam-
mary gland, 
placenta 
Aliskiren, 
atorvastatin, 
benzyl-
penicillin, 
bosentan, 
celiprolol, 
fexofenadine, 
fluvastatin, 
gliben-
clamide, 
montelukast, 
pravastatin, 
rosuvastatin, 
talinolol, 
unoprostone 
Cyclosporine, 
gemfibrozil, 
grapefruit 
juice 
Intestinal 
absorption, 
hepatic uptake, 
tissue 
distribution 
OATP4C1 
(SLCO4C1) 
Kidney Digoxin, 
methotrexate, 
sitagliptin  Renal uptake 
from blood 
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Table 1. Continued. 
Transporter 
(Gene) 
Tissue 
distribution 
Examples of substrates Examples of 
inhibitors 
Important roles 
OAT1 
(SLC22A6) 
Kidney Acyclovir, 
adefovir, 
cidofovir, 
cimetidine, 
furosemide, 
ganciclovir, 
ibuprofen, 
indomethacin, 
ketoprofen, 
lamivudine, 
methotrexate, 
ranitidine, 
tenofovir, 
tetracycline, 
zalcitabine, 
zidovudine 
Probenecid Renal uptake 
from blood, 
pharmacokinetic 
interactions 
OAT3 
(SLC22A8) 
Kidney Benzyl-
penicillin, 
cimetidine, 
famotidine, 
furosemide, 
ibuprofen, 
indomethacin, 
ketoprofen, 
methotrexate, 
ranitidine, 
tetracycline, 
zidovudine 
Probenecid Renal uptake 
from blood, 
pharmacokinetic 
interactions 
OCT1 
(SLC22A1) 
Liver, 
intestine, 
kidney 
Acyclovir, 
cimetidine, 
cisplatin, 
famotidine, 
ganciclovir, 
imatinib, 
lamivudine, 
metformin, 
oxaliplatin, 
ranitidine, 
zalcitabine Cimetidine, 
indinavir, 
nelfinavir, 
pentamidine, 
quinidine, 
repaglinide, 
ritonavir, 
rosiglitazone, 
saquinavir, 
trimethoprim 
Hepatic uptake, 
pharmacokinetic 
interactions, 
clinically 
important 
polymorphisms 
OCT2 
(SLC22A2) 
Kidney, 
neurons 
Amantadine, 
cimetidine, 
cisplatin, 
famotidine, 
metformin, 
oxaliplatin, 
ranitidine 
 Bisoprolol, 
carvedilol, 
cimetidine, 
clonidine, 
flecainide, 
imipramine, 
metoprolol, 
mexiletine, 
propranolol, 
quinidine, 
verapamil 
Renal uptake 
from blood, 
pharmacokinetic 
interactions, 
clinically 
important 
polymorphisms 
PEPT1 
(SLC15A1) 
Intestine Cephaclor, 
cephadroxil, 
valacyclovir  Intestinal 
absorption 
PEPT2 
(SLC15A2) 
Kidney Cephaclor, 
cephadroxil, 
valacyclovir  Renal uptake 
from urine 
The list of substrates and inhibitors is based primarily on in vitro data, and the clinical significance of the 
transporter on the pharmacokinetics of respective drug is not necessarily stated. 
SN-38, active metabolite of irinotecan. 
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Table 2. Selected efflux transporters, their tissue distribution, and examples of drug 
substrates and inhibitors. 
Transporter 
(Gene) 
Tissue 
distribution 
Examples of substrates Examples of 
inhibitors 
Important roles 
P-gp/MDR1 
(ABCB1) 
Intestine, 
liver, kidney, 
brain, testis, 
placenta 
Aliskiren, 
atorvastatin, 
celiprolol, 
cyclosporine, 
dexa-
methasone, 
digoxin, 
diltiazem, 
docetaxel, 
erythro-
mycin, 
etoposide, 
fexo-
fenadine, 
imatinib, 
indinavir, 
itraconazole, 
levofloxacin, 
loperamide, 
lovastatin, 
methyl-
predni-
solone, 
morphine, 
nelfinavir, 
paclitaxel, 
rifampicin, 
saquinavir, 
sirolimus, 
tacrolimus, 
talinolol, 
verapamil, 
vinblastine, 
vincristine 
Atorvastatin, 
clarithromycin, 
cyclosporine, 
erythromycin, 
itraconazole, 
ketoconazole, 
quinidine, 
ritonavir, 
verapamil 
Limiting 
intestinal 
absorption, 
limiting tissue 
distribution, 
excretion into 
urine, bile and 
intestine, 
pharmacokinetic 
interactions  
BCRP 
(ABCG2) 
Intestine, 
liver, brain, 
mammary 
gland, 
placenta, 
haemato-
poietic stem 
cells 
Atorvastatin, 
cipro-
floxacin, 
fluvastatin, 
imatinib, 
irinotecan, 
methotrexate, 
mitox-
antrone, 
norfloxacin, 
ofloxacin, 
pravastatin, 
rosuvastatin, 
topotecan 
Cyclosporine Limiting 
absorption and 
tissue 
distribution, 
excretion into 
bile,      
clinically 
important 
polymorphisms 
BSEP 
(ABCB11) 
Liver Bile acids, 
pravastatin 
 Bosentan, 
cyclosporine, 
glibenclamide, 
rifampicin 
Excretion into 
bile 
MATE1 
(SLC47A1) 
Kidney, liver, 
skeletal 
muscle, heart, 
adrenal gland, 
testis 
Metformin Cimetidine Excretion into 
bile and urine 
MATE2-K 
(SLC47A2) 
Kidney Metformin  Excretion into 
urine 
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Table 2. Continued. 
Transporter 
(Gene) 
Tissue 
distribution 
Examples of substrates Examples of 
inhibitors 
Important roles 
MRP2 
(ABCC2) 
Liver, 
intestine, 
kidney 
Glutathione, 
glucuronide, 
and sulphate 
conjugates, 
ampicillin, 
cisplatin, 
doxorubicin, 
etoposide, 
irinotecan 
and SN-38, 
metho-
trexate, 
mitox-
antrone, 
pravastatin, 
valsartan, 
vinblastine, 
vincristine 
Cyclosporine, 
delavirdine, 
efavirenz, 
emtricitabine 
Excretion into 
bile and urine,  
limiting 
absorption,  
Dubin-Johnson 
syndrome 
MRP3 
(ABCC3) 
Liver, intestine Glucuronide 
conjugates, 
bile acids, 
etoposide, 
metho-
trexate, 
teniposide 
Delavirdine, 
efavirenz, 
emtricitabine 
Transport into 
bloodstream 
MRP4 
(ABCC4) 
Kidney, brain, 
liver 
Adefovir, 
furosemide, 
hydrochloro-
thiazide, 
irinotecan 
and SN-38, 
metho-
trexate, 
tenofovir, 
topotecan, 
zidovudine 
Ibuprofen, 
indomethacin, 
ketoprofen 
Excretion into 
urine,         
limiting central 
nervous system 
distribution, 
transport into 
bloodstream 
from 
hepatocytes 
MDR3 
(ABCB4) 
Liver Digoxin, 
paclitaxel, 
vinblastine Cyclosporine, 
verapamil 
Translocation of 
phospholipids 
The list of substrates and inhibitors is based primarily on in vitro data, and the clinical significance of the 
transporter on the pharmacokinetics of respective drug is not necessarily stated. 
SN-38, active metabolite of irinotecan. 
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4. Drug metabolism 
 
Most drugs are relatively hydrophobic and need to be metabolized in order to terminate 
their therapeutic effect and facilitate their excretion from the body (Brodie et al. 1958). 
Drug metabolism occurs mainly in the liver by enzymes of the endoplasmic reticulum, 
but some drug metabolism also goes on in the gastrointestinal wall, kidneys, skin, and 
lungs (Remmer 1970; Krishna and Klotz 1994). Drugs are metabolized by two major 
types of reactions (Meyer 1996). Phase I functionalization reactions, involving 
oxidation, reduction, and hydrolysis, convert drugs into more polar and usually less 
active compounds by introducing or exposing a functional group in the drug molecule. 
However, phase I reactions may also result in the formation of metabolites with 
enhanced activity (prodrugs) or even toxic effects. During phase II conjugation 
reactions the functional group of a drug or a metabolite is conjugated with some other 
substance, such as glucuronic acid, sulphate, or glutathione, to produce a more water-
soluble compound. Some drugs undergo only phase I or II reactions, while others can 
simultaneously undergo metabolism by several pathways or even stay unmetabolized 
(Krishna and Klotz 1994). 
 
 
4.1 CYP enzymes 
 
The superfamily of cytochrome P450 (CYP) is responsible for the majority of the phase 
I oxidation reactions (Wrighton and Stevens 1992). Cytochrome P450, a cellular 
chromophore, was first named after the characteristic peak absorption wavelength (450 
nm) of the pigment (P) when reduced and bound to carbon monoxide (Omura and Sato 
1962). The human CYP superfamily comprises 57 genes encoding haem-containing 
mono-oxygenases, which are divided into 18 families sharing greater than 40% amino 
acid sequence homology (e.g. CYP3) and further into 44 subfamilies sharing greater 
than 55% amino acid homology (e.g. CYP3A) (Nelson et al. 1996). The catalytic 
mechanism appears to be common to all CYPs and involves a two-electron reduction of 
molecular oxygen to form a reactive oxygen species and water (Lin and Lu 1998). In 
addition to a major role in the metabolism of drugs and other xenobiotics (Wrighton and 
Stevens 1992), CYPs have important endogenous functions, including biosynthesis of 
bile acids, metabolism of cholesterol, and biosynthesis and metabolism of steroids and 
vitamin D3 (Nebert and Russell 2002). The CYP enzymes belonging to the CYP1, 
CYP2, and CYP3 families are principally responsible for the drug metabolism in 
humans (Table 3) (Zanger et al. 2008). 
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Non-genetic factors affecting CYP activity. In newborns, CYP activity is still 
relatively undeveloped (Tanaka 1998). In neonates, a specific foetal form, CYP3A7, has 
been found, but its activity disappears soon after birth (Lacroix et al. 1997). The 
metabolic activity of CYPs matures during the first year (Tanaka 1998), and in infants 
and young children the elimination half-lives of drugs are generally shorter than in 
adults due to the relatively large-sized liver and higher clearance of drugs per kilogram 
of body weight (Rowland and Tozer 2011). The hepatic clearance of many drugs 
diminishes with age, but this seems to reflect more a decrease in liver volume and 
hepatic blood flow than a decrease in liver CYP activity (Parkinson et al. 2004). 
 
CYP enzymes can be induced or inhibited by numerous drugs and other xenobiotics 
(Table 3) (Pelkonen et al. 2008). Drug metabolism may also be affected by disease 
states and physiological factors. For instance, cytokines released during inflammation 
can inhibit CYP activity and raise the concentrations of drugs (Aitken et al. 2006) such 
as CYP1A2 substrate clozapine (Raaska et al. 2002). Liver diseases may reduce both 
the amount of microsomal protein and the activity of CYP enzymes (Parkinson et al. 
2004; Frye et al. 2006). In addition, hormones from the pituitary, sex, adrenal, and 
thyroid glands as well as from the pancreas are involved in the regulation of CYPs, and 
changes and differences in hormonal status may have some role in intra-individual and 
interindividual variability in drug metabolism (Gibson and Skett 2001). 
 
The induction of drug metabolism usually results in reduced plasma concentrations of 
the parent compound, which may lead to loss of efficacy (Pelkonen et al. 2008). The 
induction occurs to a major extent by a mechanism where ligand activation of 
transcription factors leads to increased gene transcription and further increased protein 
synthesis (Handschin and Meyer 2003). These intracellular receptors include aryl 
hydrocarbon receptor (AhR), PXR, and CAR (Waxman 1999). In addition, oestrogen 
receptor α and glucocorticoid receptor (GR) may be involved in some induction 
phenomena (Gerbal-Chaloin et al. 2002; Hukkanen et al. 2003; Higashi et al. 2007). 
 
The inhibition of drug metabolism can result in increased exposure to the parent 
compound, potentially leading to enhanced drug efficacy and even to severe adverse 
drug reactions (Pelkonen et al. 2008). The inhibition of CYP enzymes can occur in 
either reversible or irreversible (mechanism-based) way (Hollenberg 2002). Reversible 
inhibitors bind non-covalently to the enzyme and are able to dissociate from it. The 
inhibition disappears soon after the removal of inhibitor, and the enzyme is not 
permanently destroyed. Reversible inhibition can be further divided into competitive, 
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non-competitive, and uncompetitive inhibition, depending on whether the inhibitor 
binds to the same position of the enzyme as the substrate, to a different position of the 
enzyme as the substrate, or to the enzyme-substrate complex, respectively. Mixed-type 
inhibition displays elements of both competitive and non-competitive inhibition. 
Irreversible inhibitors need to undergo metabolic activation to form intermediates that 
further inactivate the enzyme, usually by forming covalent bonds. Resynthesis of the 
enzyme is required before the activity is restored. 
 
Pharmacogenetics of CYP enzymes. The genetic variability of CYP enzymes is a 
significant cause of interindividual differences in drug response. The clinically most 
important polymorphisms are those in genes encoding CYP2C9, CYP2C19, and 
CYP2D6 (Zanger et al. 2008). CYP2C9 is involved in the metabolism of approximately 
10-20% of drugs on the market, with several NSAIDs and S-warfarin being examples of 
CYP2C9 substrates (Kirchheiner and Brockmöller 2005; Zanger et al. 2008). The two 
most investigated variant alleles of the CYP2C9 gene, CYP2C9*2 (g.3608C>T, 
p.Arg144Cys) and CYP2C9*3 (g.42614A>C, p.Ile359Leu), are common in Caucasians, 
with frequencies of approximately 13-17% and 6-7%, respectively, but are rarer in 
African and Asian populations, with frequencies of 0-4%. Both of these variants yield 
enzymes with reduced activity and are of clinical relevance. The carriers of CYP2C9*2 
and *3 alleles have been reported to experience higher incidences of adverse drug 
reactions, such as gastrointestinal bleeding from NSAIDs (Martínez et al. 2004), 
hypoglycaemia from sulphonylurea antidiabetic drugs (Holstein et al. 2005), and serious 
bleeding from warfarin treatment (Aithal et al. 1999), in which anticoagulant response 
also depends on variants in genes encoding vitamin K epoxide reductase complex 
subunit 1 and CYP4F2 (Takeuchi et al. 2009). 
 
CYP2C19 contributes to the metabolism of about 10% of commonly used drugs such as 
many proton-pump inhibitors and antidepressants (Zanger et al. 2008). The genetic 
variation in the CYP2C19 gene leads to distinct phenotypes, termed poor (PM) and 
extensive (EM) metabolizers. The PM phenotype results from two null alleles, leading 
to the absence of a functional CYP2C19 protein, whereas EMs carry at least one 
functional allele. About 3–5% of Caucasians and Africans, and up to 20% of Asians 
exhibit the PM phenotype. Moreover, the CYP2C19*17 allele (g.-806C>T SNP in the 
promoter region) has been found to cause increased CYP2C19 activity due to an 
increase in CYP2C19 transcription (Sim et al. 2006). The frequency of this allele is 
about 15-25% in Caucasians and Africans, but only about 4% in Asians (Sim et al. 
2006; Zanger et al. 2008). In vivo, the CYP2C19 polymorphism has been shown to 
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affect, for example, the responsiveness to Helicobacter pylori eradication therapy that 
includes proton-pump inhibitors (Furuta et al. 2001). 
 
CYP2D6 participates in the metabolism of about 15-25% of clinically used drugs, 
among which are beta blockers, antipsychotics, antidepressants, and opioids (Dahl and 
Bertilsson 1993; Ingelman-Sundberg 2005; Zanger et al. 2008). CYP2D6 is the only 
non-inducible enzyme among the drug-metabolizing CYPs, and therefore, genetic 
variation is of major importance for the interindividual variability in its activity. The 
genetic variants of the CYP2D6 gene have been divided into alleles causing four 
phenotypes: PM (no activity, results from two null alleles), intermediate metabolizer 
(IM; reduced activity, results from one partially defective allele in combination with a 
null allele or a partially defective allele), EM (normal activity), and ultrarapid 
metabolizer (UM; high activity, results from enzyme overexpression due to duplication 
or multiplication of the active gene) (Dahl et al. 1992; Johansson et al. 1993; Dahl et al. 
1995; Ingelman-Sundberg 2005; Zanger et al. 2008). The frequencies of PM, IM, EM, 
and UM phenotypes in Caucasians are approximately 5-10%, 10-15%, 70-85%, and     
1-5%, respectively (Zanger et al. 2008). In Asians and Africans, the UM phenotype is 
common, with a frequency of about 30%, whereas the PM phenotype exhibits a 
frequency of only 0-1%. The polymorphism of CYP2D6 has clinically significant 
consequences (Ingelman-Sundberg 2005). PMs may experience adverse drug reactions 
due to increased exposure to CYP2D6 substrates, whereas UMs may not achieve 
sufficient clinical response. However, in the case of prodrugs, such as codeine, which is 
metabolized into morphine, the UM phenotype may be associated with adverse effects 
as a result of high concentrations of the active metabolite (Gasche et al. 2004). The 
CYP2D6 polymorphism has also been shown to have a major impact on, for instance, 
the clinical outcomes of the adjuvant treatment of breast cancer with the prodrug 
tamoxifen (Schroth et al. 2009). 
 
 
4.1.1 CYP3A4 
 
CYP3A4 is the most abundant CYP enzyme in the liver and small intestine (Bork et al. 
1989; Guengerich 1989; Kolars et al. 1992), and it has been estimated to be involved in 
the metabolism of approximately 50% of the drugs in clinical use (Wrighton et al. 
2000). CYP3A4 was one of the first P450 enzymes purified from the human liver in the 
1980s (Wang et al. 1983; Watkins et al. 1985; Guengerich et al. 1986). Subsequently, 
the crystal structures of bound and unbound CYP3A4 have been constructed, and they 
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have revealed that the active site of CYP3A4 is large and flexible, explaining the broad 
substrate specificity (Williams et al. 2004; Yano et al. 2004; Ekroos and Sjögren 2006). 
The substrates of CYP3A4 vary widely in size and structure and include endogenous 
compounds, such as steroid hormones, as well as several clinically important drugs, e.g. 
midazolam (a probe substrate) and triazolam, cyclosporine, calcium-channel blockers, 
statins, and antiretroviral drugs (Dresser et al. 2000; Wrighton et al. 2000). 
 
CYP3A4 is regulated by PXR, CAR, and GR and is induced by many compounds such 
as rifampicin, phenobarbital, phenytoin, carbamazepine, dexamethasone, and St. John's 
wort (Combalbert et al. 1989; Kolars et al. 1992; Backman et al. 1996b; Lehmann et al. 
1998; Goodwin et al. 1999; Sueyoshi et al. 1999; Moore et al. 2000). CYP3A4 is also 
prone to both reversible and mechanism-based inhibition (Dresser et al. 2000; Wrighton 
et al. 2000). The most well-established inhibitors of CYP3A4 include azole antifungal 
agents (itraconazole, ketoconazole, voriconazole) (Back and Tjia 1991; Jurima-Romet 
et al. 1994; Olkkola et al. 1994; Saari et al. 2006), macrolide antibacterials 
(clarithromycin, erythromycin, telithromycin) (Olkkola et al. 1993; Jurima-Romet et al. 
1994; Gorski et al. 1998; Kajosaari et al. 2006), antiretroviral drugs (indinavir, 
nelfinavir, ritonavir, saquinavir) (Ernest et al. 2005), calcium-channel blockers 
(diltiazem and verapamil) (Backman et al. 1994), and grapefruit juice (Lown et al. 1997; 
Schmiedlin-Ren et al. 1997). Several CYP3A4 variant alleles have been found, but they 
appear to have limited clinical significance (Lamba et al. 2002; Zanger et al. 2008). 
 
In addition to CYP3A4, the CYP3A subfamily comprises the CYP3A5 and CYP3A7 
(foetal form) enzymes (Wrighton et al. 2000) as well as CYP3A43, which appears to be 
of minor clinical relevance (Westlind et al. 2001). CYP3A5 has overlapping substrate 
specificity with CYP3A4 (Daly 2006). Its expression is highly variable due to CYP3A5 
polymorphism, and only individuals with the CYP3A5*1 allele express significant 
amounts of the CYP3A5 enzyme (Hustert et al. 2001; Kuehl et al. 2001). The frequency 
of the CYP3A5*1 allele is about 5-20% in Caucasians, 25-30% in Asians, and 40-55% 
in Africans (Lamba et al. 2002; Daly 2006). In addition to the liver and intestine, 
CYP3A5 is expressed in such tissues as the kidney and lung (Haehner et al. 1996; 
Kivistö et al. 1996a; Kivistö et al. 1996b; Daly 2006). 
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Table 3. Selected substrates, inhibitors, and inducers of CYP enzymes. Adapted from Ingelman-Sundberg et al. 2007, Baxter 2008, 
Pelkonen et al. 2008, Zanger et al. 2008, and Neuvonen 2012. 
SUBSTRATES 
CYP1A2 CYP2C8 CYP2C9 CYP2C19 CYP2D6 CYP3A4 
Caffeine, 
clozapine, 
duloxetine, 
olanzapine, 
theophylline, 
tizanidine, 
zolmitriptan 
Cerivastatin, 
montelukast, 
paclitaxel, 
pioglitazone, 
repaglinide, 
rosiglitazone 
Diclofenac, 
glibenclamide, 
glimepiride, 
glipizide, 
ibuprofen, 
losartan, 
naproxen, 
phenytoin, 
tolbutamide, 
S-warfarin 
Citalopram, 
clomipramine, 
diazepam, 
esomeprazole, 
lansoprazole, 
moclobemide, 
omeprazole, 
pantoprazole 
Amitriptyline, 
codeine, 
metoprolol, 
nortriptyline, 
propranolol, 
risperidone, 
tamoxifen, 
thioridazine, 
tramadol, 
venlafaxine 
Atorvastatin, 
budesonide, 
buspirone, 
cyclo-
phosphamide, 
cyclosporine, 
dexamethasone, 
ethinyl 
estradiol, 
felodipine, 
imatinib, 
indinavir, 
lercanidipine, 
lovastatin, 
methyl-
prednisolone, 
midazolam, 
nelfinavir, 
nifedipine, 
oxycodone, 
ritonavir, 
saquinavir, 
sertraline, 
sildenafil, 
simvastatin, 
triazolam 
INHIBITORS 
Ciprofloxacin, 
fluvoxamine, 
oral contraceptives 
Gemfibrozil, 
trimethoprim 
Amiodarone, 
fluconazole, 
metronidazole, 
miconazole, 
voriconazole 
Fluconazole, 
omeprazole 
Buprobion, 
fluoxetine, 
paroxetine, 
quinidine, 
terbinafine 
Amiodarone, 
clarithromycin, 
diltiazem, 
erythromycin, 
grapefruit juice, 
indinavir, 
itraconazole, 
ketoconazole, 
nelfinavir, 
ritonavir, 
saquinavir, 
telithromycin, 
verapamil, 
voriconazole 
INDUCERS 
Carbamazepine, 
charcoal-grilled 
food, 
cigarette smoke, 
rifampicin 
Rifampicin Carbamazepine, 
phenobarbital, 
phenytoin, 
rifampicin, 
St. John's wort 
Phenobarbital, 
phenytoin, 
rifampicin, 
St. John's wort 
Non-inducible Carbamazepine, 
dexamethasone, 
phenobarbital, 
phenytoin, 
rifampicin, 
St. John's wort 
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5. Interacting drugs investigated 
 
5.1 Rifampicin 
 
Rifampicin (C43H58N4O12, 822.95 g/mol) is a broad-spectrum antibacterial drug. It was 
discovered in the 1960s as the first orally active derivative of rifamycin B, a product of 
the bacterium Amycolatopsis mediterranei, and was introduced into clinical use in 1968 
(Sensi 1983). Rifampicin is a bactericidal drug that acts by inhibiting bacterial DNA-
dependent RNA polymerase activity, thus suppressing the initiation of RNA synthesis 
(Campbell et al. 2001; Kohanski et al. 2010). Rifampicin is used to treat tuberculosis 
(Gyselen et al. 1968; Koul et al. 2011). It is also an alternative treatment for 
staphylococcal infections (Turnidge and Grayson 1993). The usual dosage of rifampicin 
in adults is 450-600 mg once daily, and it is principally used in combination with other 
antibacterial drugs to prevent the development of rifampicin resistance (Douglas and 
McLeod 1999). Rifampicin is generally well tolerated, and the most common adverse 
effects are rash, fever, and gastrointestinal disturbances. In addition, rifampicin may 
produce a benign reddish coloration of body fluids such as urine and tears. In rare cases, 
rifampicin has been shown to cause hepatotoxicity, particularly in patients with chronic 
liver disease, alcoholism, or poor nutritional status, or in patients taking other 
hepatotoxic agents (Grosset and Leventis 1983). Intermittent rifampicin therapy has 
been associated with an immune-mediated reaction showing flu-like symptoms, 
potentially leading to acute renal failure. 
 
Rifampicin is well absorbed from the gastrointestinal tract (Acocella 1978), and the 
Cmax is achieved in 2-4 hours (Douglas and McLeod 1999). Food delays the absorption 
and has been found to reduce the Cmax by 36% (Peloquin et al. 1999). The oral 
bioavailability of rifampicin is approximately 68% during continuous treatment (Loos et 
al. 1987). About 80% of the drug is bound to plasma protein (Acocella 1978), and the 
Vd at steady state is about 0.8 l/kg (Holdiness 1984). Rifampicin is metabolized by 
deacetylation to an antibacterially active metabolite (Acocella 1978). Both unchanged 
and metabolized rifampicin is excreted into bile and urine, and the unchanged form 
undergoes enterohepatic circulation. The t½ varies between 2 and 5 hours (Burman et al. 
2001); this shortens during continuous treatment because of autoinduction (Loos et al. 
1987). 
 
Rifampicin is a potent inducer of several drug-metabolizing enzymes and some drug 
transporters (Niemi et al. 2003). The mechanism of induction involves binding of 
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rifampicin to the nuclear receptor PXR, which leads to increased gene transcription and 
subsequently to increased protein synthesis (Lehmann et al. 1998). The PXR-target 
genes induced by rifampicin include CYP3A4 (Combalbert et al. 1989; Morel et al. 
1990; Kolars et al. 1992; Schuetz et al. 1996; Lehmann et al. 1998; Goodwin et al. 
1999; Glaeser et al. 2005), ABCB1 encoding P-gp (Schuetz et al. 1996; Geick et al. 
2001), CYP2A6 (Meunier et al. 2000; Rae et al. 2001; Itoh et al. 2006), CYP2B6 (Chang 
et al. 1997; Goodwin et al. 2001; Rae et al. 2001), CYP2C8, CYP2C9, and CYP2C19 
(Morel et al. 1990; Chang et al. 1997; Gerbal-Chaloin et al. 2001; Raucy et al. 2002; 
Chen et al. 2003; Madan et al. 2003; Chen et al. 2004; Ferguson et al. 2005; Glaeser et 
al. 2005), CYP3A5 (Burk et al. 2004), ABCC2 encoding MRP2 (Fromm et al. 2000; 
Kast et al. 2002), and some genes encoding phase II drug-metabolizing enzymes such as 
members of the UDP-glucuronosyltransferase and sulphotransferase families (Rae et al. 
2001; Sonoda et al. 2002). Because the induction requires de novo protein synthesis, 
full induction is reached in about one week after beginning rifampicin treatment, and 
baseline activity after discontinuing rifampicin is attained in roughly two weeks 
(Fromm et al. 1996; Niemi et al. 2003). 
 
Rifampicin is involved in many clinically important pharmacokinetic interactions, 
having its greatest effects on the pharmacokinetics of orally administered drugs that are 
substrates of CYP3A4 (Barbarash et al. 1988; Fromm et al. 1996; Niemi et al. 2003). 
For instance, rifampicin reduces the AUC of oral verapamil by 93% (Barbarash et al. 
1988), cyclosporine by 70% (Hebert et al. 1992), midazolam by 96% (Backman et al. 
1996a), saquinavir by 80% (Vella and Floridia 1998), and simvastatin (acid) by 93% 
(Kyrklund et al. 2000). Rifampicin also reduces the plasma concentrations of CYP2C 
substrates, such as the CYP2C9 substrate S-warfarin (74% reduction in AUC) (Heimark 
et al. 1987), as well as those of repaglinide, rosiglitazone, and pioglitazone, all of which 
are metabolized mainly by CYP2C8 (over 50% reductions in AUC) (Niemi et al. 2000; 
Niemi et al. 2004; Jaakkola et al. 2006). As an example of the effect of rifampicin on P-
gp in vivo, rifampicin reduces the AUC of oral digoxin by 30% by inducing P-gp in the 
small intestine, but has no effect on renal clearance (Greiner et al. 1999). Interestingly, 
PXR mRNA is found in marked quantities in the liver and small intestine, but to a much 
smaller extent in the kidneys (Kliewer et al. 1998), possibly explaining the lack of effect 
on the renal clearance of P-gp substrates. Regulatory authorities recommend rifampicin 
(600 mg orally once daily over several days) as an inducer for drug interaction studies 
involving substrates of P-gp, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP3A4/5 
(FDA 2012). 
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5.2 Itraconazole 
 
Itraconazole (C35H38Cl2N8O4, 705.64 g/mol) is a broad-spectrum triazole antifungal 
agent synthesized at the beginning of the 1980s (Van Cutsem et al. 1984). It inhibits the 
growth of fungi by inhibiting CYP enzyme lanosterol 14α-demethylase, which impairs 
fungal cell membrane ergosterol biosynthesis (Grant and Clissold 1989). The usual 
dosage for the treatment of fungal infections in adults is 100-400 mg daily. The most 
common adverse effects are gastrointestinal disturbances, rash, and a mild increase in 
liver enzymes (Grant and Clissold 1989). 
 
Itraconazole is available both as an oral capsule, better absorbed on a full stomach, and 
as a solution, better absorbed in the fasting state (Van Peer et al. 1989). The oral 
bioavailability is about 55% (Heykants et al. 1989), and the Cmax is achieved in 2-5 
hours (Van Peer et al. 1989). Itraconazole is highly (99.8%) bound to plasma protein 
(Heykants et al. 1989). The drug is widely distributed to the tissues, especially those 
rich in keratin, such as skin and nails, with an apparent Vd of 10.7 l/kg. Itraconazole is 
both a substrate and an inhibitor of CYP3A4 (Tucker et al. 1992; Olkkola et al. 1994; 
Ishigam et al. 2001; Isoherranen et al. 2004), and it undergoes extensive 
biotransformation in the liver into metabolites excreted into urine and bile (Heykants et 
al. 1989). The major metabolite hydroxyitraconazole is antifungally active. Itraconazole 
exhibits non-linear pharmacokinetics, probably as a result of saturation of the first-pass 
metabolism (Hardin et al. 1988; Van Peer et al. 1989). The half-life of itraconazole is 
15-25 hours after single dosing; this is prolonged to 34-42 hours with repeated dosing 
(Hardin et al. 1988). 
 
Itraconazole was initially believed not to interfere with mammalian drug-metabolizing 
enzymes (Heykants et al. 1989). Subsequently, itraconazole has been shown to be a 
potent competitive inhibitor of CYP3A4, with an inhibition constant (Ki) of 0.016-11 
μmol/l (Kwan et al. 1987; Back and Tjia 1991; Jurima-Romet et al. 1994; Olkkola et al. 
1994; von Moltke et al. 1996a; von Moltke et al. 1996b; Venkatakrishnan et al. 2000; 
Ishigam et al. 2001; Isoherranen et al. 2004). Moreover, itraconazole metabolites, 
hydroxyitraconazole (Ki 0.038 μmol/l), keto-itraconazole (IC50 for unbound form 7.0 
nmol/l), and N-desalkyl-itraconazole (IC50 for unbound form 0.4 nmol/l), have been 
found to inhibit CYP3A4 (Isoherranen et al. 2004), and they thus contribute to the effect 
of itraconazole on CYP3A4 in vivo (Templeton et al. 2008). The inhibitory effect of 
itraconazole on CYP3A4 begins rapidly and is dependent on its plasma concentrations, 
as evidenced by interaction studies involving itraconazole with triazolam or midazolam 
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(Neuvonen et al. 1996; Olkkola et al. 1996). A single dose of itraconazole, taken 
concomitantly with or 3, 12, or 24 hours before triazolam, increased the AUC of 
triazolam 3.1-, 4.8-, 4.6-, and 3.8-fold, respectively (Neuvonen et al. 1996). When a 
single dose of itraconazole was ingested 2 hours before midazolam, the increase in the 
AUC of midazolam was 3.4-fold compared with placebo, but after a 6-day repeated 
administration of itraconazole, the increase was 6.6-fold (Olkkola et al. 1996). 
Itraconazole also inhibits the P-gp transporter, with an IC50 of 2 μmol/l (Wang et al. 
2002), and regulatory authorities recommend itraconazole as an inhibitor in drug 
interaction studies involving substrates of CYP3A4 or P-gp (FDA 2012). 
 
Itraconazole markedly raises the AUC and enhances the effects of several CYP3A4 
and/or P-gp substrates (Table 4). In 1993, itraconazole was found to greatly increase the 
plasma concentrations of parent drug terfenadine, a non-sedating antihistamine, 
resulting in prolongation of the QT-interval in ECG and leading to torsades de pointes 
ventricular tachycardia (Honig et al. 1993; Pohjola-Sintonen et al. 1993). This 
hazardous drug interaction with CYP3A4 inhibitors led to removal of terfenadine from 
the market. Itraconazole can also increase the exposure to other QT-interval-prolonging 
agents such as cisapride and quinidine (Kaukonen et al. 1997; Wysowski et al. 2001). 
 
 
Table 4. Examples of pharmacokinetic interactions of itraconazole. 
Interacting drug Effect of itraconazole Reference 
Triazolam 27.1-fold increase in AUC Varhe et al. 1994 
Lovastatin (acid) 22.1-fold increase in AUC Neuvonen and Jalava 1996 
Simvastatin (acid) 18.6-fold increase in AUC Neuvonen et al. 1998 
Midazolam 10.8-fold increase in AUC Olkkola et al. 1994 
Felodipine 6.3-fold increase in AUC Jalava et al. 1997a 
Methylprednisolone 3.9-fold increase in AUC Varis et al. 1998 
Atorvastatin (acid) 3.3-fold increase in AUC Kantola et al. 1998a 
Fexofenadine 2.7-fold increase in AUC Shimizu et al. 2006 
Celiprolol 1.8-fold increase in AUC Lilja et al. 2003 
Digoxin 1.7-fold increase in AUC Partanen et al. 1996 
Jalava et al. 1997b 
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6. Fruit juices investigated 
 
6.1 Grapefruit juice 
 
Effect on CYP3A4. The ability of grapefruit juice to produce clinically important 
pharmacokinetic interactions was discovered by chance in 1991, when grapefruit juice 
was used to mask the taste of ethanol in a study involving the calcium-channel blocker 
felodipine (Bailey et al. 1989; Bailey et al. 1991). Unexpectedly, grapefruit juice raised 
the AUC of felodipine 2.8-fold (Bailey et al. 1991). The interaction was found to result 
from a mechanism-based inhibition of CYP3A4, principally in the small intestine 
(Lown et al. 1997; Schmiedlin-Ren et al. 1997). Furanocoumarins bergamottin and its 
derivative, 6’,7’-dihydroxybergamottin, were identified as the primary components 
responsible for inhibition, with IC50 values (for midazolam 1’-hydroxylation) of 10-30 
μmol/l and 0.3-1 μmol/l, respectively (Edwards et al. 1996; Fukuda et al. 1997; 
Schmiedlin-Ren et al. 1997; He et al. 1998; Guo et al. 2000; Greenblatt et al. 2003; 
Kakar et al. 2004). The concentrations of bergamottin and 6’,7’-dihydroxybergamottin 
vary considerably among different grapefruit juice brands and have been reported to be 
4-30 μmol/l and 1-44 μmol/l, respectively (Edwards et al. 1996; Schmiedlin-Ren et al. 
1997; He et al. 1998; Bailey et al. 2000; Guo et al. 2000; Kakar et al. 2004). 
 
The inhibitory effect of grapefruit juice on intestinal CYP3A4 begins rapidly. In vitro, 
the maximal inhibition of CYP3A4 by 6’,7’-dihydroxybergamottin has been found to 
occur within 30 minutes, whereas bergamottin has had a slower onset of action 
(maximum within 3 hours) (Paine et al. 2005). In vivo, the concentration of CYP3A4 
protein in the duodenum has been found to be reduced by an average of 30% even 1-2 
hours after ingestion of a single glass of grapefruit juice, compared with ingestion of 
water (Glaeser et al. 2007). After a 6-day ingestion of grapefruit juice three times a day, 
the reduction in the concentration of CYP3A4 in the small intestine has been 62% 
(Lown et al. 1997). The interaction between grapefruit juice and felodipine has been 
shown to reach its maximum already after the first glass of grapefruit juice taken 
concomitantly with the drug (Lundahl et al. 1998). By contrast, in a study with 
triazolam, multiple doses of double-strength grapefruit juice (three times a day for two 
days) had a greater effect on the AUC of triazolam (2.4-fold increase) than single doses 
of normal-strength or double-strength grapefruit juice (1.5-fold increases) (Lilja et al. 
2000a). Multiple doses also prolonged the t½ of triazolam, suggesting inhibition of both 
intestinal and hepatic CYP3A4. Repeated consumption of grapefruit juice has also 
prolonged the t½ of other CYP3A4 substrates, including atorvastatin, buspirone, 
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cisapride, midazolam, and oxycodone, and in one study, a decrease in the amount of 
exhaled 
14
CO2 in the erythromycin breath test was also seen (Lilja et al. 1998b; Kivistö 
et al. 1999; Lilja et al. 1999; Veronese et al. 2003; Nieminen et al. 2010). However, 
grapefruit juice has not inhibited hepatic CYP3A4, reflected as an effect on the 
pharmacokinetics of intravenously administered CYP3A4 substrates midazolam, 
cyclosporine, felodipine, or saquinavir (Ducharme et al. 1995; Kupferschmidt et al. 
1995; Lundahl et al. 1997; Kupferschmidt et al. 1998). 
 
In studies concerning the duration of the effect, the inhibitory effect of grapefruit juice 
on CYP3A4 has lasted at least 24 hours, and in some cases, some effect was seen up to 
three days after grapefruit juice ingestion (Lundahl et al. 1995; Lilja et al. 2000b; 
Takanaga et al. 2000; Greenblatt et al. 2003; Culm-Merdek et al. 2006). For instance, 
grapefruit juice taken concomitantly with, 24 hours before, or 3 days before the drug 
increased the AUC of simvastatin 3.5-, 2.1-, and 1.4-fold, respectively, compared with 
water, whereas no effect was observed when grapefruit juice was taken 7 days before 
the drug (Lilja et al. 2000b). 
 
Nowadays, grapefruit juice is known to enhance the oral bioavailabilities of several 
CYP3A4 substrate drugs (1.3 to 16-fold increases in AUC), including hypnotics 
(midazolam, triazolam) (Kupferschmidt et al. 1995; Hukkinen et al. 1995), calcium-
channel blockers (felodipine, nicardipine, nifedipine, nimodipine, nisoldipine, 
nitrendipine, verapamil) (Bailey et al. 1991; Soons et al. 1991; Bailey et al. 1993; Fuhr 
et al. 1998; Ho et al. 2000b; Uno et al. 2000; Bailey and Dresser 2004), statins 
(atorvastatin, lovastatin, simvastatin) (Kantola et al. 1998b; Lilja et al. 1998a; Lilja et al. 
1999), amiodarone (Libersa et al. 2000), buspirone (Lilja et al. 1998b), carbamazepine 
(Garg et al. 1998), cisapride (Kivistö et al. 1999), cyclosporine (Yee et al. 1995), 
diazepam (Ozdemir et al. 1998), erythromycin (Kanazawa et al. 2001), 
methylprednisolone (Varis et al. 2000), nilotinib (Yin et al. 2010), oxycodone 
(Nieminen et al. 2010), saquinavir (Kupferschmidt et al. 1998), tacrolimus (2-fold 
increase in trough concentrations in liver transplant patients) (Liu et al. 2009), and 
tolvaptan (Shoaf et al. 2012). 
 
Effect on P-glycoprotein. The effect of grapefruit juice on P-gp activity has been 
widely studied, but the results have been somewhat conflicting. Based on some early in 
vitro studies, constituents of grapefruit juice seemed to have no significant effect on P-
gp activity (Eagling et al. 1999; Edwards et al. 1999). However, these studies have been 
criticized for technical issues and for using inadequate constituent concentrations 
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(Dresser et al. 2002a). Grapefruit juice has subsequently been shown to inhibit P-gp in 
many in vitro studies using colchicine, talinolol, saquinavir, vinblastine, and vincristine 
as probes (Takanaga et al. 1998; Ikegawa et al. 2000; Honda et al. 2004; de Castro et al. 
2007; Dahan and Amidon 2009). 6’,7’-dihydroxybergamottin and naringin have 
inhibited P-gp, with IC50 values of 33 μmol/l and 3000 μmol/l, respectively (Dresser et 
al. 2002a). Bergamottin, by contrast, has not altered P-gp activity at concentrations of 
up to 50 μmol/l. However, 6’,7’-dihydroxybergamottin and naringin occur in grapefruit 
juice at relatively low concentrations in relation to IC50 values, 1-44 μmol/l and 130-
1230 μmol/l, respectively (Ameer et al. 1996; Edwards et al. 1996; Schmiedlin-Ren et 
al. 1997; Bailey et al. 2000; Guo et al. 2000; Tomás-Barberán and Clifford 2000; Kakar 
et al. 2004; Vanamala et al. 2006; Bailey et al. 2007), suggesting that they are not likely 
to produce relevant inhibition of P-gp activity in vivo. 
 
In vivo, grapefruit juice has had no significant effect on the total exposure of the P-gp 
probe digoxin (Becquemont et al. 2001; Parker et al. 2003). Moreover, no effect on the 
P-gp-protein expression level in the small intestine has been seen (Lown et al. 1997; 
Glaeser et al. 2007). In case of a substrate of both P-gp and OATP transporter, the 
OATP-inhibiting effect of grapefruit juice appears to predominate, as evidenced by 
interaction studies with fexofenadine, celiprolol, and talinolol (Karlsson et al. 1993; 
Wetterich et al. 1996; Spahn-Langguth et al. 1998; Cvetkovic et al. 1999; Dresser et al. 
2002a; Lilja et al. 2003; Nozawa et al. 2004; Schwarz et al. 2005; Glaeser et al. 2007; 
Kato et al. 2009; Shirasaka et al. 2010). 
 
Effect on OATPs. A new type of pharmacokinetic food-drug interaction emerged when 
grapefruit, orange, and apple juices were discovered to reduce the systemic exposure to 
fexofenadine by about 60-70% (Dresser et al. 2002a). The metabolism of fexofenadine 
is negligible, and it is eliminated unchanged into bile and urine (Russell et al. 1998). 
Fexofenadine is a substrate of P-gp (Cvetkovic et al. 1999), OATP1A2 (Cvetkovic et al. 
1999; Dresser et al. 2002a; Glaeser et al. 2007), OATP2B1 (Nozawa et al. 2004), 
OATP1B1 (Niemi et al. 2005), and OATP1B3 (Shimizu et al. 2005). Interestingly, 
grapefruit and orange juices were found to inhibit OATP1A2-mediated fexofenadine 
uptake in vitro in human cervical carcinoma (HeLa) cells (Dresser et al. 2002a). Thus, 
the suggested mechanism of these interactions was the inhibition of OATP1A2-
mediated uptake of fexofenadine in the small intestine by these juices. 
 
Subsequently, grapefruit juice has been found to reduce the oral bioavailabilities of 
other OATP substrate drugs. Celiprolol and talinolol are substrates of both OATP1A2 
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and OATP2B1 (Kato et al. 2009; Shirasaka et al. 2010; Ieiri et al. 2012), and grapefruit 
juice has reduced their AUC values by 87% and 36%, respectively (Lilja et al. 2003; 
Schwarz et al. 2005). In addition, grapefruit juice has had a minor, probably not 
clinically relevant, effect on the oral bioavailabilities of the OATP1A2 substrates 
acebutolol (7% reduction in AUC) and levothyroxine (9% reduction in AUC) (Fujiwara 
et al. 2001; Lilja et al. 2005a; Lilja et al. 2005b; Kato et al. 2009). 
 
Several constituents of grapefruit juice have been screened for inhibitory effects on 
intestinal OATP transporters. The foremost flavonoid in grapefruit juice, naringin, is a 
potent inhibitor of OATP1A2, with an IC50 value of 3.6 μmol/l (Bailey et al. 2007), 
which also is significant relative to its corresponding concentration in grapefruit juice 
(130-1230 μmol/l) (Ameer et al. 1996; Bailey et al. 2000; Tomás-Barberán and Clifford 
2000; Vanamala et al. 2006; Bailey et al. 2007). A drug is generally considered to be an 
inhibitor of OATP transporter in vivo if it shows an IC50 value of less than 10 times its 
unbound peak concentration (Giacomini et al. 2010). Thus, naringin is believed to be 
mainly responsible for the inhibition of OATP1A2 in vivo (Bailey et al. 2007). 
However, pure naringin solution has decreased the bioavailability of fexofenadine by 
only half the amount seen with whole grapefruit juice containing the same naringin 
concentration, suggesting that grapefruit juice also contains other OATP1A2 inhibitors. 
Of other constituents, quercetin, reported to occur in grapefruit juice at concentrations 
of 17-26 μmol/l (Vanamala et al. 2006), has been noted to inhibit OATP1A2, with an 
IC50 of 12.6 μmol/l (Mandery et al. 2010). 
 
Naringin, at a concentration of 10 μmol/l, has inhibited the OATP2B1-mediated uptake 
of estrone-3-sulphate by 39% in vitro in HEK293 cells, and it probably contributes to 
the inhibition of OATP2B1 by grapefruit juice in vivo (Satoh et al. 2005). Furthermore, 
naringenin (an aglycone form of naringin), quercetin, bergamottin, and 6’,7’-
dihydroxybergamottin, all at concentrations of 10 μmol/l, have been found to inhibit the 
OATP2B1-mediated transport by 28%, 21%, 60%, and 43%, respectively (Satoh et al. 
2005). Moreover, naringenin has inhibited the OATP1B1- and OATP1B3-mediated 
bromosulphophthalein transport in HEK293 cells, with IC50 values of 81.6 μmol/l and 
101.1 μmol/l, respectively (Mandery et al. 2012). 
 
The duration of the effect of grapefruit juice on OATP transporters appears to be much 
shorter than on CYP3A4, indicating a different mechanism of action. Grapefruit juice 
taken concomitantly with or 2 hours before fexofenadine has decreased the AUC of 
fexofenadine by 52% and 38%, respectively, compared with water, but it has had no 
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effect when taken 4 hours before the drug (Glaeser et al. 2007). Furthermore, no change 
in the duodenal OATP1A2-protein expression level has been seen 1-2 hours after 
grapefruit juice ingestion. Moreover, repeated consumption of grapefruit juice seems to 
have a similar effect on OATP1A2 as a single dose. Ingestion of a single 300-ml dose of 
grapefruit juice concomitantly with talinolol decreased the AUC of talinolol to a similar 
extent as the ingestion of 300 ml of grapefruit juice three times daily for 6 days, prior to 
talinolol administration (Schwarz et al. 2005). The effect of grapefruit juice volume on 
the reduction of fexofenadine bioavailability has also been studied. Ingestion of 300 or 
1200 ml of grapefruit juice concomitantly with fexofenadine led to 42% and 64% 
decreases in the AUC values of fexofenadine, respectively, compared with water 
(Dresser et al. 2005). 
 
 
6.2 Orange juice 
 
Orange juice appears to be a potent inhibitor of intestinal OATP1A2 in vivo, as 
observed in an interaction study, in which it had a similar effect on fexofenadine 
exposure as grapefruit juice (60-70% reduction in AUC) (Dresser et al. 2002a). Orange 
juice has also reduced the AUC values of OATP1A2 and OATP2B1 substrate celiprolol 
as well as those of OATP1A2 substrates atenolol and ciprofloxacin by 83%, 40%, and 
22%, respectively (Neuhofel et al. 2002; Lilja et al. 2004; Lilja et al. 2005c; Maeda et 
al. 2007; Kato et al. 2009; Ieiri et al. 2012). However, in contrast to grapefruit juice, 
orange juice has had no effect on CYP3A4 (Bailey et al. 1991; Yee et al. 1995; Edwards 
et al. 1996; Kakar et al. 2004). 
 
The major flavonoid in orange juice, hesperidin, is most probably mainly responsible 
for the inhibition of OATP1A2 (Bailey et al. 2007). Hesperidin has been found to 
inhibit OATP1A2 in vitro, with an IC50 of 2.7 μmol/l (Bailey et al. 2007), which is 
much lower than the concentration normally occurring in orange juices (106-1965 
μmol/l) (Ameer et al. 1996; Tomás-Barberán and Clifford 2000; Vanamala et al. 2006; 
Bailey et al. 2007). No published studies exist on the possible effects of hesperidin on 
OATP2B1. However, tangeritin and nobiletin, occurring in orange juice at 
concentrations of 0.35-1.6 μmol/l and 2.5-11 μmol/l, respectively (Rouseff and Ting 
1979; Sendra et al. 1988), have been found to inhibit the OATP2B1-mediated uptake of 
estrone-3-sulphate in HEK293 cells by 42% and 60%, respectively, at 10 µmol/l 
concentrations (Satoh et al. 2005). 
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6.3 Apple juice 
 
Studies regarding the pharmacokinetic interactions of apple juice are sparse. Similarly 
to grapefruit and orange juices, apple juice has reduced the AUC fexofenadine by 73% 
(Dresser et al. 2002a). In addition, apple juice has decreased the exposure to OATP1A2 
substrate atenolol by 82% (Jeon et al. 2012). Thus, these studies suggest the inhibition 
of intestinal OATPs by apple juice. At 5% concentration, apple juice has only slightly 
inhibited OATP1A2 in vitro (Dresser et al. 2002a), and it has had no effect on 
OATP2B1 (Satoh et al. 2005). However, at 20% concentration, apple juice has inhibited 
OATP2B1-mediated transport of fexofenadine in cRNA-injected oocytes by 
approximately 70% (Imanaga et al. 2011). Moreover, apple juice has reduced the Cmax 
of midazolam by 20%, with no effect on the other pharmacokinetic variables, 
suggesting a negligible effect on CYP3A4 (Imanaga et al. 2011). 
 
Among the flavonoids occurring in apple juice are phlorizin (6-450 μmol/l), epicatechin 
(41 μmol/l), quercetin (4-23 μmol/l), and kaempferol (0.5 μmol/l) (Young et al. 1999; 
Tomás-Barberán and Clifford 2000; Schieber et al. 2001). Of these quercetin and 
kaempferol have inhibited the OATP1A2-mediated uptake of bromosulphophthalein in 
HEK293 cells, with Ki values of 22.0 µmol/l and 25.2 µmol/l, respectively, and 
OATP2B1-mediated uptake, with Ki values of 8.7 µmol/l and 15.1 µmol/l, respectively 
(Mandery et al. 2010). Furthermore, extracts of green tea, containing catechin and 
epicatechin, and Ginkgo biloba, containing quercetin and kaempferol, have inhibited 
OATP2B1 in vitro (Fuchikami et al. 2006). Quercetin has also been reported to inhibit 
hepatic OATP transporters OATP1B1 and OATP1B3, with Ki values of 8.8 µmol/l and 
7.8 µmol/l, respectively, and kaempferol, with Ki values of 32.4 µmol/l and 24.4 µmol/l, 
respectively (Mandery et al. 2012). 
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AIMS OF THE STUDY 
 
 
Considerable interindividual variability exists in the pharmacokinetics of the direct 
renin inhibitor aliskiren. Aliskiren is a substrate of the P-gp efflux and OATP influx 
transporters, and its pharmacokinetic properties, such as low oral bioavailability and 
minor metabolism, render it susceptible to transporter-mediated pharmacokinetic 
interactions. Moreover, several sequence variations have been discovered in the ABCB1 
and SLCO2B1 genes encoding P-gp and OATP2B1, respectively, some of which have 
been suggested to be associated with altered transporter activity. These studies were 
conducted to investigate the effects of induction and inhibition of P-gp on the 
pharmacokinetics and pharmacodynamics of aliskiren. Furthermore, we investigated 
whether certain OATP-inhibiting fruit juices affect aliskiren exposure and 
pharmacodynamic factors. In addition, the effects of ABCB1 and SLCO2B1 
polymorphisms on the pharmacokinetics and pharmacodynamics of aliskiren were 
studied. 
 
 
Specific aims of the study were as follows: 
 
 
Study I 
 
 
 
Study II 
 
 
 
Study III 
 
 
 
Study IV 
 
 
Study V 
 
 
Study VI 
To investigate the effects of rifampicin, an inducer of P-gp and 
CYP3A4, on the pharmacokinetics and pharmacodynamics of 
aliskiren. 
 
To investigate the effects of itraconazole, an inhibitor of P-gp and 
CYP3A4, on the pharmacokinetics and pharmacodynamics of 
aliskiren. 
 
To investigate the effects of grapefruit juice, an inhibitor of intestinal 
CYP3A4, OATP1A2, and OATP2B1 in vitro, on the 
pharmacokinetics and pharmacodynamics of aliskiren. 
 
To investigate the effects of orange juice and apple juice on the 
pharmacokinetics and pharmacodynamics of aliskiren. 
 
To investigate whether the common ABCB1 haplotypes affect the 
pharmacokinetics and pharmacodynamics of aliskiren. 
 
To investigate whether the SLCO2B1 c.935G>A SNP affects the 
pharmacokinetics and pharmacodynamics of aliskiren. 
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MATERIALS AND METHODS 
 
 
1. Subjects 
 
A total of 93 (39 female and 54 male) healthy Finnish volunteers participated in the 
studies (Table 5). Some of the volunteers participated in two studies. The number of 
participants for each study was estimated to be sufficient to detect at least a 50% 
difference in the AUC of aliskiren between phases or groups, with a power of 80% (α-
level 5%), except in Study VI, in which the number of participants in each genotype 
group was sufficient to detect a 50% higher or 33% lower difference in the AUC of 
aliskiren between the SLCO2B1 c.935GA and c.935GG groups and a 100% higher or 
50% lower difference between the c.935AA and c.935GG groups. Originally, 12 
volunteers were recruited for each pharmacokinetic interaction study (Studies I-IV), but 
in Study II, one subject dropped out after the first phase for personal reasons, and in 
Study III, one subject was subsequently excluded because of non-compliance with the 
diet. 
 
The participants for the pharmacogenetic studies (Studies V and VI) were recruited 
from a pool of over 800 genotyped individuals. For Study V, the participants were 
selected and divided into two groups based on the genotypes composed of the ABCB1 
c.1236C>T (rs1128503), c.2677G>T/A (p.Ala893Ser/Thr; rs2032582), and c.3435C>T 
(rs1045642) SNPs; both the ABCB1 c.1236T-c.2677T-c.3435T/c.1236T-c.2677T-
c.3435T and c.1236C-c.2677G-c.3435C/c.1236C-c.2677G-c.3435C groups comprised 
11 participants. To minimize variability in aliskiren pharmacokinetics due to other 
genetic variants, only non-carriers of the ABCB1 c.1199G>A (p.Ser400Asn; rs2229109) 
and CYP3A5*1 (g.6986A; CYP3A5 expressor) alleles were recruited (Fanta et al. 
2008). For Study VI, the participants were selected based on the SLCO2B1 c.935G>A 
(p.Arg312Gln; rs12422149) SNP, and they were allocated into one of three groups 
according to genotype; the SLCO2B1 c.935AA group comprised five participants, the 
c.935GA group 12 participants, and the c.935GG (control) group 16 participants. 
 
The participants were ascertained to be healthy by medical history, clinical examination, 
and laboratory tests. Female subjects gave a negative pregnancy test before entering the 
studies. Subjects with a systolic blood pressure of less than 110 mmHg were not 
included in Studies I, II, and V, and those with less than 100 mmHg were not included 
in Studies III, IV, and VI. None of the participants was on any continuous medication, 
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including hormonal contraceptives, and none was a tobacco smoker. Use of other drugs 
was prohibited for one week before and one week after the day of administration of 
aliskiren (Studies I and II), or for one week before and three days after the day of 
administration of aliskiren (Studies III-VI). Use of grapefruit products was prohibited 
for 2-5 days before and three days after the day of administration of aliskiren in Studies 
I, II, V, and VI. In Study III, use of grapefruit products was prohibited during the entire 
study, starting from two weeks before the first day of administration of aliskiren, as was 
the use of orange juice and apple juice for two days before and three days after the day 
of administration of aliskiren. In Study IV, use of fruit juices and grapefruit, orange, and 
apple products was prohibited during the entire study, starting from one week before the 
first day of administration of aliskiren. Use of alcohol was prohibited for 1-5 days prior 
to the day of administration of aliskiren and during the days of blood sampling. 
Participation in any other trial or blood donation within three months before and after 
each study was also prohibited. 
 
 
Table 5. Characteristics of participants. 
Study no. 
(n) 
Genotype                       
(n) 
Sex    
(f/m) 
Age  
(years) 
Height 
(cm) 
Weight 
(kg) 
      
I (12)  7/5 21 (20-25) 174  10 66  11 
      
II (11)  5/6 25 (21-34) 174  11 68  13 
      
III (11)  5/6 22 (20-28) 178  8 71  10 
      
IV (12)  5/7 22 (20-28) 173  7 69  10 
      
V (22) ABCB1 TTT/TTT (11) 5/6 24 (21-27) 175  10 69  12 
 ABCB1 CGC/CGC (11) 4/7 26 (22-37) 178  9 74  11 
      
VI (33) SLCO2B1 c.935AA (5) 1/4 28 (26-30) 173  4 69  7 
 SLCO2B1 c.935GA (12) 3/9 25 (21-31) 177  8 73  13 
 SLCO2B1 c.935GG (16) 8/8 23 (20-30) 174  10 67  10 
Age data are means (range), height and weight data means  SD. F, females; m, males. 
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1.1 DNA preparation and genotyping 
 
For Studies V and VI, 10-ml ethylenediaminetetraacetic acid (EDTA) blood samples 
were obtained from healthy volunteers and stored at -20ºC until DNA extraction. 
Genomic DNA was extracted with standard methods (QIAamp DNA Mini Kit; Qiagen, 
Hilden, Germany). The subjects were genotyped for the alleles described above (see 
Subjects, Section 1), and the genotyping was carried out by allelic discrimination with 
Taqman® Genotyping Assays (Table 6). Polymerase chain reactions (PCRs) with a 
reaction volume of 10 μl were performed in an Applied Biosystems 7300 Real-Time 
PCR System or 2720 Thermal Cycler (Applied Biosystems, Foster City, CA, USA). 
Pre- and post-PCR fluorescence measurements and genotype calls were made with the 
7300 Real-Time PCR System. PCR cycling conditions were as follows: 1 cycle at 95ºC 
for 10 minutes, followed by 40 cycles of melting at 95ºC for 15 seconds, and annealing 
and extending at 60ºC for 1 minute. 
 
 
Table 6. Single-nucleotide polymorphisms investigated and sequences of primers and 
probes or Applied Biosystems Assay identification numbers (AB Assay ID) for the 
genotyping assays used. 
Gene SNP Primers and probes or AB Assay ID 
ABCB1 
ABCB1 
ABCB1 
 
 
 
 
ABCB1 
 
 
 
CYP3A5 
 
 
 
SLCO2B1 
 
c.1199G>A 
c.1236C>T 
c.2677G>T/A 
 
 
 
 
c.3435C>T 
 
 
 
g.6986A>G 
 
 
 
g.-282G>A 
c.601G>A 
c.935G>A 
c.1457C>T 
AB Assay ID: C_15951365_20 
AB Assay ID: C_7586662_10 
5'-GACAAGCACTGAAAGATAAGAAAGAACT-3' 
5'-GTAGGGAGTAACAAAATAACACTGATTAGAAT-3' 
5'-VIC-CCTTCCCAGCACCT-MGB-3' 
5'-FAM-CTTCCCAGAACCTT-MGB-3' 
5'-NED-CTTCCCAGTACCTTC-MGB-3' 
5'-ATTGCTGAGAACATTGCCTATGG-3' 
5'-CAGTGACTCGATGAAGGCATGTAT-3' 
5'-VIC-CCTCACGATCTCTT-MGB-3' 
5'-FAM-CCTCACAATCTCTT-MGB-3' 
5'-ATGGAGAGTGGCATAGGAGATACC-3' 
5'-GGTAATGTGGTCCAAACAGGG-3' 
5'-VIC-TGTCTTTCAGTATCTCTT-MGB-3' 
5'-FAM-TGTCTTTCAATATCTCTT-MGB-3' 
AB Assay ID: C_1786365_10 
AB Assay ID: C_25606765_20 
AB Assay ID: C_3101331_10 
AB Assay ID: C_16193013_20 
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In Study IV, genomic DNA was extracted from the 10-ml EDTA blood samples, and 
the participants were genotyped for the SLCO2B1 g.-282G>A (rs2712807), c.601G>A 
(p.Val201Met; rs35199625), c.935G>A, and c.1457C>T (p.Ser486Phe; rs2306168) 
alleles for exploratory purposes. 
 
 
2. Study designs 
 
Studies were carried out at the Department of Clinical Pharmacology, University of 
Helsinki, and Helsinki University Central Hospital, in 2008-2010. Studies I-IV were 
randomized, placebo-controlled cross-over studies with 2-3 phases and washout periods 
of 2-4 weeks (Table 7). Studies V and VI were prospective genotype panel studies. 
Study VI was a part of a 2-phase study investigating the effects of the SLCO2B1 
polymorphism on the pharmacokinetics of montelukast and aliskiren, with a washout 
period of at least one week. 
 
Aliskiren (Rasilez 150-mg tablet; Novartis, Horsham, UK) was supplied by the 
Pharmacy of Helsinki University Central Hospital. The pretreatment medications 
(rifampicin: Rimapen 600-mg tablet; Orion Pharma, Espoo, Finland; itraconazole: 
Sporanox 100-mg capsule; Janssen-Cilag, Borgo San Michele, Italy) and matched 
placebos were also supplied, packed, and labelled according to a randomization list for 
each participant by the Pharmacy of Helsinki University Central Hospital. Grapefruit 
juice (Valio Greippitäysmehu; Valio, Helsinki, Finland), orange juice (Valio 
Appelsiinitäysmehu; Valio, Helsinki, Finland), and apple juice (Valio Omenatäysmehu; 
Valio, Helsinki, Finland) were purchased from local grocery stores and picked from the 
same production batch whenever possible (Table 8). 200-ml doses of juice, taken 
unsupervised at home, were bottled beforehand by the researchers. The randomization 
for Studies III and IV was done by the researchers. 
 
On the study days, following at least an 8-hour overnight fast, the participants ingested 
a single 150-mg oral dose of aliskiren with 150 ml of water (Studies I, II, V, and VI) or 
with 200 ml of water or study juice (Studies III and IV) at 08:00 (Studies I and III-VI) 
or at 09:00 (Study II). A standardized warm meal was served 4 hours after the 
administration of aliskiren, and a standardized light meal after 7 hours and 10 hours. 
The participants were under direct medical supervision for 12 hours after the 
administration of aliskiren. Fluids for intravenous infusion were available for immediate 
use in the event of hypotension, but were not needed. 
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Table 7. Structure of the pharmacokinetic interaction studies. 
Study no. Pretreatment medication / juice Administration of       
a single 150-mg dose 
of aliskiren 
Washout 
period 
(weeks) 
I 600 mg of rifampicin or placebo once 
daily at 20:00 for 5 days 
On day 6 at 08:00 4 
II 100 mg of itraconazole (first dose      
200 mg) or placebo twice daily at 09:00 
(on day 3 at 08:00) and 21:00 for 5 days 
On day 3 at 09:00 4 
III 200 ml of grapefruit juice or water three 
times a day at 08:00, 12:00, and 20:00 
for 5 days 
On day 3 at 08:00 2 
IV 200 ml of orange juice, apple juice, or 
water three times a day at 08:00, 12:00, 
and 20:00 for 5 days 
On day 3 at 08:00 2 
 
 
Table 8. Characteristics of the fruit juices investigated. 
Nutritional value    
/100 g 
Grapefruit juice Orange juice Apple juice 
pH 3.3 3.8 3.6 
Carbohydrates 8 g 9 g 10 g 
    Sucrose ~ 1.8 g
* 
~ 3.6 g
* 
~ 1.4 g
*
 
    Fructose ~ 3.4 g
* 
~ 2.7 g
* 
~ 5.7 g
*
 
    Glucose ~ 2.8 g
* 
~ 2.7 g
*
 ~ 2.9 g
*
 
Organic acids 0.3 g
* 
0.6 g
*
 0.4 g
*
 
Proteins < 1 g < 1 g < 1 g 
Fibre < 1 g < 1 g < 1 g 
Data are from the producer, except for values indicated with an asterisk, which are from Fineli 
2010. 
 
 
3. Blood and urine sampling and blood pressure measurements 
 
On the days of administration of aliskiren, a forearm vein of each participant was 
cannulated for blood sampling. Timed blood samples for drug concentration 
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measurements (5 or 10 ml each) were drawn prior to and 0.5, 1, 2, 3, 4, 5, 7, 9, 12, 24, 
34, 48, and 72 hours after aliskiren administration into tubes containing EDTA. Blood 
samples for the determination of plasma renin activity (5 ml each) were drawn before 
the administration of aliskiren and 4 hours and 24 hours thereafter into chilled EDTA 
tubes, which were placed on ice immediately after sampling, except in Study III, in 
which the blood samples were kept at room temperature according to the instructions of 
Medix Laboratories (Espoo, Finland). Plasma was separated by centrifugation within 30 
minutes. Urine was collected up to 12 hours after the administration of aliskiren. Urine 
aliquots and plasma were stored at -70ºC until analysis. Sitting systolic and diastolic 
blood pressures, as well as heart rates, were measured twice (mean value used in the 
calculations) from the forearm with an automatic oscillometric blood pressure monitor 
(Omron M5-I; Omron Healthcare Europe BV, Hoofddorp, The Netherlands) prior to 
and 2, 4, 7, 9, 12, and 24 hours after the administration of aliskiren. 
 
 
4. Determination of drug concentrations and renin activity 
 
4.1 Aliskiren 
 
Plasma concentrations of aliskiren were quantified by use of solid-phase extraction and 
liquid chromatography-tandem mass spectrometry (LC/MS/MS) (Waldmeier et al. 
2007). An aliquot of 700 µl of each plasma sample was mixed with 100 µl of 10% 
phosphoric acid and 50 µl of internal standard solution (1000 ng/ml acebutolol in 1:1 
methanol:water). The mixture was then loaded to the extraction cartridge (Oasis MCX 
1cc/30 mg; Waters, Milford, MA, USA), which had been preconditioned with 1 ml of 
methanol and 1 ml of 1% acetic acid. The cartridge was subsequently washed with 1 ml 
of methanol and 1 ml of 1% acetic acid. The analytes were eluted out twice with 0.6 ml 
of 2% ammonium hydroxide in methanol. The eluent was dried at 50°C under a 
nitrogen stream. The residue was dissolved in 100 µl of the mobile phase, and 15 µl of 
the sample was injected into the LC/MS/MS system. The chromatographic separation 
was carried out on an AtlantisT3 column (2.1×100 mm, 3 µm) protected by an 
AtlantisT3 (2.1×10 mm, 3 µm) guard cartridge (Waters). The mobile phase consisted of 
(A) 2 mmol/l ammonium acetate (pH 4.90) and (B) methanol. The total running time 
was 15 minutes with the mobile phase gradient of 0.5 minute at 70% A, from 70 to 5% 
A in 0.5 minute, 3 minutes at 5% A, from 5 to 70% A in 0.1 minute, and 10.9 minutes at 
70% A. The flow rate of the mobile phase was 250 µl/min. The column temperature was 
40°C. Mass spectra were obtained using an Applied Biosystems SCIEX API 2000 Q 
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Trap mass spectrometer operated in positive ion mode (Sciex Division of MDS, 
Toronto, ON, Canada). The ion transitions were mass-to-charge ratio (m/z) 552.4 → m/z 
436.3 for aliskiren and m/z 337.3 to m/z 116.3 for acebutolol. The lower limit of 
quantification of plasma aliskiren was 0.24 ng/ml (Study IV) or 0.25 ng/ml (Studies I-
III, V, and VI), and the between-day CV was 6.1% at 1.8 ng/ml, 4.6% at 18 ng/ml, and 
7.0% at 180 ng/ml (n = 10). The calibration curve for plasma aliskiren was linear over 
the range 0.24-600 ng/ml (r > 0.999, weighting 1/x), and the extraction recoveries were 
over 80%. 
 
For the determination of aliskiren concentrations in urine, an aliquot of 300 µl of each 
urine sample was mixed with 300 µl of fresh frozen plasma, 100 µl of 10% phosphoric 
acid, and 50 µl internal standard solution (1000 ng/ml acebutolol in 1:1 
methanol:water). The extraction, chromatographic separation, and mass spectrometric 
detection were performed as described for plasma aliskiren. The lower limit of 
quantification of urine aliskiren was 9 ng/ml (Studies I-III and V) or 21 ng/ml (Studies 
IV and VI), and the intra-day CV was below 5% at relevant concentrations. The 
calibration curve for urine aliskiren was linear over the range 9-1800 ng/ml (r > 0.999, 
weighting 1/x), and the extraction recoveries were over 80%. 
 
 
4.2 Itraconazole and hydroxyitraconazole 
 
Plasma itraconazole and hydroxyitraconazole concentrations were determined by high-
performance liquid chromatography with fluorescence detection (Dionex Ultimate 3000 
HPLC system and Dionex RF 2000 Fluorescence Detector; Dionex Softron GmbH, 
Germering, Germany), as described previously (Remmel et al. 1988; Allenmark et al. 
1990). The lower limit of quantification was 20 ng/ml for both compounds, and the 
between-day CV was 8.6% at 192 ng/ml and 3.3% at 1200 ng/ml for itraconazole, and 
10.2% at 192 ng/ml and 4.3% at 1200 ng/ml for hydroxyitraconazole (n = 4). 
 
 
4.3 Renin activity 
 
Plasma renin activity was determined by radioimmunoassay of generated angiotensin I 
with a commercially available method (RENCTK; DiaSorin, Saluggia, Italy) at the 
HUSLAB laboratory (Helsinki, Finland) (Studies I, II, and V) or at Medix Laboratories 
(Studies III, IV, and VI). The lower limit of quantification was 0.1 μg/l/h (Studies I, II, 
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and V) or 0.2 μg/l/h (Studies III, IV, and VI). In Studies I, II, and V, the renin activity 
data were multiplied by 1.449 according to earlier HUSLAB practice. 
 
 
5. Pharmacokinetics 
 
In all studies, the pharmacokinetics of aliskiren were characterized by Cmax, time to 
peak concentration (tmax), t½, AUC values from 0 to 72 hours (AUC0-72) and from time 0 
to infinity (AUC0-∞), the amount of unchanged aliskiren excreted into urine from 0 to 12 
hours (Ae), and renal clearance (Clrenal), and also by oral clearance (Cl/F) in Study III. 
The pharmacokinetics of itraconazole and hydroxyitraconazole (Study II) were 
characterized by Cmax and AUC0-13 on day three and the morning trough concentration 
on days 3-6. Pharmacokinetic parameters were calculated by conventional non-
compartmental methods using MK-Model, version 5.0 (Biosoft, Cambridge, UK). The 
terminal log-linear part of each concentration-time curve was identified visually. The 
elimination rate constant (ke) was determined by linear regression analysis of the log-
linear part of the plasma drug concentration-time curve, using a minimum of three data 
points and nominal sampling times. The t½ was calculated by the equation t½ = ln2/ke. 
The AUC values were calculated by a combination of the linear (for increasing 
concentrations) and log-linear (for decreasing concentrations) trapezoidal rules with 
extrapolation to infinity, when appropriate, by division of the last measured 
concentration by ke. The Clrenal of aliskiren was calculated by the equation               
Clrenal = Ae/AUC0-12, and the Cl/F by the equation Cl/F = dose/AUC0-∞. 
 
 
6. Pharmacodynamics 
 
The pharmacodynamics of aliskiren were characterized by estimating plasma renin 
activity at 4 hours and 24 hours after the administration of aliskiren, as well as by 
average sitting systolic and diastolic blood pressures, and heart rate. Average values of 
systolic and diastolic blood pressures and heart rate were calculated by dividing the area 
under the effect-time curve from 0 to 24 hours by 24 hours. 
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7. Statistical analysis 
 
The data were analysed using the statistical program SPSS for Windows, version 16.0, 
17.0, or 19.0 (SPSS, Chicago, IL, USA). Differences were considered significant when 
P < 0.05. In Study I, results are expressed as geometric means with 95% confidence 
intervals (CIs) (Cmax, AUC, Ae, and Clrenal) or means  SDs (t½ and pharmacodynamic 
variables). In Study II, results (except tmax) are expressed as means  SDs. In Study III, 
results are expressed as geometric means with 90% CIs (Cmax, AUC, Cl/F, Ae, and 
Clrenal) or means  SDs (t½, ke, and plasma renin activity). In Study IV, results (except 
tmax) are expressed as geometric means with 95% CIs. In Study V, results are expressed 
as estimated marginal means with 95% CIs adjusting for body weight (Cmax, AUC, and 
Ae) or estimated marginal means with 95% CIs (t½, Clrenal, and plasma renin activity) in 
text and tables, and as weight-adjusted means  standard error of the means (SEM) or 
means  SEMs in figures. In Study VI, results (except tmax) are expressed as geometric 
means with CVs (adjusting Cmax, AUC, and Ae for body weight) in text and tables, and 
as weight-adjusted geometric means with 90% CIs in figures. In all studies, tmax data are 
expressed as medians with ranges. Geometric mean ratios with 90% or 95% CIs or 
mean differences with 95% CIs were calculated for the pharmacokinetic and 
pharmacodynamic variables, except for tmax. Furthermore, to enable comparison, the 
results are also expressed as percentage changes in geometric means in Table 9 and as 
percentage changes in geometric means with 90% CIs in Figures 5-8 (CPT 2010). 
 
In case an individual plasma renin activity value was below the lower limit of 
quantification, it was replaced with zero (Studies I and V) or half of the lower limit of 
quantification (Studies II-IV, VI, and calculations for summarizing report). Logarithmic 
transformation was performed before statistical analysis for Cmax, AUC, Ae, Clrenal, and 
Cl/F data in Studies I-III and V, and for all data, except tmax, in Studies IV and VI. 
 
In pharmacokinetic interaction studies, statistical comparisons of the pharmacokinetic 
(except tmax) and pharmacodynamic variables between phases were carried out using 
repeated-measures analysis of variance (ANOVA) with treatment phase as a within-
subjects factor and treatment sequence as a between-subjects factor (Studies I-III) or 
using repeated-measures ANOVA with a priori pairwise comparisons with the Fisher’s 
Least Significant Difference method (Study IV). In pharmacogenetic studies, statistical 
comparisons of the pharmacokinetic (except tmax) and pharmacodynamic variables 
between participants with the different genotypes were made using ANOVA with a 
priori pairwise comparisons with the Fisher’s Least Significant Difference method, 
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when appropriate (Studies V and VI). Body weight was set as a covariate for Cmax, 
AUC, and Ae (Jarugula et al. 2010). The tmax data were compared using the Wilcoxon 
signed-rank test (Studies I-III), Friedman’s ANOVA with a priori pairwise comparisons 
with the Wilcoxon signed-rank test (Study IV), the Mann-Whitney test (Study V), or the 
Kruskall-Wallis test with a priori pairwise comparisons with the Mann-Whitney U-test 
(Study VI). In Study I, the frequencies of individuals with a double peak in the plasma 
aliskiren concentration-time curve were compared between the phases using 
McNemar’s test. Possible correlations between subject characteristics and 
pharmacokinetic variables and between pharmacokinetic and pharmacodynamic 
variables and their changes were investigated with the Pearson correlation coefficient 
(Studies I, II, and IV). 
 
 
8. Ethical considerations 
 
The study protocols were approved by the Coordinating Ethics Committee of the 
Helsinki and Uusimaa Hospital District, and the National Agency for Medicines in 
Finland. All participants received both oral and written information and gave written 
informed consent before they were enrolled in the studies. 
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RESULTS 
 
 
1. Effects of rifampicin on the pharmacokinetics and 
pharmacodynamics of aliskiren (Study I) 
 
Rifampicin markedly reduced the plasma concentrations of aliskiren (Figure 5, Table 9). 
Aliskiren Cmax was reduced by 39% (effect on Cmax ranged from a 78% decrease to a 
9% increase, P = 0.017), AUC0-∞ by 56% (range, 20-76%, P < 0.001), and Ae by 48% 
(effect on Ae ranged from a 73% decrease to a 4% increase, P = 0.001) by rifampicin. 
Rifampicin had no significant effect on the tmax, t½, or Clrenal of aliskiren. The plasma 
aliskiren concentration-time curve showed a double peak in 11 out of 12 participants 
during the placebo phase and in 6 out of 12 participants during the rifampicin phase    
(P = 0.063). None of the pharmacokinetic variables of aliskiren correlated with subject's 
body weight during either the placebo or the rifampicin phase (r < 0.38, P > 0.23). 
 
The reduction in plasma aliskiren concentrations resulted also in attenuation of the 
renin-inhibiting effect of aliskiren (Figure 5, Table 9). Plasma renin activity 24 hours 
after aliskiren ingestion was 61% higher during the rifampicin phase than during the 
placebo phase (P = 0.008). No significant differences existed in blood pressure or heart 
rate between the rifampicin and placebo phases. 
 
 
 
Figure 5. Effects of rifampicin on the Cmax, AUC0-∞, t½, and renin-inhibiting effect of aliskiren. 
Bars represent percentage changes in geometric means with 90% confidence intervals. 
* P < 0.05 compared with placebo phase. 
** P < 0.001 compared with placebo phase. 
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2. Effects of itraconazole on the pharmacokinetics and 
pharmacodynamics of aliskiren (Study II) 
 
Itraconazole markedly raised the plasma concentrations of aliskiren (Figure 6, Table 9). 
Aliskiren Cmax was raised 5.8-fold (range, 1.1-24.3-fold, P < 0.001) and AUC0-∞ 6.5-
fold (range, 2.6-20.5-fold, P < 0.001) by itraconazole. The Cmax of aliskiren occurred 
later during the itraconazole phase (median, 4 hours) than during the placebo phase 
(median, 1 hour) (P = 0.006). Itraconazole had no significant effect on the t½ of 
aliskiren. The Ae of aliskiren was increased 8.0-fold (range, 3.6-19.9-fold, P < 0.001) 
and its Clrenal 1.2-fold (effect on Clrenal ranged from a 21% decrease to a 74% increase,  
P = 0.042). 
 
In agreement with the effects of itraconazole on the pharmacokinetics of aliskiren, the 
renin-inhibiting effect of aliskiren was also enhanced by itraconazole (Figure 6, Table 
9). Plasma renin activity 24 hours after aliskiren intake was 68% lower during the 
itraconazole phase than during the placebo phase (P = 0.011). No significant difference 
existed in blood pressure or heart rate between the itraconazole and placebo. 
 
The Cmax and AUC0-13 of itraconazole on day three were 275  85 ng/ml and 2355  631 
ng•h/ml, respectively, and those of hydroxyitraconazole were 619  122 ng/ml and  
6964  1385 ng•h/ml, respectively. The Cmax and AUC0-13 of itraconazole and 
hydroxyitraconazole showed no significant correlation with the relative increase in the 
Cmax or AUC0-∞ of aliskiren (r < 0.52, P > 0.10). 
 
 
 
Figure 6. Effects of itraconazole on the Cmax, AUC0-∞, t½, and renin-inhibiting effect of 
aliskiren. Bars represent percentage changes in geometric means with 90% confidence intervals. 
** P < 0.001 compared with placebo phase. 
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3. Effects of grapefruit juice, orange juice, and apple juice on the 
pharmacokinetics and pharmacodynamics of aliskiren (Studies III and 
IV) 
 
Three glasses a day of normal-strength grapefruit juice, orange juice, or apple juice for 
five days greatly reduced the plasma concentrations of aliskiren (Figure 7, Table 9). 
Grapefruit juice reduced aliskiren Cmax by 81% (range, 42-91%, P < 0.001), AUC0-∞ by 
61% (range, 15-72%, P < 0.001), and Ae by 66% (range, 6-81%, P < 0.001). Orange 
juice reduced aliskiren Cmax by 80% (effect on Cmax ranged from a 95% decrease to a 
24% increase, P < 0.001), AUC0-∞ by 62% (range, 9-87%, P < 0.001), and Ae by 67% 
(range, 32-87%, P < 0.001). Apple juice reduced aliskiren Cmax by 84% (range, 2-96%, 
P < 0.001), AUC0-∞ by 63% (range, 13-87%, P < 0.001), and Ae by 69% (range, 14-
87%, P < 0.001). The Cmax of aliskiren occurred later during the grapefruit juice phase 
(median, 1 hour) than during the water phase (median, 0.5 hour) (P = 0.016), and the t½ 
of aliskiren was shortened from 26.1 to 23.6 hours by grapefruit juice (P = 0.020). 
Grapefruit juice had no significant effect on the Clrenal of aliskiren. Neither orange juice 
nor apple juice had an effect on the tmax, t½, or Clrenal of aliskiren. 
 
In Study III, aliskiren AUC0-∞ values varied 6.1-fold and 5.8-fold between individual 
participants during the water and grapefruit juice phases, respectively. In Study IV, 
aliskiren AUC0-∞ values varied 7.9-fold, 4.0-fold, and 4.2-fold between individual 
participants during the water, orange juice, and apple juice phases, respectively, and the 
changes in aliskiren AUC0-∞ by orange juice and apple juice correlated with each other, 
and with the AUC0-∞ of aliskiren during the water phase (r = 0.98, P < 0.001 for all 
pairs). 
 
No significant differences existed in plasma renin activity between the grapefruit juice 
and water phases (Figure 8, Table 9). Orange juice and apple juice significantly reduced 
the renin-inhibiting effect of aliskiren. Plasma renin activity 4 hours and 24 hours after 
aliskiren administration was 63% (P = 0.023) and 87% (P = 0.037) higher, respectively, 
during the orange juice phase than during the water phase. During the apple juice phase 
plasma renin activity was 67% higher 24 hours after aliskiren administration than 
during the water phase (P = 0.036). Moreover, in Study IV, during the water phase the 
plasma aliskiren concentration at 24 hours correlated significantly with the plasma renin 
activity at 24 hours (r = -0.615, P = 0.033), and the relative change in plasma aliskiren 
concentration at 24 hours by orange juice or apple juice correlated with the 
corresponding relative change in plasma renin activity (orange juice: r = -0.580, P = 
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0.048; apple juice: r = -0.716, P = 0.009). No significant differences in blood pressure 
or heart rate were observed between the phases in either of these studies. 
 
In Study IV, no obvious differences were seen in the pharmacokinetics of aliskiren 
between participants with different SLCO2B1 genotypes, but the number of individuals 
with different genotypes was too small to draw any conclusions. 
 
 
 
Figure 7. Effects of grapefruit juice (GFJ), orange juice (OJ), and apple juice (AJ) on the Cmax, 
AUC0-∞, and t½ of aliskiren. Bars represent percentage changes in geometric means with 90% 
confidence intervals. 
* P < 0.05 compared with water phase. 
** P < 0.001 compared with water phase. 
 
 
 
Figure 8. Effects of grapefruit juice (GFJ), orange juice (OJ), and apple juice (AJ) on the 
renin-inhibiting effect of aliskiren. Bars represent percentage changes in geometric means with 
90% confidence intervals. 
* P < 0.05 compared with water phase. 
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4. Effects of the ABCB1 haplotypes on the pharmacokinetics and 
pharmacodynamics of aliskiren (Study V) 
 
The ABCB1 haplotypes were not significantly associated with the pharmacokinetics or 
pharmacodynamics of aliskiren. The geometric mean ratios (95% CI) of aliskiren Cmax 
and AUC0-∞ in participants homozygous for the ABCB1 c.1236T-c.2677T-c.3435T 
haplotype to those in participants homozygous for the c.1236C-c.2677G-c.3435C 
haplotype were 1.14 (0.66, 1.96; P = 0.631) and 1.01 (0.58, 1.76; P = 0.960), 
respectively. As a post-hoc analysis, fractional AUC values (AUC0-1, AUC0-2, AUC0-3, 
AUC0-4, and AUC0-5) were also calculated for aliskiren, but no tendency for a difference 
between the genotype groups was observed in these values (P > 0.3, data not shown). 
Aliskiren Cmax, AUC0–∞, Ae, and Clrenal varied 14.1-, 16.2-, 10.4-, and 3.1-fold, 
respectively, between individual participants. 
 
 
5. Effects of the SLCO2B1 c.935G>A SNP on the pharmacokinetics and 
pharmacodynamics of aliskiren (Study VI) 
 
The SLCO2B1 c.935G>A SNP had no significant effect on the pharmacokinetics or 
pharmacodynamics of aliskiren. The geometric mean ratios (90% CI) of aliskiren Cmax 
in participants with the SLCO2B1 c.935GA or c.935AA genotype to those with the 
c.935GG genotype were 1.11 (0.78, 1.60) and 1.47 (0.91, 2.39), respectively (ANOVA 
P = 0.408), and the corresponding geometric mean ratios (90% CI) of aliskiren AUC0-∞ 
were 0.98 (0.74, 1.30) and 1.24 (0.85, 1.80) (ANOVA P = 0.576). Aliskiren Cmax, 
AUC0-∞, Ae, and Clrenal varied 8.8-, 5.0-, 6.0-, and 4.2-fold, respectively, between 
individual participants. 
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6. Summary 
 
Rifampicin, grapefruit juice, orange juice, and apple juice markedly reduced the plasma 
concentrations of aliskiren. Grapefruit juice also slightly shortened the t½ of aliskiren. 
The reduction in aliskiren exposure by rifampicin, orange juice, and apple juice resulted 
in attenuation of the renin-inhibiting effect of aliskiren. Itraconazole greatly raised the 
plasma concentrations of aliskiren, with no effect on t½, and, consistent with increased 
exposure, enhanced the renin-inhibiting effect of aliskiren. The results of the 
pharmacokinetic interaction studies with aliskiren are summarized in Table 9. 
 
The ABCB1 c.1236C-c.2677G-c.3435C and c.1236T-c.2677T-c.3435T haplotypes as 
well as the SLCO2B1 c.935G>A SNP were not significantly associated with the 
pharmacokinetics or pharmacodynamics of aliskiren. 
 
Table 9. Results of the pharmacokinetic interaction studies with aliskiren. 
Pretreatment medication / 
juice 
Effect on aliskiren 
pharmacokinetics 
Effect on aliskiren 
pharmacodynamics 
Rifampicin Cmax 39% ↓ 
* 
AUC 56% ↓ ** 
t½  
Renin activity 
at 4 hours  
at 24 hours 117% ↑ * 
Itraconazole Cmax 481% ↑ 
** 
AUC 554% ↑ ** 
t½  
Renin activity 
at 4 hours  
at 24 hours 72% ↓ ** 
Grapefruit juice Cmax 81% ↓ 
**
 
AUC 61% ↓ ** 
t½ 10% ↓ 
* 
Renin activity 
at 4 hours  
at 24 hours  
Orange juice Cmax 80% ↓ 
** 
AUC 62% ↓ ** 
t½  
Renin activity 
at 4 hours 63% ↑ * 
at 24 hours 87% ↑ * 
Apple juice Cmax 84% ↓ 
** 
AUC 63% ↓ ** 
t½  
Renin activity 
at 4 hours  
at 24 hours 67% ↑ * 
Data are given as percentage change in geometric means. Therefore, the results may slightly 
differ from those presented in the text. 
*
 P < 0.05 compared with placebo/water phase. 
**
 P < 0.001 compared with placebo/water phase. 
 No statistically significant difference. 
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DISCUSSION 
 
 
1. Methodological considerations 
 
These studies investigated the pharmacokinetic interactions and pharmacogenetic 
factors affecting the pharmacokinetics and pharmacodynamics of aliskiren. All six 
studies were carried out with healthy, relatively young (20-37 years) volunteers to 
minimize possible confounding factors such as chronic diseases or long-term 
medication. Based on the variation in the AUC of aliskiren in previous studies, the 
number of participants for each study was estimated to be sufficient to detect possible 
clinically meaningful differences in the AUC of aliskiren between phases or groups, 
while avoiding unnecessary exposure of healthy volunteers to drugs. The 
pharmacokinetics of aliskiren has been shown to be similar in normotensive and 
hypertensive individuals (Vaidyanathan et al. 2008c; EMA 2012), making it possible to 
extrapolate the pharmacokinetic data from these studies to patient populations. 
However, hypertensive patients may exhibit characteristics that increase the extent of 
the interactions. 
 
The pharmacokinetic interaction studies (I-IV) were placebo- or water-controlled, 
randomized cross-over studies with washout periods of 2-4 weeks. The cross-over 
design was used to minimize variation and to reduce sample size, as participants served 
as their own controls. Balanced randomization and adequate washout periods minimized 
the risk of a possible carry-over effect. The pharmacogenetic studies (V and VI) were 
prospective genotype panel studies. In these studies, no significant differences in age, 
height, or weight were observed between groups. Furthermore, the pharmacokinetic 
variables were adjusted for body weight, when appropriate (Jarugula et al. 2010). To 
reduce further variation in all studies, restrictions were imposed concerning the use of 
drugs, alcohol, and certain fruit juices and fruits before and during the studies. To 
minimize variability due to the food effect, aliskiren was administered after an 
overnight fast and food intake during the study days was standardized and controlled. 
 
In all studies, aliskiren was administered at the lowest recommended dose (150 mg). In 
previous studies with healthy volunteers, once-daily doses of up to 640 mg have been 
well tolerated (Nussberger et al. 2002). In addition, in an interaction study with the P-gp 
and CYP3A4 inhibitor ketoconazole, aliskiren was well tolerated at a dose of 300 mg 
once daily for several days (Vaidyanathan et al. 2008b). 
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In clinical practice, aliskiren is administered on a regular basis. In these studies, a single 
dose, instead of multiple dosing, was chosen for safety and practical reasons. The 
single-dose study design enabled the participants to be kept under medical supervision 
and their blood pressure to be monitored during the greatest exposure to aliskiren (the 
first 12 hours after the administration). A single dose of aliskiren was considered safe 
because it is not expected to have a marked effect on blood pressure in healthy subjects, 
although the response in renin activity is detectable already 30 minutes after aliskiren 
ingestion (Nussberger et al. 2002). According to pharmacokinetic theory, the AUC0-∞ 
after a single dose is equal to the dose-interval AUC at steady state (Rowland and Tozer 
2011). However, the pharmacokinetics of aliskiren is slightly non-linear (Vaidyanathan 
et al. 2008c), potentially interfering with the direct extrapolation of the results from the 
single-dose studies to the steady state. 
 
The sampling schedule was selected to cover the plasma concentration-time curve 
sufficiently long to provide a reliable estimate of the extent of exposure. According to 
the guidelines for bioequivalence studies, this is achieved if AUC0-t covers at least 80% 
of AUC0-∞ (EMA 2010a). In all of these studies, AUC0-72 covered at least 82% of  
AUC0-∞. Urine was collected only during the time spent at the Clinical Research Unit to 
ensure compliance. 
 
Rifampicin is widely used and recommended as a model inducer of drug-metabolizing 
enzymes and transporters in pharmacokinetic drug interaction studies in humans (FDA 
2012). Because the induction by rifampicin requires the synthesis of new enzyme or 
transporter protein, it takes about one week to achieve maximal induction (Fromm et al. 
1996; Niemi et al. 2003). Baseline activity returns two weeks after discontinuing 
rifampicin. Thus, in Study I, with the administration of rifampicin for five days, nearly 
maximal induction of intestinal CYP3A4 and P-gp was attained. To avoid the possible 
competitive inhibitory effect of rifampicin (Vavricka et al. 2002; Kajosaari et al. 
2005a), the last dose of rifampicin was administered 12 hours before aliskiren ingestion. 
 
Itraconazole is recommended as an inhibitor in drug interaction studies involving 
substrates of CYP3A4 and P-gp (FDA 2012). Inhibition by itraconazole is dependent on 
its plasma concentrations (Back and Tjia 1991; Jurima-Romet et al. 1994; Neuvonen et 
al. 1996; Olkkola et al. 1996; von Moltke et al. 1996a). In Study II, after a loading dose 
on day one, the administration of itraconazole for five days was sufficient to achieve 
nearly maximal inhibition of CYP3A4 and P-gp, thus revealing a potentially clinically 
important pharmacokinetic interaction. This dosing regimen was also used to ensure the 
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tissue distribution of itraconazole to achieve a systemic effect in addition to the effect at 
the intestinal level. The timing of administration of itraconazole (one hour before 
aliskiren) was chosen to ensure its adequate absorption before aliskiren ingestion. 
 
In Study III, a 5-day regimen of grapefruit juice three times daily was used to ensure 
nearly maximal inhibition of CYP3A4. Ingestion of aliskiren on day three corresponded 
to the clinical situation in which subjects consume grapefruit juice daily. Because 
aliskiren has a long t½ and is known to undergo enterohepatic circulation, the 
administration of grapefruit juice was continued after aliskiren ingestion to investigate 
the effect of grapefruit juice on the elimination of aliskiren. For comparison, the same 
protocol was used in Study IV with orange and apple juices. 
 
Compliance with pretreatment drugs and juices in pharmacokinetic interaction studies 
was assessed by records of participants in their pretreatment diaries. Furthermore, in 
Study II, the concentrations of itraconazole and hydroxyitraconazole were measured on 
study days. 
 
The common synonymous ABCB1 c.3435C>T SNP, forming a part of the haplotype 
investigated in Study V, has been variably associated with reduced expression and 
function of P-gp in vitro and increased plasma concentrations of P-gp substrate drugs in 
vivo (Hoffmeyer et al. 2000; Kimchi-Sarfaty et al. 2007; Keskitalo et al. 2008). 
However, the mechanism underlying these associations is not completely understood. 
Because the ABCB1 c.3435C>T SNP is in strong linkage disequilibrium with the 
c.1236C>T (synonymous) and c.2677G>T/A (p.Ala893Ser/Thr) SNPs within the same 
gene (Kim et al. 2001; Kroetz et al. 2003; Keskitalo et al. 2008), we chose to study the 
two most common haplotypes in the Finnish population based on these SNPs (Keskitalo 
et al. 2008), instead of a single variant allele. In addition, these haplotypes have affected 
the pharmacokinetics of simvastatin (acid) and atorvastatin in the Finnish population 
(Keskitalo et al. 2008). Only non-carriers of the ABCB1 c.1199A and CYP3A5 g.6986A 
(CYP3A5 expressor) alleles were included in the study to exclude other polymorphisms 
possibly affecting the pharmacokinetics of aliskiren. 
 
The SLCO2B1 c.935G>A SNP, investigated in Study VI, was selected based on a 
previous study in which it had been associated with reduced plasma concentrations of 
and impaired response to montelukast in patients with asthma (Mougey et al. 2009). In 
the Finnish population, the frequency of this variant allele is 13.6% (Laitinen and Niemi 
2011). 
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2. Effects of rifampicin on the pharmacokinetics and 
pharmacodynamics of aliskiren (Study I) 
 
In Study I, rifampicin reduced aliskiren Cmax, AUC0-∞, and Ae by 39%, 56%, and 48%, 
respectively. In line with the reduced exposure to aliskiren, plasma renin activity 24 
hours after aliskiren administration was 61% higher during the rifampicin phase than 
during the placebo phase. Decreased Cmax, AUC0-∞, and Ae of aliskiren, without a 
change in t½ and Clrenal, are consistent with increased first-pass elimination of aliskiren 
with no or minimal effect on its systemic clearance. 
 
Aliskiren is a substrate of P-gp and is slightly metabolized by CYP3A4 (Waldmeier et 
al. 2007; Vaidyanathan et al. 2008b), both of which are induced by rifampicin 
(Combalbert et al. 1989; Kolars et al. 1992; Backman et al. 1996a; Schuetz et al. 1996; 
Greiner et al. 1999). Because aliskiren has a low hepatic extraction ratio (0.10) (Azizi et 
al. 2006) and its t½ was not shortened by rifampicin, it is unlikely that induction of its 
hepatic elimination would explain this interaction. Furthermore, the incidence of double 
peaks in the plasma aliskiren concentration-time curve, a characteristic of enterohepatic 
circulation, appeared to diminish during the rifampicin phase compared with the 
placebo phase. This finding could be explained by reduced intestinal reabsorption of 
aliskiren due to induction of intestinal P-gp and CYP3A4. Thus, the interaction between 
rifampicin and aliskiren most likely occurred as a result of induction of P-gp-mediated 
efflux and CYP3A4-catalysed metabolism of aliskiren in the small intestine. It is 
noteworthy that intestinal P-gp and CYP3A4 act synergistically to reduce the oral 
bioavailability of their joint substrates (Kivistö et al. 2004). 
 
Similarly to rifampicin, a high-fat meal can reduce the AUC of aliskiren by about 70% 
(Vaidyanathan et al. 2008c). To minimize variability due to the food effect, aliskiren is 
recommended to be taken with a light meal or on a regular schedule with regard to 
meals (EMA 2012; Novartis 2012). No published studies exist on the interactions of 
aliskiren with other dual inducers of P-gp and CYP3A4 such as phenytoin or St. John's 
wort (Rameis 1985; Backman et al. 1996b; Johne et al. 1999; Wang et al. 2001). Based 
on the results of Study I, these other inducers might also reduce the concentrations and 
effects of aliskiren. 
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3. Effects of itraconazole on the pharmacokinetics and 
pharmacodynamics of aliskiren (Study II) 
 
In Study II, itraconazole raised the Cmax, AUC0-∞, and Ae of aliskiren 5.8-, 6.5-, and 8.0-
fold, respectively, and also considerably enhanced the renin-inhibiting effect of 
aliskiren. The unaffected t½ of aliskiren indicates that the interaction occurred mainly 
during the first-pass phase. This is also supported by the finding that the extent of the 
interaction did not correlate with the systemic (plasma) concentrations of itraconazole 
and hydroxyitraconazole. 
 
Itraconazole is a potent inhibitor of P-gp and CYP3A4 (Jurima-Romet et al. 1994; 
Olkkola et al. 1994; Jalava et al. 1997b; Wang et al. 2002). Because aliskiren has a low 
hepatic extraction ratio and is eliminated mainly unchanged (Azizi et al. 2006; 
Waldmeier et al. 2007), the mechanism of this interaction is probably inhibition of P-gp 
in the small intestine. Inhibition of the CYP3A4-catalysed metabolism of aliskiren by 
itraconazole may, however, also contribute to the interaction. In a previous study, 
itraconazole reduced the Clrenal of digoxin by 20% by inhibiting P-gp in renal tubule 
cells (Jalava et al. 1997b). The minor increase in the Clrenal of aliskiren by itraconazole, 
seen in this study, probably results from other mechanisms such as saturation of 
reuptake systems in the kidneys due to a high aliskiren concentration. 
 
The interaction between itraconazole and aliskiren was much stronger (6.5-fold increase 
in aliskiren AUC) than previously described between the other azole antifungal agent 
ketoconazole and aliskiren (76% increase in aliskiren AUC) (Vaidyanathan et al. 
2008b). Itraconazole and ketoconazole are similarly potent inhibitors of P-gp (IC50        
2 μmol/l and 6 μmol/l, respectively) and CYP3A4 (Ki 0.27-11 μmol/l and 0.0037-       
10 μmol/l, respectively) in vitro (Back and Tjia 1991; Jurima-Romet et al. 1994; von 
Moltke et al. 1996a; von Moltke et al. 1996b; Venkatakrishnan et al. 2000; Wang et al. 
2002), and their effects on P-gp and CYP3A4 activity have also been quite similar in 
vivo (Olkkola et al. 1994; Shon et al. 2005; Sanofi-Aventis 2007). One explanation for 
the different effects of itraconazole and ketoconazole on the pharmacokinetics of 
aliskiren could be the non-optimal dosage of ketoconazole in the previous study (200 
mg twice daily). Because the interaction between ketoconazole and aliskiren probably 
occurred at the intestinal level (Vaidyanathan et al. 2008b), the 400 mg of ketoconazole 
once daily could have produced a larger interaction (Zhao et al. 2009). On the other 
hand, several active metabolites and the long t½ of itraconazole relative to ketoconazole, 
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as well as their different tissue distributions, could explain the differences in extent of 
the interaction. 
 
Another dual inhibitor of P-gp and CYP3A4, verapamil, has raised the AUC of aliskiren 
2-fold (Rebello et al. 2011b). Furthermore, the concomitant administration of 
cyclosporine with a small (75-mg) dose of aliskiren has raised the AUC of aliskiren 5-
fold (Rebello et al. 2011a). In contrast to itraconazole, cyclosporine has also prolonged 
the t½ of aliskiren. 
 
 
4. Effects of grapefruit juice, orange juice, and apple juice on the 
pharmacokinetics and pharmacodynamics of aliskiren (Studies III and 
IV) 
 
Studies III and IV demonstrated that the intake of grapefruit juice, orange juice, or apple 
juice three times a day can markedly reduce the plasma concentrations of aliskiren. The 
reduction in plasma aliskiren concentrations by orange and apple juices also resulted in 
attenuation of the renin-inhibiting effect of aliskiren, whereas grapefruit juice had no 
significant effect on the renin activity response to aliskiren. 
 
Grapefruit juice, orange juice, and apple juice decreased the Cmax, AUC, and Ae of 
aliskiren, without affecting its Clrenal, consistent with a reduction in oral bioavailability. 
In previous studies, these juices have decreased the oral bioavailabilities of some 
substrates of intestinal OATPs such as fexofenadine (Dresser et al. 2002a; Bailey 2010). 
In addition, certain constituents of these juices have been found to inhibit OATP2B1 
and/or OATP1A2 in vitro (Dresser et al. 2002a; Satoh et al. 2005; Fuchikami et al. 
2006; Bailey et al. 2007; Mandery et al. 2010). Aliskiren has been shown to be a 
substrate of OATP2B1, with a Km of 72 μmol/l (Vaidyanathan et al. 2008b), and more 
recently, a substrate of OATP1A2 (Km could not be estimated at concentrations of up to 
50 μmol/l) (Rebello et al. 2011c). Therefore, inhibition of OATP2B1- and/or 
OATP1A2-mediated absorption of aliskiren from gut lumen by grapefruit, orange, and 
apple juices probably mainly explains the interactions seen in Studies III and IV. This is 
supported by the finding that orange juice and apple juice had no effect on the t½ of 
aliskiren. Grapefruit juice, by contrast, slightly shortened aliskiren t½. In previous 
studies, repeated consumption of grapefruit juice has had the opposite (slightly 
prolonging) effect on the t½ of some CYP3A4 substrate drugs (Lilja et al. 1998b; 
Kivistö et al. 1999; Lilja et al. 1999; Lilja et al. 2000a; Veronese et al. 2003; Nieminen 
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et al. 2010). The shortened t½ seen in Study III may have resulted from inhibition of the 
reabsorption of aliskiren during enterohepatic circulation. Moreover, the tmax of aliskiren 
was extended during the grapefruit juice phase, consistent with delayed absorption. 
 
To our knowledge, Studies III and IV were the first to suggest that grapefruit juice, 
orange juice, and apple juice may be clinically important inhibitors of OATP2B1, 
although inhibition of OATP1A2 may also have contributed to these interactions. The 
results of Study III contradicted the findings of previous studies in which grapefruit 
juice increased the AUC of the OATP2B1 substrates atorvastatin (2.5-fold) and 
amiodarone (1.5-fold) (Lilja et al. 1999; Libersa et al. 2000; Grube et al. 2006; Seki et 
al. 2009). Both atorvastatin and amiodarone are, however, significantly metabolized by 
CYP3A4 (Libersa et al. 2000; Neuvonen et al. 2006), and the inhibition of intestinal 
CYP3A4 by grapefruit juice probably mainly explains these interactions. Moreover, 
grapefruit juice has had no significant effect on the pharmacokinetics of the OATP2B1 
substrates glibenclamide and pravastatin (Lilja et al. 1999; Nozawa et al. 2004; Satoh et 
al. 2005; Lilja et al. 2007), suggesting that OATP2B1 is not important for the intestinal 
absorption of these drugs. 
 
Several constituents of fruit juices have been screened for inhibitory effects on intestinal 
OATP transporters. However, the prediction of in vivo pharmacokinetic interactions 
from in vitro data is challenging because flavonoids in these juices are usually found as 
glycoside conjugates that require hydrolysis to active aglycones in vivo (Erlund et al. 
2001; Walle 2004; Walle et al. 2005). Naringin is considered to be the major constituent 
of grapefruit juice responsible for inhibition of OATP1A2 in vivo (Bailey et al. 2007), 
and it could also play an important role in the inhibition of OATP2B1 in vivo. In 
addition, naringin and its aglycone form naringenin, as well as quercetin, bergamottin, 
and 6’,7’-dihydroxybergamottin, all occurring in grapefruit juice, have inhibited 
OATP2B1 in vitro (Satoh et al. 2005). The major flavonoid in orange juice, hesperidin, 
has inhibited OATP1A2 in vitro (Bailey et al. 2007), but it is not known whether it also 
inhibits OATP2B1. However, tangeritin and nobiletin, also found in orange juice, have 
been shown to have an inhibitory effect on OATP2B1 (Satoh et al. 2005). Possible 
OATP2B1- and/or OATP1A2-inhibiting flavonoids in apple juice include epicatechin, 
quercetin, and kaempferol (Fuchikami et al. 2006; Mandery et al. 2010). 
 
In addition to the direct inhibition of OATP2B1 and/or OATP1A2 by fruit juice 
constituents, other theoretical mechanisms of interaction may be suggested. These 
include formation of insoluble complexes between fruit juice constituents and aliskiren, 
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increased ionization of aliskiren because of an alteration in intestinal pH by organic 
acids, an increase in intestinal fluid volume by an osmotic effect of carbohydrates that 
could decrease the intestinal aliskiren concentration, or delayed gastric emptying caused 
by carbohydrates. Further studies are required to clarify the exact mechanisms of the 
pharmacokinetic interactions between fruit juices and aliskiren. 
 
As evidenced by a previous study with fexofenadine, the duration of the inhibitory 
effect of grapefruit juice on OATP1A2 is more than 2 hours but less than 4 hours 
(Glaeser et al. 2007). Furthermore, a concomitantly ingested single dose of grapefruit 
juice has decreased talinolol exposure to a similar extent as grapefruit juice ingested 
three times daily for six days (Schwarz et al. 2005). Thus, it appears possible that 
ingestion of only a single 200-ml dose of grapefruit, orange, or apple juice 
concomitantly with or a few hours before has a similar effect on the exposure to 
aliskiren as ingestion of 200 ml three times daily. 
 
 
5. Lack of effect of the ABCB1 haplotypes and the SLCO2B1 c.935G>A 
SNP on the pharmacokinetics and pharmacodynamics of aliskiren 
(Studies V and VI) 
 
In Studies V and VI, no pharmacogenetic explanation for the high interindividual 
variability seen in aliskiren pharmacokinetics was found, as neither the ABCB1 
c.1236C-c.2677G-c.3435C and c.1236T-c.2677T-c.3435T haplotypes nor the SLCO2B1 
c.935G>A SNP were associated with altered pharmacokinetics or pharmacodynamics of 
aliskiren. Study V had a sufficient power to detect a 50% difference in the AUC0-∞ of 
aliskiren between ABCB1 genotype groups, and in Study VI, the power was sufficient to 
detect a 50% higher or 33% lower difference in the AUC0-∞ of aliskiren between the 
SLCO2B1 c.935GA and c.935GG groups and a 100% higher or 50% lower difference 
between the c.935AA and c.935GG groups. Thus, a small difference cannot be ruled 
out. However, the mean AUC0–∞ values of aliskiren were almost identical in the 
genotype groups in both studies. 
 
The lack of effect of these genetic variants does not indicate that P-gp or OATP2B1 is 
not otherwise important for aliskiren pharmacokinetics. Based on in vitro studies, 
aliskiren is a substrate of P-gp (Km 2.1 μmol/l) and OATP2B1 (Km 72 μmol/l) 
(Vaidyanathan et al. 2008b). The importance of P-gp has also been demonstrated in 
vivo, e.g. in Studies I and II, in which both the induction and inhibition of P-gp 
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markedly affected the pharmacokinetics of aliskiren. In Studies III and IV, the 
OATP2B1- and OATP1A2-inhibiting fruit juices greatly reduced the exposure to 
aliskiren, supporting important roles of these transporters in aliskiren pharmacokinetics. 
 
In previous studies, ABCB1 genotypes have explained only a fraction of the variability 
in P-gp expression (Hoffmeyer et al. 2000). In addition, the findings from many studies 
on the effect of ABCB1 polymorphisms on drug pharmacokinetics have not been 
consistently reproduced (Chinn and Kroetz 2007; Giacomini et al. 2010). For instance, 
the results from studies investigating the effects of the ABCB1 c.3435C>T SNP on the 
pharmacokinetics of digoxin have been conflicting, with a meta-analysis suggesting no 
effect at all (Greiner et al. 1999; Hoffmeyer et al. 2000; Sakaeda et al. 2001; Johne et al. 
2002; Verstuyft et al. 2003; Chowbay et al. 2005). Moreover, the effect of ABCB1 
haplotypes has been modest. In a previous study, the differences in the AUC values of 
simvastatin (acid) and atorvastatin were 60% and 55%, respectively, between the 
ABCB1 TTT/TTT and CGC/CGC genotype groups (Keskitalo et al. 2008). It has been 
suggested that the ABCB1 c.3435C>T SNP, or its combination with the c.1236C>T or 
c.2677G>T/A SNP, may alter the substrate specificity of P-gp (Kimchi-Sarfaty et al. 
2007). Therefore, the effect of the ABCB1 genotype on the pharmacokinetics of 
different P-gp substrates may vary, which might also explain the lack of effect on 
aliskiren pharmacokinetics. 
 
At the time that Study VI was performed, the c.935G>A SNP was the only sequence 
variant in the SLCO2B1 gene reported to have affected the pharmacokinetics and 
efficacy of an OATP2B1 substrate drug in vivo in studies involving montelukast 
(Mougey et al. 2009; Mougey et al. 2011). Subsequently, no relationship has been found 
between c.935G>A and the pharmacokinetics of celiprolol (Ieiri et al. 2012). There are 
no in vitro studies investigating the effect of this SNP on the expression or function of 
OATP2B1. The findings from Study VI do not support functional significance of the 
SLCO2B1 c.935G>A SNP on OATP2B1 activity in vivo. In addition to the c.935G>A 
SNP, various other sequence variants have been described in the SLCO2B1 gene with 
yet unknown clinical relevance (Nozawa et al. 2002; Ho et al. 2006a; Aoki et al. 2009; 
Mougey et al. 2009). Overall, further pharmacogenetic studies are needed to identify the 
factors explaining the large interindividual variability in the pharmacokinetics of 
aliskiren. 
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6. Clinical implications 
 
Aliskiren proved to be susceptible to transporter-mediated pharmacokinetic interactions 
of clinical significance. In Studies I and II, both induction and inhibition of P-gp efflux 
transporter had a marked effect on the systemic exposure to aliskiren, although a minor 
part of the effect may also have resulted from induction and inhibition of CYP3A4. 
Thus, considering the pharmacokinetic and pharmacodynamic properties of aliskiren, it 
could be a suitable probe drug for evaluating P-gp-mediated drug interactions in vivo in 
humans. Studies III and IV suggested that aliskiren may also be prone to inhibition of 
the OATP2B1 influx transporter. However, the common haplotypes of ABCB1 gene 
encoding P-gp (Study V) and the polymorphism in SLCO2B1 gene encoding OATP2B1 
(Study VI) were not associated with altered pharmacokinetics of aliskiren. 
 
In all pharmacokinetic interaction studies (I-IV), the extent of the interaction showed 
marked interindividual variability even among young healthy volunteers. The variability 
is likely even larger in patient populations using aliskiren because of comorbidities, 
concomitant medications, and increasing age (Vaidyanathan et al. 2007b). 
 
In Studies I, II, and IV, in line with the alterations in pharmacokinetics of aliskiren, 
changes in the pharmacodynamic response to aliskiren were also seen, as rifampicin, 
orange juice, and apple juice all attenuated and itraconazole enhanced the renin-
inhibiting effect of aliskiren. Grapefruit juice, in turn, had no significant effect on 
plasma renin activity, although it greatly reduced the plasma aliskiren concentrations. 
 
Because of the delayed start of the blood pressure-lowering effect of aliskiren (EMA 
2012; Novartis 2012), no differences in haemodynamic effects were observed between 
different phases or groups in these single-dose studies with healthy volunteers. In any 
case, the pharmacodynamic response to aliskiren may be different in hypertensive 
patients using aliskiren daily than in normotensive individuals (Vaidyanathan et al. 
2008c; EMA 2012). 
 
Aliskiren shows a dose-response relationship in the range of 150-300 mg, but has no 
clear effect on blood pressure at lower doses (Oh et al. 2007; EMA 2012). Therefore, 
the decreased exposure to aliskiren by rifampicin, grapefruit juice, orange juice, or 
apple juice may lead to a reduced antihypertensive effect of aliskiren. In clinical 
practice, the interaction between rifampicin and aliskiren may result in a need to adjust 
the aliskiren dose. In addition, the intake of aliskiren concomitantly with grapefruit, 
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orange, or apple juice is best avoided. Accordingly, after publishing Study III, EMA has 
recommended that aliskiren not be taken together with grapefruit juice (EMA 2012). 
 
The antihypertensive efficacy of aliskiren 600 mg once daily has been similar to 300 mg 
once daily (Gradman et al. 2005; Weir et al. 2007). Thus, the increased systemic 
exposure to aliskiren by itraconazole does not necessarily result in an enhanced 
antihypertensive effect, but may increase the risk of adverse reactions. It is noteworthy 
that inhibition of P-gp by itraconazole may potentially increase the tissue permeability 
of aliskiren (Schinkel et al. 1997; Eyal et al. 2009). The inhibition of P-gp at the blood-
brain barrier might increase brain exposure to aliskiren. The concomitant use of 
aliskiren with cyclosporine has been contraindicated by the EMA because of a similar 
pharmacokinetic interaction (EMA 2012). Thus, the concomitant use of itraconazole 
and aliskiren is best avoided; it has also been contraindicated by EMA after Study II 
was published (EMA 2012). 
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CONCLUSIONS 
 
 
The following conclusions can be drawn on the basis of the results of these six studies: 
 
 
Study I 
 
 
 
 
Study II 
 
 
 
 
 
Study III 
 
 
 
 
 
 
Study IV 
 
 
 
 
 
 
 
 
Study V 
 
 
 
Study VI 
 
 
 
 
 
Rifampicin, an inducer of P-gp and CYP3A4, considerably reduces 
the plasma concentrations and the renin-inhibiting effect of aliskiren 
by decreasing its oral bioavailability, and therefore, rifampicin may 
reduce the antihypertensive efficacy of aliskiren. 
 
Itraconazole markedly raises the plasma concentrations of aliskiren 
and enhances its renin-inhibiting effect, probably mainly by inhibiting 
the P-gp-mediated efflux of aliskiren in the small intestine, with a 
minor contribution from inhibition of CYP3A4. Concomitant use of 
aliskiren and itraconazole is best avoided. 
 
Grapefruit juice greatly reduces the plasma concentrations of aliskiren, 
probably by inhibiting its OATP2B1- and/or OATP1A2-mediated 
influx in the small intestine. The concomitant use of aliskiren and 
grapefruit juice is best avoided. To our knowledge, this is the first 
published study suggesting that grapefruit juice may be a clinically 
important inhibitor of OATP2B1. 
 
Orange juice and apple juice greatly reduce the plasma concentrations 
of aliskiren and its renin-inhibiting effect, probably by reducing its 
absorption from the gastrointestinal tract. The interactions may be 
caused by inhibition of the OATP2B1- and/or OATP1A2-mediated 
intestinal absorption of aliskiren by constituents of these juices, but 
further studies are required to clarify the mechanisms involved. 
Concomitant intake of aliskiren with orange or apple juice is best 
avoided. 
 
The ABCB1 c.1236C-c.2677G-c.3435C and c.1236T-c.2677T-
c.3435T haplotypes have no clinically meaningful effect on the 
pharmacokinetics or pharmacodynamics of aliskiren. 
 
The SLCO2B1 c.935G>A SNP does not significantly affect the 
pharmacokinetics or pharmacodynamics of aliskiren. Further studies 
are needed to clarify the possible pharmacogenetic factors explaining 
the considerable interindividual variability in the pharmacokinetics of 
aliskiren. 
 
 
 87 
ACKNOWLEDGEMENTS 
 
 
This work was carried out at the Department of Clinical Pharmacology, University of 
Helsinki, Finland, in 2008-2012. I am most grateful to everyone who helped and 
supported me during these years. 
 
I have been privileged to work under the encouraging supervision of Professor Emeritus 
Pertti Neuvonen, Head of the Department of Clinical Pharmacology, at the time of my 
studies. His outstanding knowledge of clinical pharmacology and enthusiasm for 
scientific work are truly impressive. I am very grateful for the inspiring atmosphere and 
exceptional working environment that he created at KLIFA. 
 
My sincere gratitude is due to my main supervisor, Professor Mikko Niemi, for sharing 
his vast expertise and talent in pharmacogenetics and clinical pharmacology and for 
excellent guidance in scientific research. His kind, patient, and dynamic teaching style 
has made my work rewarding. 
 
Professor Janne Backman is gratefully acknowledged for friendly and fluent 
collaboration and contribution in Studies II and VI. 
 
I am very grateful to Docent Jari Lilja and Professor Ullamari Pesonen for their 
thorough review and constructive comments on this thesis. Carol Ann Pelli is warmly 
acknowledged for editing the English language. 
 
My sincere appreciation goes to the personnel of the Department of Clinical 
Pharmacology: Kaisa Kurkinen, Jouko Laitila, and Mikko Neuvonen are thanked for 
their expert drug concentration determinations, Eija Mäkinen-Pulli and Lisbet Partanen 
for their skilled assistance and cheerful company on study days, and Tuija Itkonen for 
kind company and valuable help with many practical matters. Olli Lehtinen is also 
gratefully acknowledged. 
 
I thank all of my colleagues at the Department of Clinical Pharmacology for pleasant 
company and collaboration: Kati Ahonen, Samuel Fanta, Anne Filppula, Päivi 
Hirvensalo, Mikko Holmberg, Johanna Honkalammi, Mika Isohanni, Tiina Jaakkola, 
Annikka Kalliokoski, Jenni Keskitalo, Marja Pasanen, Paavo Pietarinen, Päivi 
Ruokoniemi, Katriina Tarkiainen, Aleksi Tornio, Juha Vakkilainen, and Xiang 
 88 
Xiaoqianq. Kalle Hoppu, Outi Lapatto-Reiniluoto, Heli Malm, and the staff at the 
Poison Information Centre and at the Teratology Information Service are also thanked. 
Tiina Karonen is acknowledged for collaboration in Study VI. 
 
I am grateful to all of the volunteers who kindly participated in the studies. 
 
This work was financially supported by the Clinical Drug Research Graduate School, 
the Helsinki University Central Hospital Research Fund, the Sigrid Jusélius Foundation, 
and the Finnish Medical Society Duodecim, all of which are gratefully acknowledged. 
 
Finally, I thank my family and friends for support and encouragement. Warm thanks are 
also due to the crew at "Helina's play park" for hilarious moments in the sandpit, nicely 
counterbalancing scientific writing. Most of all, my heartfelt thanks go to Sami for 
devotion and for managing juice logistics and to my lovely daughter Olivia for being 
the sunshine of my life. 
 
 
Helsinki, November 2012 
 
Tuija Tapaninen 
 89 
REFERENCES 
 
 
Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, Nomura H, Unno M, Suzuki 
M, Naitoh T, Matsuno S, Yawo H. Identification of a novel gene family encoding 
human liver-specific organic anion transporter LST-1. J Biol Chem 1999;274:17159-63. 
Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, Nakagomi R, Adachi H, Fujiwara K, 
Okabe M, Suzuki T, Nunoki K, Sato E, Kakyo M, Nishio T, Sugita J, Asano N, 
Tanemoto M, Seki M, Date F, Ono K, Kondo Y, Shiiba K, Suzuki M, Ohtani H, 
Shimosegawa T, Iinuma K, Nagura H, Ito S, Matsuno S. LST-2, a human liver-
specific organic anion transporter, determines methotrexate sensitivity in 
gastrointestinal cancers. Gastroenterology 2001;120:1689-99. 
Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978;3:108-27. 
Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome 
P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. 
Lancet 1999;353:717-9. 
Aitken AE, Richardson TA, Morgan ET. Regulation of drug-metabolizing enzymes and 
transporters in inflammation. Annu Rev Pharmacol Toxicol 2006;46:123-49. 
Allenmark S, Edebo A, Lindgren K. Determination of itraconazole in serum with high-
performance liquid chromatography and fluorescence detection. J Chromatogr 
1990;532:203-6. 
Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang 
Q, Urbatsch IL, Chang G. Structure of P-glycoprotein reveals a molecular basis for 
poly-specific drug binding. Science 2009;323:1718-22. 
Ameer B, Weintraub RA, Johnson JV, Yost RA, Rouseff RL. Flavanone absorption after 
naringin, hesperidin, and citrus administration. Clin Pharmacol Ther 1996;60:34-40. 
Aoki M, Terada T, Ogasawara K, Katsura T, Hatano E, Ikai I, Inui K. Impact of regulatory 
polymorphisms in organic anion transporter genes in the human liver. Pharmacogenet 
Genomics 2009;19:647-56. 
Ayalasomayajula S, Tchaloyan S, Yeh CM, Bizot MN, Dieterich HA, Howard D, Dole WP. 
A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with 
allopurinol, celecoxib and cimetidine in healthy subjects. Curr Med Res Opin 
2008;24:717-26. 
Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: where are 
we now, and where are we going? J Hypertens 2006;24:243-56. 
Bachmakov I, Glaeser H, Endress B, Mörl F, König J, Fromm MF. Interaction of beta-
blockers with the renal uptake transporter OCT2. Diabetes Obes Metab 2009;11:1080-
3. 
Bachmakov I, Glaeser H, Fromm MF, König J. Interaction of oral antidiabetic drugs with 
hepatic uptake transporters: focus on organic anion transporting polypeptides and 
organic cation transporter 1. Diabetes 2008;57:1463-9. 
Back DJ, Tjia JF. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, 
itraconazole and terbinafine on the metabolism of cyclosporin by human liver 
microsomes. Br J Clin Pharmacol 1991;32:624-6. 
 90 
Backman JT, Olkkola KT, Aranko K, Himberg JJ, Neuvonen PJ. Dose of midazolam 
should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 
1994;37:221-5. 
Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations 
and effects of oral midazolam. Clin Pharmacol Ther 1996a;59:7-13. 
Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ. Concentrations and 
effects of oral midazolam are greatly reduced in patients treated with carbamazepine or 
phenytoin. Epilepsia 1996b;37:253-7. 
Bailey DG. Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Brit J 
Clin Pharmacol 2010;70:645-55. 
Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD. Effect of grapefruit juice and 
naringin on nisoldipine pharmacokinetics. Clin Pharmacol Ther 1993;54:589-94. 
Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. Am J 
Cardiovasc Drugs 2004;4:281-97. 
Bailey DG, Dresser GK, Kreeft JH, Munoz C, Freeman DJ, Bend JR. Grapefruit-felodipine 
interaction: effect of unprocessed fruit and probable active ingredients. Clin Pharmacol 
Ther 2000;68:468-77. 
Bailey DG, Dresser GK, Leake BF, Kim RB. Naringin is a major and selective clinical 
inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. 
Clin Pharmacol Ther 2007;81:495-502. 
Bailey DG, Spence JD, Edgar B, Bayliff CD, Arnold JM. Ethanol enhances the 
hemodynamic effects of felodipine. Clin Invest Med 1989;12:357-62. 
Bailey DG, Spence JD, Munoz C, Arnold JM. Interaction of citrus juices with felodipine and 
nifedipine. Lancet 1991;337:268-9. 
Barbarash RA, Bauman JL, Fischer JH, Kondos GT, Batenhorst RL. Near-total reduction 
in verapamil bioavailability by rifampin. Electrocardiographic correlates. Chest 
1988;94:954-9. 
Baxter K. Stockley's Drug Interactions, 8th ed. London: Pharmaceutical Press. 2008. 
Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Genetic 
variation in the multidrug and toxin extrusion 1 transporter protein influences the 
glucose-lowering effect of metformin in patients with diabetes: a preliminary study. 
Diabetes 2009;58:745-9. 
Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. 
Interaction between polymorphisms in the OCT1 and MATE1 transporter and 
metformin response. Pharmacogenet Genomics 2010;20:38-44. 
Becquemont L, Verstuyft C, Kerb R, Brinkmann U, Lebot M, Jaillon P, Funck-Brentano 
C. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol 
Ther 2001;70:311-6. 
Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: 
cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 1970;30:1174-
84. 
 91 
Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, 
Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, 
Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA. The conduct 
of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and 
Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003;31:815-32. 
Booth N, Jula A, Aronen P, Kaila M, Klaukka T, Kukkonen-Harjula K, Reunanen A, 
Rissanen P, Sintonen H, Mäkelä M. Cost-effectiveness analysis of guidelines for 
antihypertensive care in Finland. BMC Health Serv Res 2007;7:172. 
Bork RW, Muto T, Beaune PH, Srivastava PK, Lloyd RS, Guengerich FP. Characterization 
of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the 
regulation of catalytic activity. J Biol Chem 1989;264:910-9. 
Brandsch M. Transport of drugs by proton-coupled peptide transporters: pearls and pitfalls. 
Expert Opin Drug Metab Toxicol 2009;5:887-905. 
Brodie BB, Gillette JR, La Du BN. Enzymatic metabolism of drugs and other foreign 
compounds. Annu Rev Biochem 1958;27:427-54. 
Bronger H, König J, Kopplow K, Steiner HH, Ahmadi R, Herold-Mende C, Keppler D, 
Nies AT. ABCC drug efflux pumps and organic anion uptake transporters in human 
gliomas and the blood-tumor barrier. Cancer Res 2005;65:11419-28. 
Brown MH, Paulsen IT, Skurray RA. The multidrug efflux protein NorM is a prototype of a 
new family of transporters. Mol Microbiol 1999;31:394-5. 
Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM. Aliskiren and the calcium 
channel blocker amlodipine combination as an initial treatment strategy for 
hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet 
2011;377:312-20. 
Burk O, Arnold KA, Geick A, Tegude H, Eichelbaum M. A role for constitutive androstane 
receptor in the regulation of human intestinal MDR1 expression. Biol Chem 
2005;386:503-13. 
Burk O, Brenner SS, Hofmann U, Tegude H, Igel S, Schwab M, Eichelbaum M, Alscher 
MD. The impact of thyroid disease on the regulation, expression, and function of 
ABCB1 (MDR1/P glycoprotein) and consequences for the disposition of digoxin. Clin 
Pharmacol Ther 2010;88:685-94. 
Burk O, Koch I, Raucy J, Hustert E, Eichelbaum M, Brockmoller J, Zanger UM, 
Wojnowski L. The induction of cytochrome P450 3A5 (CYP3A5) in the human liver 
and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and 
constitutively activated receptor (CAR). J Biol Chem 2004;279:38379-85. 
Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and 
pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001;40:327-
41. 
Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, Darst SA. 
Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell 
2001;104:901-12. 
Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, 
Eichelbaum M, Brinkmann U, Roots I. Frequency of single nucleotide 
polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. 
Clin Pharmacol Ther 2001;69:169-74. 
 92 
Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H. Identification 
and characterization of human organic anion transporter 3 expressing predominantly in 
the kidney. Mol Pharmacol 2001;59:1277-86. 
Chang TK, Yu L, Maurel P, Waxman DJ. Enhanced cyclophosphamide and ifosfamide 
activation in primary human hepatocyte cultures: response to cytochrome P-450 
inducers and autoinduction by oxazaphosphorines. Cancer Res 1997;57:1946-54. 
Chen Y, Ferguson SS, Negishi M, Goldstein JA. Identification of constitutive androstane 
receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. Mol 
Pharmacol 2003;64:316-24. 
Chen Y, Ferguson SS, Negishi M, Goldstein JA. Induction of human CYP2C9 by rifampicin, 
hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp 
Ther 2004;308:495-501. 
Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK, Urban TJ, Chen L, Yee 
SW, Choi JH, Huang Y, Brett CM, Burchard EG, Giacomini KM. Effect of genetic 
variation in the organic cation transporter 2 on the renal elimination of metformin. 
Pharmacogenet Genomics 2009;19:497-504. 
Cheung VG, Spielman RS. Genetics of human gene expression: mapping DNA variants that 
influence gene expression. Nat Rev Genet 2009;10:595-604. 
Childs S, Yeh RL, Georges E, Ling V. Identification of a sister gene to P-glycoprotein. 
Cancer Res 1995;55:2029-34. 
Chinn LW, Kroetz DL. ABCB1 pharmacogenetics: progress, pitfalls, and promise. Clin 
Pharmacol Ther 2007;81:265-9. 
Choudhuri S, Klaassen CD. Structure, function, expression, genomic organization, and single 
nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 
(BCRP) efflux transporters. Int J Toxicol 2006;25:231-59. 
Chowbay B, Li H, David M, Cheung YB, Lee EJ. Meta-analysis of the influence of MDR1 
C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J 
Clin Pharmacol 2005;60:159-71. 
Chu XY, Bleasby K, Yabut J, Cai X, Chan GH, Hafey MJ, Xu S, Bergman AJ, Braun MP, 
Dean DC, Evers R. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by 
human organic anion transporter 3, organic anion transporting polypeptide 4C1, and 
multidrug resistance P-glycoprotein. J Pharmacol Exp Ther 2007;321:673-83. 
Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B, Pavenstädt H, 
Lanvers-Kaminsky C, am Zehnhoff-Dinnesen A, Schinkel AH, Koepsell H, 
Jürgens H, Schlatter E. Organic cation transporter 2 mediates cisplatin-induced oto- 
and nephrotoxicity and is a target for protective interventions. Am J Pathol 
2010;176:1169-80. 
Ciarimboli G, Ludwig T, Lang D, Pavenstädt H, Koepsell H, Piechota HJ, Haier J, Jaehde 
U, Zisowsky J, Schlatter E. Cisplatin nephrotoxicity is critically mediated via the 
human organic cation transporter 2. Am J Pathol 2005;167:1477-84. 
Combalbert J, Fabre I, Fabre G, Dalet I, Derancourt J, Cano JP, Maurel P. Metabolism of 
cyclosporin A. IV. Purification and identification of the rifampicin-inducible human 
liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene 
subfamily. Drug Metab Dispos 1989;17:197-207. 
 93 
Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of 
the multidrug resistance gene product (P-glycoprotein) in human normal and tumor 
tissues. J Histochem Cytochem 1990;38:1277-87. 
CPT. Statistical guide for clinical pharmacology & therapeutics. Clin Pharmacol Ther 
2010;88:150-2. 
Culm-Merdek KE, von Moltke LL, Gan L, Horan KA, Reynolds R, Harmatz JS, Court 
MH, Greenblatt DJ. Effect of extended exposure to grapefruit juice on cytochrome 
P450 3A activity in humans: comparison with ritonavir. Clin Pharmacol Ther 
2006;79:243-54. 
Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. OATP and P-glycoprotein 
transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab 
Dispos 1999;27:866-71. 
Dahan A, Amidon GL. Grapefruit juice and its constituents augment colchicine intestinal 
absorption: potential hazardous interaction and the role of p-glycoprotein. Pharm Res 
2009;26:883-92. 
Dahl ML, Bertilsson L. Genetically variable metabolism of antidepressants and neuroleptic 
drugs in man. Pharmacogenetics 1993;3:61-70. 
Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F. Ultrarapid 
hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular 
genetic basis. J Pharmacol Exp Ther 1995;274:516-20. 
Dahl ML, Johansson I, Palmertz MP, Ingelman-Sundberg M, Sjöqvist F. Analysis of the 
CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish 
population. Clin Pharmacol Ther 1992;51:12-7. 
Daly AK. Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet 
2006;45:13-31. 
Danhof M, de Jongh J, De Lange EC, Della Pasqua O, Ploeger BA, Voskuyl RA. 
Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, 
receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol 
2007;47:357-400. 
de Castro WV, Mertens-Talcott S, Derendorf H, Butterweck V. Grapefruit juice-drug 
interactions: Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) 
mediated transport of talinolol in Caco-2 cells. J Pharm Sci 2007;96:2808-17. 
de Vree JM, Jacquemin E, Sturm E, Cresteil D, Bosma PJ, Aten J, Deleuze JF, Desrochers 
M, Burdelski M, Bernard O, Oude Elferink RP, Hadchouel M. Mutations in the 
MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci U S 
A 1998;95:282-7. 
Deleuze JF, Jacquemin E, Dubuisson C, Cresteil D, Dumont M, Erlinger S, Bernard O, 
Hadchouel M. Defect of multidrug-resistance 3 gene expression in a subtype of 
progressive familial intrahepatic cholestasis. Hepatology 1996;23:904-8. 
Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of 
antihypertensive treatment by crossover rotation of four major classes. Lancet 
1999;353:2008-13. 
Dieterle W, Corynen S, Mann J. Effect of the oral renin inhibitor aliskiren on the 
pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy 
subjects. Br J Clin Pharmacol 2004;58:433-6. 
 94 
Dieterle W, Corynen S, Vaidyanathan S, Mann J. Pharmacokinetic interactions of the oral 
renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin 
Pharmacol Ther 2005;43:527-35. 
Dietz R, Dechend R, Yu CM, Bheda M, Ford J, Prescott MF, Keefe DL. Effects of the 
direct renin inhibitor aliskiren and atenolol alone or in combination in patients with 
hypertension. J Renin Angiotensin Aldosterone Syst 2008;9:163-75. 
Douglas JG, McLeod MJ. Pharmacokinetic factors in the modern drug treatment of 
tuberculosis. Clin Pharmacokinet 1999;37:127-46. 
Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. A multidrug 
resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 
1998;95:15665-70. 
Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB. Fruit 
juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease 
the oral availability of fexofenadine. Clin Pharmacol Ther 2002a;71:11-20. 
Dresser GK, Kim RB, Bailey DG. Effect of grapefruit juice volume on the reduction of 
fexofenadine bioavailability: possible role of organic anion transporting polypeptides. 
Clin Pharmacol Ther 2005;77:170-7. 
Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and 
clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-
57. 
Dresser MJ, Xiao G, Leabman MK, Gray AT, Giacomini KM. Interactions of n-
tetraalkylammonium compounds and biguanides with a human renal organic cation 
transporter (hOCT2). Pharm Res 2002b;19:1244-7. 
Dubin IN, Johnson FB. Chronic idiopathic jaundice with unidentified pigment in liver cells; a 
new clinicopathologic entity with a report of 12 cases. Medicine (Baltimore) 
1954;33:155-97. 
Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine 
after administration with grapefruit juice. Clin Pharmacol Ther 1995;57:485-91. 
Eagling VA, Profit L, Back DJ. Inhibition of the CYP3A4-mediated metabolism and P-
glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by 
grapefruit juice components. Br J Clin Pharmacol 1999;48:543-52. 
Edwards DJ, Bellevue FH, 3rd, Woster PM. Identification of 6',7'-dihydroxybergamottin, a 
cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos 1996;24:1287-90. 
Edwards DJ, Fitzsimmons ME, Schuetz EG, Yasuda K, Ducharme MP, Warbasse LH, 
Woster PM, Schuetz JD, Watkins P. 6',7'-Dihydroxybergamottin in grapefruit juice 
and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and 
P-glycoprotein. Clin Pharmacol Ther 1999;65:237-44. 
Eechoute K, Franke RM, Loos WJ, Scherkenbach LA, Boere I, Verweij J, Gurney H, Kim 
RB, Tirona RG, Mathijssen RH, Sparreboom A. Environmental and genetic factors 
affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther 2011;89:816-20. 
Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized 
drug therapy. Annu Rev Med 2006;57:119-37. 
Ekroos M, Sjögren T. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc 
Natl Acad Sci U S A 2006;103:13682-7. 
 95 
EMA. ICH Topic E15: Definitions for genomic biomarkers, pharmacogenomics, 
pharmacogenetics, genomic data and sample coding categories. Available at 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09
/WC500002880.pdf (last accessed 3 January 2011). 2007. 
EMA. Guideline on the investigation of bioequivalence. Available at 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01
/WC500070039.pdf (last accessed 13 December 2010). 2010a. 
EMA. Guideline on the investigation of drug interactions (draft). Available at 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/05
/WC500090112.pdf (last accessed 10 November 2010). 2010b. 
EMA. European public assessment report for Rasilez. Available at 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/0007
80/human_med_001013.jsp&mid=WC0b01ac058001d124 (last accessed 30 May 
2012). 2012. 
Englund G, Rorsman F, Rönnblom A, Karlbom U, Lazorova L, Gråsjö J, Kindmark A, 
Artursson P. Regional levels of drug transporters along the human intestinal tract: co-
expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J 
Pharm Sci 2006;29:269-77. 
Erlund I, Meririnne E, Alfthan G, Aro A. Plasma kinetics and urinary excretion of the 
flavanones naringenin and hesperetin in humans after ingestion of orange juice and 
grapefruit juice. J Nutr 2001;131:235-41. 
Ernest CS, 2nd, Hall SD, Jones DR. Mechanism-based inactivation of CYP3A by HIV 
protease inhibitors. J Pharmacol Exp Ther 2005;312:583-91. 
Eyal S, Hsiao P, Unadkat JD. Drug interactions at the blood-brain barrier: fact or fantasy? 
Pharmacol Ther 2009;123:80-104. 
Fahrmayr C, Fromm MF, König J. Hepatic OATP and OCT uptake transporters: their role for 
drug-drug interactions and pharmacogenetic aspects. Drug Metab Rev 2010;42:380-401. 
Fairchild CR, Ivy SP, Kao-Shan CS, Whang-Peng J, Rosen N, Israel MA, Melera PW, 
Cowan KH, Goldsmith ME. Isolation of amplified and overexpressed DNA sequences 
from adriamycin-resistant human breast cancer cells. Cancer Res 1987;47:5141-8. 
Fanta S, Niemi M, Jonsson S, Karlsson MO, Holmberg C, Neuvonen PJ, Hoppu K, 
Backman JT. Pharmacogenetics of cyclosporine in children suggests an age-dependent 
influence of ABCB1 polymorphisms. Pharmacogenet Genomics 2008;18:77-90. 
FDA. Tekturna drug approval package. Available at 
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021985s000TOC.cfm (last 
accessed 10 November 2010). 2007. 
FDA. Guidance for industry (draft). Drug interaction studies - study design, data analysis, 
implications for dosing and labeling recommendations. Available at 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Gui
dances/UCM292362.pdf (last accessed 31 May 2012). 2012. 
Fei YJ, Kanai Y, Nussberger S, Ganapathy V, Leibach FH, Romero MF, Singh SK, Boron 
WF, Hediger MA. Expression cloning of a mammalian proton-coupled oligopeptide 
transporter. Nature 1994;368:563-6. 
 96 
Ferguson SS, Chen Y, LeCluyse EL, Negishi M, Goldstein JA. Human CYP2C8 is 
transcriptionally regulated by the nuclear receptors constitutive androstane receptor, 
pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha. Mol 
Pharmacol 2005;68:747-57. 
Fiegenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires 
RC, Hutz MH. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes 
in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther 
2005;78:551-8. 
Fineli. Finnish Food Composition Database. Available at 
http://www.fineli.fi/index.php?lang=en (last accessed 24 December 2010). 2010. 
Fromm MF. The influence of MDR1 polymorphisms on P-glycoprotein expression and 
function in humans. Adv Drug Deliv Rev 2002;54:1295-310. 
Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 
2004;25:423-9. 
Fromm MF, Busse D, Kroemer HK, Eichelbaum M. Differential induction of prehepatic and 
hepatic metabolism of verapamil by rifampin. Hepatology 1996;24:796-801. 
Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, Eichelbaum 
M, Siegmund W, Schrenk D. The effect of rifampin treatment on intestinal expression 
of human MRP transporters. Am J Pathol 2000;157:1575-80. 
Frye RF, Zgheib NK, Matzke GR, Chaves-Gnecco D, Rabinovitz M, Shaikh OS, Branch 
RA. Liver disease selectively modulates cytochrome P450-mediated metabolism. Clin 
Pharmacol Ther 2006;80:235-45. 
Fuchikami H, Satoh H, Tsujimoto M, Ohdo S, Ohtani H, Sawada Y. Effects of herbal 
extracts on the function of human organic anion-transporting polypeptide OATP-B. 
Drug Metab Dispos 2006;34:577-82. 
Fuhr U, Maier-Brüggemann A, Blume H, Mück W, Unger S, Kuhlmann J, Huschka C, 
Zaigler M, Rietbrock S, Staib AH. Grapefruit juice increases oral nimodipine 
bioavailability. Int J Clin Pharmacol Ther 1998;36:126-32. 
Fujiwara K, Adachi H, Nishio T, Unno M, Tokui T, Okabe M, Onogawa T, Suzuki T, 
Asano N, Tanemoto M, Seki M, Shiiba K, Suzuki M, Kondo Y, Nunoki K, 
Shimosegawa T, Iinuma K, Ito S, Matsuno S, Abe T. Identification of thyroid 
hormone transporters in humans: different molecules are involved in a tissue-specific 
manner. Endocrinology 2001;142:2005-12. 
Fukuda K, Ohta T, Oshima Y, Ohashi N, Yoshikawa M, Yamazoe Y. Specific CYP3A4 
inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. 
Pharmacogenetics 1997;7:391-6. 
Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, 
Kaneko E. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter 
pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and 
clarithromycin. Clin Pharmacol Ther 2001;69:158-68. 
Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med 2008;264:224-
36. 
Ganapathy V, Leibach FH. Role of pH gradient and membrane potential in dipeptide transport 
in intestinal and renal brush-border membrane vesicles from the rabbit. Studies with L-
carnosine and glycyl-L-proline. J Biol Chem 1983;258:14189-92. 
 97 
Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier PJ. Organic anion-
transporting polypeptides mediate transport of opioid peptides across blood-brain 
barrier. J Pharmacol Exp Ther 2000;294:73-9. 
Gao B, Huber RD, Wenzel A, Vavricka SR, Ismair MG, Remé C, Meier PJ. Localization of 
organic anion transporting polypeptides in the rat and human ciliary body epithelium. 
Exp Eye Res 2005;80:61-72. 
Garg SK, Kumar N, Bhargava VK, Prabhakar SK. Effect of grapefruit juice on 
carbamazepine bioavailability in patients with epilepsy. Clin Pharmacol Ther 
1998;64:286-8. 
Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J. Codeine 
intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 
2004;351:2827-31. 
Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of 
intestinal MDR1 by rifampin. J Biol Chem 2001;276:14581-7. 
Gerbal-Chaloin S, Daujat M, Pascussi JM, Pichard-Garcia L, Vilarem MJ, Maurel P. 
Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and 
constitutive androstane receptor. J Biol Chem 2002;277:209-17. 
Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, Daujat M, Waechter F, Fabre JM, 
Carrere N, Maurel P. Induction of CYP2C genes in human hepatocytes in primary 
culture. Drug Metab Dispos 2001;29:242-51. 
Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, Hofmann AF, Meier 
PJ. The sister of P-glycoprotein represents the canalicular bile salt export pump of 
mammalian liver. J Biol Chem 1998;273:10046-50. 
Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers 
R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee 
CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Wah Yee 
S, Zamek-Gliszczynski MJ, Zhang L. Membrane transporters in drug development. 
Nat Rev Drug Discov 2010;9:215-236. 
Gibaldi M, Schwartz MA. Apparent effect of probenecid on the distribution of penicillins in 
man. Clin Pharmacol Ther 1968;9:345-9. 
Gibson GG, Skett P. Introduction to drug metabolism, 3rd ed. Cheltenham: Nelson Thornes 
Publishers. 2001. 
Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, Jolicoeur E, Lee 
W, Leake BF, Tirona RG, Kim RB. Intestinal drug transporter expression and the 
impact of grapefruit juice in humans. Clin Pharmacol Ther 2007;81:362-70. 
Glaeser H, Drescher S, Eichelbaum M, Fromm MF. Influence of rifampicin on the 
expression and function of human intestinal cytochrome P450 enzymes. Br J Clin 
Pharmacol 2005;59:199-206. 
Goodwin B, Hodgson E, Liddle C. The orphan human pregnane X receptor mediates the 
transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. 
Mol Pharmacol 1999;56:1329-39. 
Goodwin B, Moore LB, Stoltz CM, McKee DD, Kliewer SA. Regulation of the human 
CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 2001;60:427-31. 
 98 
Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, 
Baumann C, Lang F, Busch AE, Koepsell H. Cloning and characterization of two 
human polyspecific organic cation transporters. DNA Cell Biol 1997;16:871-81. 
Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM, Jr., Hall SD. The 
contribution of intestinal and hepatic CYP3A to the interaction between midazolam and 
clarithromycin. Clin Pharmacol Ther 1998;64:133-43. 
Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a 
novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy 
and placebo-like tolerability in hypertensive patients. Circulation 2005;111:1012-8. 
Grant SM, Clissold SP. Itraconazole. A review of its pharmacodynamic and pharmacokinetic 
properties, and therapeutic use in superficial and systemic mycoses. Drugs 
1989;37:310-44. 
Greenblatt DJ, von Moltke LL, Harmatz JS, Chen G, Weemhoff JL, Jen C, Kelley CJ, 
LeDuc BW, Zinny MA. Time course of recovery of cytochrome p450 3A function 
after single doses of grapefruit juice. Clin Pharmacol Ther 2003;74:121-9. 
Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer 
HK. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J 
Clin Invest 1999;104:147-53. 
Groneberg DA, Döring F, Eynott PR, Fischer A, Daniel H. Intestinal peptide transport: ex 
vivo uptake studies and localization of peptide carrier PEPT1. Am J Physiol 
Gastrointest Liver Physiol 2001;281:G697-704. 
Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis 1983;5 Suppl 3:S440-50. 
Grube M, Köck K, Oswald S, Draber K, Meissner K, Eckel L, Böhm M, Felix SB, 
Vogelgesang S, Jedlitschky G, Siegmund W, Warzok R, Kroemer HK. Organic 
anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is 
expressed in the human heart. Clin Pharmacol Ther 2006;80:607-20. 
Grube M, Reuther S, Meyer zu Schwabedissen H, Köck K, Draber K, Ritter CA, Fusch C, 
Jedlitschky G, Kroemer HK. Organic anion transporting polypeptide 2B1 and breast 
cancer resistance protein interact in the transepithelial transport of steroid sulfates in 
human placenta. Drug Metab Dispos 2007;35:30-5. 
Guengerich FP. Characterization of human microsomal cytochrome P-450 enzymes. Annu Rev 
Pharmacol Toxicol 1989;29:241-64. 
Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ. 
Characterization of rat and human liver microsomal cytochrome P-450 forms involved 
in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug 
metabolism. J Biol Chem 1986;261:5051-60. 
Guo LQ, Fukuda K, Ohta T, Yamazoe Y. Role of furanocoumarin derivatives on grapefruit 
juice-mediated inhibition of human CYP3A activity. Drug Metab Dispos 2000;28:766-
71. 
Gyselen A, Verbist L, Cosemans J, Lacquet LM, Vandenbergh E. Rifampin and ethambutol 
in the retreatment of advanced pulmonary tuberculosis. Am Rev Respir Dis 
1968;98:933-41. 
Haehner BD, Gorski JC, Vandenbranden M, Wrighton SA, Janardan SK, Watkins PB, 
Hall SD. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol 
Pharmacol 1996;50:52-9. 
 99 
Hagenbuch B, Gui C. Xenobiotic transporters of the human organic anion transporting 
polypeptides (OATP) family. Xenobiotica 2008;38:778-801. 
Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/ SLC21 
family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature 
and molecular/functional properties. Pflugers Arch 2004;447:653-65. 
Handschin C, Meyer UA. Induction of drug metabolism: the role of nuclear receptors. 
Pharmacol Rev 2003;55:649-73. 
Hardin TC, Graybill JR, Fetchick R, Woestenborghs R, Rinaldi MG, Kuhn JG. 
Pharmacokinetics of itraconazole following oral administration to normal volunteers. 
Antimicrob Agents Chemother 1988;32:1310-3. 
He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, Hollenberg PF. Inactivation of cytochrome 
P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 
1998;11:252-9. 
Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporine with 
concomitant rifampin administration is markedly less than predicted by hepatic enzyme 
induction. Clin Pharmacol Ther 1992;52:453-7. 
Heimark LD, Gibaldi M, Trager WF, O'Reilly RA, Goulart DA. The mechanism of the 
warfarin-rifampin drug interaction in humans. Clin Pharmacol Ther 1987;42:388-94. 
Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrijsen K, 
Woestenborghs R, Van Cutsem J, Cauwenbergh G. The clinical pharmacokinetics of 
itraconazole: an overview. Mycoses 1989;32 Suppl 1:67-87. 
Higashi E, Fukami T, Itoh M, Kyo S, Inoue M, Yokoi T, Nakajima M. Human CYP2A6 is 
induced by estrogen via estrogen receptor. Drug Metab Dispos 2007;35:1935-41. 
Ho ES, Lin DC, Mendel DB, Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and 
cidofovir is induced by the expression of human renal organic anion transporter 1. J Am 
Soc Nephrol 2000a;11:383-93. 
Ho PC, Ghose K, Saville D, Wanwimolruk S. Effect of grapefruit juice on pharmacokinetics 
and pharmacodynamics of verapamil enantiomers in healthy volunteers. Eur J Clin 
Pharmacol 2000b;56:693-8. 
Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. 
Clin Pharmacol Ther 2005;78:260-77. 
Ho RH, Leake BF, Kim RB, Wang Y. OATP2B1 allelic variants differentially transport 
rosuvastatin in vitro [abstract]. Drug Metab Dispos 2006a;38:240-241. 
Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB. Drug and 
bile acid transporters in rosuvastatin hepatic uptake: function, expression, and 
pharmacogenetics. Gastroenterology 2006b;130:1793-806. 
Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, 
Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the 
human multidrug-resistance gene: multiple sequence variations and correlation of one 
allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 
2000;97:3473-8. 
Holdiness MR. Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet 
1984;9:511-44. 
Hollenberg PF. Characteristics and common properties of inhibitors, inducers, and activators of 
CYP enzymes. Drug Metab Rev 2002;34:17-35. 
 100 
Holstein A, Plaschke A, Ptak M, Egberts EH, El-Din J, Brockmöller J, Kirchheiner J. 
Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia 
on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol 
2005;60:103-6. 
Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, 
Ohtani H, Sawada Y. Effects of grapefruit juice and orange juice components on P-
glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol 2004;143:856-64. 
Honig PK, Wortham DC, Hull R, Zamani K, Smith JE, Cantilena LR. Itraconazole affects 
single-dose terfenadine pharmacokinetics and cardiac repolarization 
pharmacodynamics. J Clin Pharmacol 1993;33:1201-6. 
Hosoyamada M, Sekine T, Kanai Y, Endou H. Molecular cloning and functional expression 
of a multispecific organic anion transporter from human kidney. Am J Physiol 
1999;276:F122-8. 
Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG. A novel 
human hepatic organic anion transporting polypeptide (OATP2). Identification of a 
liver-specific human organic anion transporting polypeptide and identification of rat and 
human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 
1999;274:37161-8. 
Huang HL, Vaidyanathan S, Yeh CM, Bizot MN, Dieterich HA, Dole WP, Howard D. 
Effect of aliskiren, an oral direct renin inhibitor, on the pharmacokinetics and 
pharmacodynamics of a single dose of acenocoumarol in healthy volunteers. Curr Med 
Res Opin 2008;24:2449-56. 
Hukkanen J, Väisänen T, Lassila A, Piipari R, Anttila S, Pelkonen O, Raunio H, Hakkola 
J. Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-
derived cells. J Pharmacol Exp Ther 2003;304:745-52. 
Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ. Plasma concentrations of triazolam are 
increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther 
1995;58:127-31. 
Hulot JS, Villard E, Maguy A, Morel V, Mir L, Tostivint I, William-Faltaos D, Fernandez 
C, Hatem S, Deray G, Komajda M, Leblond V, Lechat P. A mutation in the drug 
transporter gene ABCC2 associated with impaired methotrexate elimination. 
Pharmacogenet Genomics 2005;15:277-85. 
Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, 
Klattig J, Eiselt R, Koch I, Zibat A, Brockmöller J, Halpert JR, Zanger UM, 
Wojnowski L. The genetic determinants of the CYP3A5 polymorphism. 
Pharmacogenetics 2001;11:773-9. 
Ieiri I, Doi Y, Maeda K, Sasaki T, Kimura M, Hirota T, Chiyoda T, Miyagawa M, Irie S, 
Iwasaki K, Sugiyama Y. Microdosing Clinical Study: Pharmacokinetic, 
Pharmacogenomic (SLCO2B1), and Interaction (Grapefruit Juice) Profiles of Celiprolol 
Following the Oral Microdose and Therapeutic Dose. J Clin Pharmacol 2012;52:1078-
89. 
Iisalo E. Clinical pharmacokinetics of digoxin. Clin Pharmacokinet 1977;2:1-16. 
Ikegawa T, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Naito M, Tsuruo T, Ohtani 
H, Sawada Y. Inhibition of P-glycoprotein by orange juice components, 
polymethoxyflavones in adriamycin-resistant human myelogenous leukemia 
(K562/ADM) cells. Cancer Lett 2000;160:21-8. 
 101 
Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T, Miki Y, Sugimoto Y. 
C421A polymorphism in the human breast cancer resistance protein gene is associated 
with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 
2002;1:611-6. 
Imanaga J, Kotegawa T, Imai H, Tsutsumi K, Yoshizato T, Ohyama T, Shirasaka Y, 
Tamai I, Tateishi T, Ohashi K. The effects of the SLCO2B1 c.1457C>T 
polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam 
in humans. Pharmacogenet Genomics 2011;21:84-93. 
Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical 
consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 
2005;5:6-13. 
Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome 
P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and 
clinical aspects. Pharmacol Ther 2007;116:496-526. 
Ishigam M, Uchiyama M, Kondo T, Iwabuchi H, Inoue S, Takasaki W, Ikeda T, Komai T, 
Ito K, Sugiyama Y. Inhibition of in vitro metabolism of simvastatin by itraconazole in 
humans and prediction of in vivo drug-drug interactions. Pharm Res 2001;18:622-31. 
Isoherranen N, Kunze KL, Allen KE, Nelson WL, Thummel KE. Role of itraconazole 
metabolites in CYP3A4 inhibition. Drug Metab Dispos 2004;32:1121-31. 
Itoh M, Nakajima M, Higashi E, Yoshida R, Nagata K, Yamazoe Y, Yokoi T. Induction of 
human CYP2A6 is mediated by the pregnane X receptor with peroxisome proliferator-
activated receptor-gamma coactivator 1alpha. J Pharmacol Exp Ther 2006;319:693-
702. 
Ivanov M, Kacevska M, Ingelman-Sundberg M. Epigenomics and interindividual differences 
in drug response. [Epub ahead of print]. Clin Pharmacol Ther 2012. 
Jaakkola T, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ. Effect of rifampicin on the 
pharmacokinetics of pioglitazone. Br J Clin Pharmacol 2006;61:70-8. 
Jacquemin E, Cresteil D, Manouvrier S, Boute O, Hadchouel M. Heterozygous non-sense 
mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy. Lancet 
1999;353:210-1. 
Jacquemin E, Hagenbuch B, Stieger B, Wolkoff AW, Meier PJ. Expression cloning of a rat 
liver Na(+)-independent organic anion transporter. Proc Natl Acad Sci U S A 
1994;91:133-7. 
Jalava KM, Olkkola KT, Neuvonen PJ. Itraconazole greatly increases plasma concentrations 
and effects of felodipine. Clin Pharmacol Ther 1997a;61:410-5. 
Jalava KM, Partanen J, Neuvonen PJ. Itraconazole decreases renal clearance of digoxin. Ther 
Drug Monit 1997b;19:609-13. 
Jarugula V, Yeh CM, Howard D, Bush C, Keefe DL, Dole WP. Influence of body weight 
and gender on the pharmacokinetics, pharmacodynamics, and antihypertensive efficacy 
of aliskiren. J Clin Pharmacol 2010;50:1358-66. 
Jeon H, Jang IJ, Lee S, Ohashi K, Kotegawa T, Ieiri I, Cho JY, Yoon SH, Shin SG, Yu KS, 
Lim KS. Apple juice greatly reduces systemic exposure to atenolol. [Epub ahead of 
print]. Br J Clin Pharmacol 2012. 
 102 
Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M. 
Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a 
cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A 
1993;90:11825-9. 
Johne A, Brockmöller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic 
interaction of digoxin with an herbal extract from St John's wort (Hypericum 
perforatum). Clin Pharmacol Ther 1999;66:338-45. 
Johne A, Köpke K, Gerloff T, Mai I, Rietbrock S, Meisel C, Hoffmeyer S, Kerb R, Fromm 
MF, Brinkmann U, Eichelbaum M, Brockmöller J, Cascorbi I, Roots I. Modulation 
of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. 
Clin Pharmacol Ther 2002;72:584-94. 
Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster 
ovary cell mutants. Biochim Biophys Acta 1976;455:152-62. 
Jung N, Lehmann C, Rubbert A, Knispel M, Hartmann P, van Lunzen J, Stellbrink HJ, 
Faetkenheuer G, Taubert D. Relevance of the organic cation transporters 1 and 2 for 
antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab 
Dispos 2008;36:1616-23. 
Jurima-Romet M, Crawford K, Cyr T, Inaba T. Terfenadine metabolism in human liver. In 
vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 
1994;22:849-57. 
Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. Polymorphisms in the multidrug 
resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-
specific manner. Am J Cardiol 2004;93:1046-50. 
Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT. Metabolism of repaglinide by CYP2C8 
and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol 
2005a;97:249-56. 
Kajosaari LI, Niemi M, Backman JT, Neuvonen PJ. Telithromycin, but not montelukast, 
increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 
substrate repaglinide. Clin Pharmacol Ther 2006;79:231-42. 
Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT. Cyclosporine 
markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther 
2005b;78:388-99. 
Kakar SM, Paine MF, Stewart PW, Watkins PB. 6'7'-Dihydroxybergamottin contributes to 
the grapefruit juice effect. Clin Pharmacol Ther 2004;75:569-79. 
Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 
2009;158:693-705. 
Kanazawa S, Ohkubo T, Sugawara K. The effects of grapefruit juice on the pharmacokinetics 
of erythromycin. Eur J Clin Pharmacol 2001;56:799-803. 
Kantola T, Kivistö KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of 
atorvastatin. Clin Pharmacol Ther 1998a;64:58-65. 
Kantola T, Kivistö KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations 
of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998b;63:397-402. 
Karlsson J, Kuo SM, Ziemniak J, Artursson P. Transport of celiprolol across human 
intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters 
including P-glycoprotein. Br J Pharmacol 1993;110:1009-16. 
 103 
Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug 
resistance in mammalian cell lines. Science 1983;221:1285-8. 
Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, Tontonoz P, Kliewer 
S, Willson TM, Edwards PA. Regulation of multidrug resistance-associated protein 2 
(ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, 
and constitutive androstane receptor. J Biol Chem 2002;277:2908-15. 
Kastarinen M, Antikainen R, Peltonen M, Laatikainen T, Barengo NC, Jula A, Salomaa 
V, Jousilahti P, Nissinen A, Vartiainen E, Tuomilehto J. Prevalence, awareness and 
treatment of hypertension in Finland during 1982-2007. J Hypertens 2009;27:1552-9. 
Kato Y, Miyazaki T, Kano T, Sugiura T, Kubo Y, Tsuji A. Involvement of influx and efflux 
transport systems in gastrointestinal absorption of celiprolol. J Pharm Sci 
2009;98:2529-39. 
Kaukonen KM, Olkkola KT, Neuvonen PJ. Itraconazole increases plasma concentrations of 
quinidine. Clin Pharmacol Ther 1997;62:510-7. 
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of 
hypertension: analysis of worldwide data. Lancet 2005;365:217-23. 
KELA. Statistical Yearbook of the Social Insurance Institution 2010. Available at 
http://www.kela.fi/it/kelasto/kelasto.nsf/alias/Yearbook_10_pdf/$File/Yearbook_10.pdf
?OpenElement (last accessed 20 June 2012). 2011. 
Keskitalo JE, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCB1 haplotypes differentially affect 
the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin 
Pharmacol Ther 2008;84:457-61. 
Keskitalo JE, Pasanen MK, Neuvonen PJ, Niemi M. Different effects of the ABCG2 
c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. 
Pharmacogenomics 2009a;10:1617-24. 
Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCG2 
polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. 
Clin Pharmacol Ther 2009b;86:197-203. 
Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, 
McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR. 
Identification of functionally variant MDR1 alleles among European Americans and 
African Americans. Clin Pharmacol Ther 2001;70:189-99. 
Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman 
MM. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 
2007;315:525-8. 
Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, Inui K. Metformin is a 
superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. 
Drug Metab Pharmacokinet 2005;20:379-86. 
Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome P450 2C9 
polymorphisms. Clin Pharmacol Ther 2005;77:1-16. 
Kivistö KT, Bookjans G, Fromm MF, Griese EU, Munzel P, Kroemer HK. Expression of 
CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. Br J Clin Pharmacol 
1996a;42:387-9. 
 104 
Kivistö KT, Griese EU, Fritz P, Linder A, Hakkola J, Raunio H, Beaune P, Kroemer HK. 
Expression of cytochrome P 450 3A enzymes in human lung: a combined RT-PCR and 
immunohistochemical analysis of normal tissue and lung tumours. Naunyn 
Schmiedebergs Arch Pharmacol 1996b;353:207-12. 
Kivistö KT, Grisk O, Hofmann U, Meissner K, Möritz KU, Ritter C, Arnold KA, 
Lütjoohann D, von Bergmann K, Klöting I, Eichelbaum M, Kroemer HK. 
Disposition of oral and intravenous pravastatin in MRP2-deficient TR- rats. Drug 
Metab Dispos 2005;33:1593-6. 
Kivistö KT, Lilja JJ, Backman JT, Neuvonen PJ. Repeated consumption of grapefruit juice 
considerably increases plasma concentrations of cisapride. Clin Pharmacol Ther 
1999;66:448-53. 
Kivistö KT, Niemi M, Fromm MF. Functional interaction of intestinal CYP3A4 and P-
glycoprotein. Fundam Clin Pharmacol 2004;18:621-6. 
Klaassen CD, Aleksunes LM. Xenobiotic, bile acid, and cholesterol transporters: function and 
regulation. Pharmacol Rev 2010;62:1-96. 
Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, McKee DD, 
Oliver BB, Willson TM, Zetterström RH, Perlmann T, Lehmann JM. An orphan 
nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 
1998;92:73-82. 
Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, Schwarz UI, Lemke CJ, Leake 
BF, Kim RB, Tirona RG. Human skeletal muscle drug transporters determine local 
exposure and toxicity of statins. Circ Res 2010;106:297-306. 
Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Involvement of human organic 
anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across 
intestinal apical membrane. J Pharmacol Exp Ther 2003;306:703-8. 
Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, 
physiological roles, and biopharmaceutical implications. Pharm Res 2007;24:1227-51. 
Kohanski MA, Dwyer DJ, Collins JJ. How antibiotics kill bacteria: from targets to networks. 
Nat Rev Microbiol 2010;8:423-35. 
Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-
inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 
1992;90:1871-8. 
Kondo C, Suzuki H, Itoda M, Ozawa S, Sawada J, Kobayashi D, Ieiri I, Mine K, Ohtsubo 
K, Sugiyama Y. Functional analysis of SNPs variants of BCRP/ABCG2. Pharm Res 
2004;21:1895-903. 
Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F, Borst P. 
Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of 
the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. 
Cancer Res 1997;57:3537-47. 
Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree JM, Smith AJ, Jansen G, 
Peters GJ, Ponne N, Scheper RJ, Elferink RP, Baas F, Borst P. MRP3, an organic 
anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci U S A 
1999;96:6914-9. 
Koul A, Arnoult E, Lounis N, Guillemont J, Andries K. The challenge of new drug 
discovery for tuberculosis. Nature 2011;469:483-90. 
 105 
Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 
1994;26:144-60. 
Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryke D, 
Ferrin TE, DeYoung J, Taylor T, Carlson EJ, Herskowitz I, Giacomini KM, Clark 
AG. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, 
multidrug resistance transporter) gene. Pharmacogenetics 2003;13:481-94. 
Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton 
SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, 
Strom S, Thummel K, Boguski MS, Schuetz E. Sequence diversity in CYP3A 
promoters and characterization of the genetic basis of polymorphic CYP3A5 
expression. Nat Genet 2001;27:383-91. 
Kullak-Ublick GA, Hagenbuch B, Stieger B, Schteingart CD, Hofmann AF, Wolkoff AW, 
Meier PJ. Molecular and functional characterization of an organic anion transporting 
polypeptide cloned from human liver. Gastroenterology 1995;109:1274-82. 
Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger 
K, Meier PJ, Hagenbuch B. Organic anion-transporting polypeptide B (OATP-B) and 
its functional comparison with three other OATPs of human liver. Gastroenterology 
2001;120:525-33. 
Kupferschmidt HH, Fattinger KE, Ha HR, Follath F, Krahenbuhl S. Grapefruit juice 
enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin 
Pharmacol 1998;45:355-9. 
Kupferschmidt HH, Ha HR, Ziegler WH, Meier PJ, Krähenbühl S. Interaction between 
grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995;58:20-8. 
Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ. Rifampin 
greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol 
Ther 2000;68:592-7. 
König J, Cui Y, Nies AT, Keppler D. Localization and genomic organization of a new 
hepatocellular organic anion transporting polypeptide. J Biol Chem 2000a;275:23161-8. 
König J, Cui Y, Nies AT, Keppler D. A novel human organic anion transporting polypeptide 
localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver 
Physiol 2000b;278:G156-64. 
König J, Zolk O, Singer K, Hoffmann C, Fromm MF. Double-transfected MDCK cells 
expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and 
transcellular translocation of organic cations. Br J Pharmacol 2011;163:546-55. 
Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T. Expression of CYP3A in the 
human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs 
immediately after birth. Eur J Biochem 1997;247:625-34. 
Laitinen A, Niemi M. Frequencies of single nucleotide polymorphisms of SLCO1A2, 
SLCO1B3 and SLCO2B1 genes in a Finnish population. Basic Clin Pharmacol Toxicol 
2011;108:9-13. 
Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human 
CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002;54:1271-94. 
Lang C, Meier Y, Stieger B, Beuers U, Lang T, Kerb R, Kullak-Ublick GA, Meier PJ, 
Pauli-Magnus C. Mutations and polymorphisms in the bile salt export pump and the 
multidrug resistance protein 3 associated with drug-induced liver injury. 
Pharmacogenet Genomics 2007;17:47-60. 
 106 
Leabman MK, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, 
Taylor T, Clark AG, Herskowitz I, Giacomini KM. Polymorphisms in a human 
kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 
2002;12:395-405. 
Lee W, Glaeser H, Smith LH, Roberts RL, Moeckel GW, Gervasini G, Leake BF, Kim RB. 
Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): 
implications for altered drug disposition and central nervous system drug entry. J Biol 
Chem 2005;280:9610-7. 
Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human 
orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene 
expression and cause drug interactions. J Clin Invest 1998;102:1016-23. 
Lemma GL, Wang Z, Hamman MA, Zaheer NA, Gorski JC, Hall SD. The effect of short- 
and long-term administration of verapamil on the disposition of cytochrome P450 3A 
and P-glycoprotein substrates. Clin Pharmacol Ther 2006;79:218-30. 
Leschziner GD, Andrew T, Pirmohamed M, Johnson MR. ABCB1 genotype and PGP 
expression, function and therapeutic drug response: a critical review and 
recommendations for future research. Pharmacogenomics J 2007;7:154-79. 
Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, 
MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005;204:216-
37. 
Leuthold S, Hagenbuch B, Mohebbi N, Wagner CA, Meier PJ, Stieger B. Mechanisms of 
pH-gradient driven transport mediated by organic anion polypeptide transporters. Am J 
Physiol Cell Physiol 2009;296:C570-82. 
Li L, Lee TK, Meier PJ, Ballatori N. Identification of glutathione as a driving force and 
leukotriene C4 as a substrate for oatp1, the hepatic sinusoidal organic solute transporter. 
J Biol Chem 1998;273:16184-91. 
Li L, Meier PJ, Ballatori N. Oatp2 mediates bidirectional organic solute transport: a role for 
intracellular glutathione. Mol Pharmacol 2000;58:335-40. 
Libersa CC, Brique SA, Motte KB, Caron JF, Guédon-Moreau LM, Humbert L, Vincent 
A, Devos P, Lhermitte MA. Dramatic inhibition of amiodarone metabolism induced by 
grapefruit juice. Br J Clin Pharmacol 2000;49:373-8. 
Lilja JJ, Backman JT, Laitila J, Luurila H, Neuvonen PJ. Itraconazole increases but 
grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin Pharmacol 
Ther 2003;73:192-8. 
Lilja JJ, Juntti-Patinen L, Neuvonen PJ. Orange juice substantially reduces the 
bioavailability of the beta-adrenergic-blocking agent celiprolol. Clin Pharmacol Ther 
2004;75:184-90. 
Lilja JJ, Kivistö KT, Backman JT, Lamberg TS, Neuvonen PJ. Grapefruit juice 
substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther 
1998b;64:655-60. 
Lilja JJ, Kivistö KT, Backman JT, Neuvonen PJ. Effect of grapefruit juice dose on grapefruit 
juice-triazolam interaction: repeated consumption prolongs triazolam half-life. Eur J 
Clin Pharmacol 2000a;56:411-5. 
Lilja JJ, Kivistö KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum 
concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. 
Clin Pharmacol Ther 1998a;64:477-83. 
 107 
Lilja JJ, Kivistö KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of 
atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther 1999;66:118-27. 
Lilja JJ, Kivistö KT, Neuvonen PJ. Duration of effect of grapefruit juice on the 
pharmacokinetics of the CYP3A4 substrate simvastatin. Clin Pharmacol Ther 
2000b;68:384-90. 
Lilja JJ, Laitinen K, Neuvonen PJ. Effects of grapefruit juice on the absorption of 
levothyroxine. Br J Clin Pharmacol 2005a;60:337-41. 
Lilja JJ, Niemi M, Fredrikson H, Neuvonen PJ. Effects of clarithromycin and grapefruit juice 
on the pharmacokinetics of glibenclamide. Br J Clin Pharmacol 2007;63:732-40. 
Lilja JJ, Raaska K, Neuvonen PJ. Effects of grapefruit juice on the pharmacokinetics of 
acebutolol. Br J Clin Pharmacol 2005b;60:659-63. 
Lilja JJ, Raaska K, Neuvonen PJ. Effects of orange juice on the pharmacokinetics of atenolol. 
Eur J Clin Pharmacol 2005c;61:337-40. 
Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. 
Clin Pharmacokinet 1998;35:361-90. 
Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins 
R. SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J 
Med 2008;359:789-99. 
Liu C, Shang YF, Zhang XF, Zhang XG, Wang B, Wu Z, Liu XM, Yu L, Ma F, Lv Y. Co-
administration of grapefruit juice increases bioavailability of tacrolimus in liver 
transplant patients: a prospective study. Eur J Clin Pharmacol 2009;65:881-5. 
Liu W, Liang R, Ramamoorthy S, Fei YJ, Ganapathy ME, Hediger MA, Ganapathy V, 
Leibach FH. Molecular cloning of PEPT 2, a new member of the H+/peptide 
cotransporter family, from human kidney. Biochim Biophys Acta 1995;1235:461-6. 
Loos U, Musch E, Jensen JC, Schwabe HK, Eichelbaum M. Influence of the enzyme 
induction by rifampicin on its presystemic metabolism. Pharmacol Ther 1987;33:201-4. 
Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, 
Guo W, Watkins PB. Grapefruit juice increases felodipine oral availability in humans 
by decreasing intestinal CYP3A protein expression. J Clin Invest 1997;99:2545-53. 
Lundahl J, Regårdh CG, Edgar B, Johnsson G. Relationship between time of intake of 
grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine 
in healthy subjects. Eur J Clin Pharmacol 1995;49:61-7. 
Lundahl J, Regårdh CG, Edgar B, Johnsson G. Effects of grapefruit juice ingestion--
pharmacokinetics and haemodynamics of intravenously and orally administered 
felodipine in healthy men. Eur J Clin Pharmacol 1997;52:139-45. 
Lundahl JU, Regårdh CG, Edgar B, Johnsson G. The interaction effect of grapefruit juice is 
maximal after the first glass. Eur J Clin Pharmacol 1998;54:75-81. 
Ma TK, Kam KK, Yan BP, Lam YY. Renin-angiotensin-aldosterone system blockade for 
cardiovascular diseases: current status. Br J Pharmacol 2010;160:1273-92. 
Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, 
Czerwinski M, Forster J, Ribadeneira MD, Gan LS, LeCluyse EL, Zech K, 
Robertson P, Jr., Koch P, Antonian L, Wagner G, Yu L, Parkinson A. Effects of 
prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured 
human hepatocytes. Drug Metab Dispos 2003;31:421-31. 
 108 
Maeda T, Takahashi K, Ohtsu N, Oguma T, Ohnishi T, Atsumi R, Tamai I. Identification 
of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm 
2007;4:85-94. 
Mager DE, Wyska E, Jusko WJ. Diversity of mechanism-based pharmacodynamic models. 
Drug Metab Dispos 2003;31:510-8. 
Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, 
van De Vijver MJ, Scheper RJ, Schellens JH. Subcellular localization and 
distribution of the breast cancer resistance protein transporter in normal human tissues. 
Cancer Res 2001;61:3458-64. 
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, 
Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, 
Schmieder RE, Struijker Boudier HA, Zanchetti A, Vahanian A, Camm J, De 
Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, 
Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, 
Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm 
LH, Manolis A, Nilsson PM, Redon J, Struijker-Boudier HA, Viigimaa M, 
Adamopoulos S, Bertomeu V, Clement D, Farsang C, Gaita D, Lip G, Mallion JM, 
Manolis AJ, O'Brien E, Ponikowski P, Ruschitzka F, Tamargo J, van Zwieten P, 
Waeber B, Williams B. 2007 Guidelines for the management of arterial hypertension: 
The Task Force for the Management of Arterial Hypertension of the European Society 
of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 
2007;28:1462-536. 
Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova 
R, Clement D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, 
Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, 
Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, 
Schmieder RE, Struijker-Boudier HA, van Zwieten PA, Viigimaa M, Zanchetti A. 
Reappraisal of European guidelines on hypertension management: a European Society 
of Hypertension Task Force document. J Hypertens 2009;27:2121-58. 
Mandery K, Balk B, Bujok K, Schmidt I, Fromm MF, Glaeser H. Inhibition of hepatic 
uptake transporters by flavonoids. Eur J Pharm Sci 2012;46:79-85. 
Mandery K, Bujok K, Schmidt I, Keiser M, Siegmund W, Balk B, König J, Fromm MF, 
Glaeser H. Influence of the flavonoids apigenin, kaempferol and quercetin on the 
function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol 
2010;80:1746-53. 
Martínez C, Blanco G, Ladero JM, Garcia-Martín E, Taxonera C, Gamito FG, Diaz-
Rubio M, Agúndez JA. Genetic predisposition to acute gastrointestinal bleeding after 
NSAIDs use. Br J Pharmacol 2004;141:205-8. 
Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): 
recent advances and clinical relevance. Clin Pharmacol Ther 2004;75:13-33. 
Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, Katsura T, Ogawa O, Inui 
K. Identification and functional characterization of a new human kidney-specific 
H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc 
Nephrol 2006;17:2127-35. 
Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger 
RJ, Fye C, Lakshman R, Gottdiener J, Ramirez EA, Henderson WG. Single-drug 
therapy for hypertension in men. A comparison of six antihypertensive agents with 
placebo. N Engl J Med 1993;328:914-21. 
 109 
Matsushima S, Maeda K, Inoue K, Ohta KY, Yuasa H, Kondo T, Nakayama H, Horita S, 
Kusuhara H, Sugiyama Y. The inhibition of human multidrug and toxin extrusion 1 is 
involved in the drug-drug interaction caused by cimetidine. Drug Metab Dispos 
2009;37:555-9. 
Mayer R, Kartenbeck J, Buchler M, Jedlitschky G, Leier I, Keppler D. Expression of the 
MRP gene-encoded conjugate export pump in liver and its selective absence from the 
canalicular membrane in transport-deficient mutant hepatocytes. J Cell Biol 
1995;131:137-50. 
Meier-Abt F, Mokrab Y, Mizuguchi K. Organic anion transporting polypeptides of the 
OATP/SLCO superfamily: identification of new members in nonmammalian species, 
comparative modeling and a potential transport mode. J Membr Biol 2005;208:213-27. 
Meunier V, Bourrie M, Julian B, Marti E, Guillou F, Berger Y, Fabre G. Expression and 
induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human 
hepatocytes: a 10-year follow-up. Xenobiotica 2000;30:589-607. 
Meyer UA. Overview of enzymes of drug metabolism. J Pharmacokinet Biopharm 
1996;24:449-59. 
Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB. Human 
multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional 
characterization, interaction with OCT2 (SLC22A2), and single nucleotide 
polymorphisms. Am J Physiol Renal Physiol 2010;298:F997-F1005. 
Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, 
Masuda S, Tokui T, Eto N, Abe M, Satoh F, Unno M, Hishinuma T, Inui K, Ito S, 
Goto J, Abe T. Isolation and characterization of a digoxin transporter and its rat 
homologue expressed in the kidney. Proc Natl Acad Sci U S A 2004;101:3569-74. 
Mizuarai S, Aozasa N, Kotani H. Single nucleotide polymorphisms result in impaired 
membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int 
J Cancer 2004;109:238-46. 
Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, Collins JL, 
Kliewer SA. St. John's wort induces hepatic drug metabolism through activation of the 
pregnane X receptor. Proc Natl Acad Sci U S A 2000;97:7500-2. 
Morel F, Beaune PH, Ratanasavanh D, Flinois JP, Yang CS, Guengerich FP, Guillouzo A. 
Expression of cytochrome P-450 enzymes in cultured human hepatocytes. Eur J 
Biochem 1990;191:437-44. 
Morita Y, Kodama K, Shiota S, Mine T, Kataoka A, Mizushima T, Tsuchiya T. NorM, a 
putative multidrug efflux protein, of Vibrio parahaemolyticus and its homolog in 
Escherichia coli. Antimicrob Agents Chemother 1998;42:1778-82. 
Mougey EB, Feng H, Castro M, Irvin CG, Lima JJ. Absorption of montelukast is transporter 
mediated: a common variant of OATP2B1 is associated with reduced plasma 
concentrations and poor response. Pharmacogenet Genomics 2009;19:129-38. 
Mougey EB, Lang JE, Wen X, Lima JJ. Effect of Citrus Juice and SLCO2B1 Genotype on 
the Pharmacokinetics of Montelukast. J Clin Pharmacol 2011;51:751-60. 
Müller F, Fromm MF. Transporter-mediated drug-drug interactions. Pharmacogenomics 
2011;12:1017-37. 
Naito M, Tsuruo T. Competitive inhibition by verapamil of ATP-dependent high affinity 
vincristine binding to the plasma membrane of multidrug-resistant K562 cells without 
calcium ion involvement. Cancer Res 1989;49:1452-5. 
 110 
Nakken KE, Labori KJ, Rodningen OK, Nakken S, Berge KE, Eiklid K, Raeder MG. 
ABCB4 sequence variations in young adults with cholesterol gallstone disease. Liver 
Int 2009;29:743-7. 
NCBI. Database resources of the National Center for Biotechnology Information. Available at 
http://www.ncbi.nlm.nih.gov/gene?term=(slco1b7[gene]) AND (Homo sapiens[orgn]) 
AND alive[prop] NOT newentry[gene]&sort=weight (last accessed 17 August 2012). 
2012. 
Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 
2002;360:1155-62. 
Nebert DW, Vesell ES. Advances in pharmacogenomics and individualized drug therapy: 
exciting challenges that lie ahead. Eur J Pharmacol 2004;500:267-80. 
Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, 
Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. 
P450 superfamily: update on new sequences, gene mapping, accession numbers and 
nomenclature. Pharmacogenetics 1996;6:1-42. 
Neuhofel AL, Wilton JH, Victory JM, Hejmanowsk LG, Amsden GW. Lack of 
bioequivalence of ciprofloxacin when administered with calcium-fortified orange juice: 
a new twist on an old interaction. J Clin Pharmacol 2002;42:461-6. 
Neuvonen PJ. Towards safer and more predictable drug treatment--reflections from studies of 
the First BCPT Prize awardee. Basic Clin Pharmacol Toxicol 2012;110:207-18. 
Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of 
lovastatin and lovastatin acid. Clin Pharmacol Ther 1996;60:54-61. 
Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not pravastatin is very susceptible to 
interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998;63:332-
41. 
Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: 
mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80:565-81. 
Neuvonen PJ, Varhe A, Olkkola KT. The effect of ingestion time interval on the interaction 
between itraconazole and triazolam. Clin Pharmacol Ther 1996;60:326-31. 
Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 
2007;8:787-802. 
Niemi M, Arnold KA, Backman JT, Pasanen MK, Gödtel-Armbrust U, Wojnowski L, 
Zanger UM, Neuvonen PJ, Eichelbaum M, Kivistö KT, Lang T. Association of 
genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 
expression and pravastatin pharmacokinetics. Pharmacogenet Genomics 2006a;16:801-
8. 
Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT. Pharmacokinetic 
interactions with rifampicin : clinical relevance. Clin Pharmacokinet 2003;42:819-50. 
Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivistö KT. Rifampin decreases the 
plasma concentrations and effects of repaglinide. Clin Pharmacol Ther 2000;68:495-
500. 
Niemi M, Backman JT, Neuvonen PJ. Effects of trimethoprim and rifampin on the 
pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clin Pharmacol 
Ther 2004;76:239-49. 
 111 
Niemi M, Kivistö KT, Hofmann U, Schwab M, Eichelbaum M, Fromm MF. Fexofenadine 
pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding 
OATP1B1). Br J Clin Pharmacol 2005;59:602-4. 
Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the 
pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 
2006b;80:356-66. 
Niemi M, Pasanen MK, Neuvonen PJ. Organic Anion Transporting Polypeptide 1B1: a 
Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake. 
Pharmacol Rev 2011;63:157-81. 
Nieminen TH, Hagelberg NM, Saari TI, Neuvonen M, Neuvonen PJ, Laine K, Olkkola 
KT. Grapefruit juice enhances the exposure to oral oxycodone. Basic Clin Pharmacol 
Toxicol 2010;107:782-8. 
Nies AT, Jedlitschky G, König J, Herold-Mende C, Steiner HH, Schmitt HP, Keppler D. 
Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 
(ABCC1-ABCC6), in human brain. Neuroscience 2004;129:349-60. 
Niessen J, Jedlitschky G, Grube M, Bien S, Schwertz H, Ohtsuki S, Kawakami H, Kamiie 
J, Oswald S, Starke K, Strobel U, Siegmund W, Rosskopf D, Greinacher A, 
Terasaki T, Kroemer HK. Human platelets express organic anion-transporting peptide 
2B1, an uptake transporter for atorvastatin. Drug Metab Dispos 2009;37:1129-37. 
Novartis. Tekturna prescribing information. Available at 
http://www.pharma.us.novartis.com/product/pi/pdf/tekturna.pdf (last accessed 30 May 
2012). 2012. 
Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Functional characterization of pH-sensitive 
organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther 
2004;308:438-45. 
Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, Tsuji A, Yokoi T. Genetic 
polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B 
(SLC21A9): allele frequencies in the Japanese population and functional analysis. J 
Pharmacol Exp Ther 2002;302:804-13. 
Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans 
by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. 
Hypertension 2002;39:E1-8. 
Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin 
inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure 
control in patients with hypertension. J Am Coll Cardiol 2007;49:1157-63. 
Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antimycotics, itraconazole 
and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and 
oral midazolam. Anesth Analg 1996;82:511-6. 
Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg JJ, Neuvonen PJ. A 
potentially hazardous interaction between erythromycin and midazolam. Clin 
Pharmacol Ther 1993;53:298-305. 
Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving 
the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 
1994;55:481-5. 
Omura T, Sato R. A new cytochrome in liver microsomes. J Biol Chem 1962;237:1375-6. 
 112 
Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined 
use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind 
trial. Lancet 2007;370:221-9. 
Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y. A human 
transporter protein that mediates the final excretion step for toxic organic cations. Proc 
Natl Acad Sci U S A 2005;102:17923-8. 
Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A. Interaction between grapefruit juice 
and diazepam in humans. Eur J Drug Metab Pharmacokinet 1998;23:55-9. 
Paine MF, Criss AB, Watkins PB. Two major grapefruit juice components differ in time to 
onset of intestinal CYP3A4 inhibition. J Pharmacol Exp Ther 2005;312:1151-60. 
Parker RB, Yates CR, Soberman JE, Laizure SC. Effects of grapefruit juice on intestinal P-
glycoprotein: evaluation using digoxin in humans. Pharmacotherapy 2003;23:979-87. 
Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM. The effects of gender, age, 
ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver 
microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 
2004;199:193-209. 
Partanen J, Jalava KM, Neuvonen PJ. Itraconazole increases serum digoxin concentration. 
Pharmacol Toxicol 1996;79:274-6. 
Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with 
losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-46. 
Pasanen MK, Backman JT, Neuvonen PJ, Niemi M. Frequencies of single nucleotide 
polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 
SLCO1B1 gene in a Finnish population. Eur J Clin Pharmacol 2006a;62:409-15. 
Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 
polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin 
Pharmacol Ther 2007;82:726-33. 
Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly 
affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 
2006b;16:873-9. 
Pastinen T, Ge B, Hudson TJ. Influence of human genome polymorphism on gene expression. 
Hum Mol Genet 2006;15 Spec No 1:R9-16. 
Paulusma CC, Bosma PJ, Zaman GJ, Bakker CT, Otter M, Scheffer GL, Scheper RJ, 
Borst P, Oude Elferink RP. Congenital jaundice in rats with a mutation in a multidrug 
resistance-associated protein gene. Science 1996;271:1126-8. 
Paulusma CC, Kool M, Bosma PJ, Scheffer GL, ter Borg F, Scheper RJ, Tytgat GN, Borst 
P, Baas F, Oude Elferink RP. A mutation in the human canalicular multispecific 
organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 
1997;25:1539-42. 
Peach MJ. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol Rev 
1977;57:313-70. 
Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio H. Inhibition 
and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 
2008;82:667-715. 
Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of rifampin under fasting 
conditions, with food, and with antacids. Chest 1999;115:12-8. 
 113 
Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, 
Breckenridge AM. Adverse drug reactions as cause of admission to hospital: 
prospective analysis of 18 820 patients. BMJ 2004;329:15-9. 
Pizzagalli F, Varga Z, Huber RD, Folkers G, Meier PJ, St-Pierre MV. Identification of 
steroid sulfate transport processes in the human mammary gland. J Clin Endocrinol 
Metab 2003;88:3902-12. 
Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen P. Torsades de pointes after 
terfenadine-itraconazole interaction. BMJ 1993;306:186. 
Pomari E, Nardi A, Fiore C, Celeghin A, Colombo L, Dalla Valle L. Transcriptional control 
of human organic anion transporting polypeptide 2B1 gene. J Steroid Biochem Mol Biol 
2009;115:146-52. 
Raaska K, Raitasuo V, Arstila M, Neuvonen PJ. Bacterial pneumonia can increase serum 
concentration of clozapine. Eur J Clin Pharmacol 2002;58:321-2. 
Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampin is a selective, pleiotropic 
inducer of drug metabolism genes in human hepatocytes: studies with cDNA and 
oligonucleotide expression arrays. J Pharmacol Exp Ther 2001;299:849-57. 
Rameis H. On the interaction between phenytoin and digoxin. Eur J Clin Pharmacol 
1985;29:49-53. 
Rao US, Scarborough GA. Direct demonstration of high affinity interactions of 
immunosuppressant drugs with the drug binding site of the human P-glycoprotein. Mol 
Pharmacol 1994;45:773-6. 
Raucy JL, Mueller L, Duan K, Allen SW, Strom S, Lasker JM. Expression and induction of 
CYP2C P450 enzymes in primary cultures of human hepatocytes. J Pharmacol Exp 
Ther 2002;302:475-82. 
Rebello S, Compain S, Feng A, Hariry S, Dieterich HA, Jarugula V. Effect of cyclosporine 
on the pharmacokinetics of aliskiren in healthy subjects. J Clin Pharmacol 
2011a;51:1549-60. 
Rebello S, Leon S, Hariry S, Dahlke M, Jarugula V. Effect of Verapamil on the 
Pharmacokinetics of Aliskiren in Healthy Participants. J Clin Pharmacol 2011b;51:218-
28. 
Rebello S, Zhao S, Hariry S, Dahlke M, Alexander N, Vapurcuyan A, Hanna I, Jarugula 
V. Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit 
juice on aliskiren pharmacokinetics in healthy subjects. Eur J Clin Pharmacol 
2011c;68:697-708. 
Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P. 
The human multidrug resistance protein MRP4 functions as a prostaglandin efflux 
transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci 
U S A 2003;100:9244-9. 
Remmel RP, Dombrovskis D, Canafax DM. Assay of itraconazole in leukemic patient plasma 
by reversed-phase small-bore liquid chromatography. J Chromatogr 1988;432:388-94. 
Remmer H. The role of the liver in drug metabolism. Am J Med 1970;49:617-29. 
Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, Keppler D. Cotransport of reduced 
glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte 
membrane. Hepatology 2003;38:374-84. 
 114 
Rizwan AN, Burckhardt G. Organic anion transporters of the SLC22 family: 
biopharmaceutical, physiological, and pathological roles. Pharm Res 2007;24:450-70. 
Rouseff RL, Ting SV. Quantitation of polymethoxylated flavones in orange juice by high-
performance liquid chromatography. J Chromatogr 1979;176:75-87. 
Rowland M, Tozer TN. Clinical pharmacokinetics and pharmacodynamics: concepts and 
applications. Baltimore: Lippincott Williams & Wilkins. 2011. 
Ruggenenti P, Cravedi P, Remuzzi G. The RAAS in the pathogenesis and treatment of 
diabetic nephropathy. Nat Rev Nephrol 2010;6:319-30. 
Russell T, Stoltz M, Weir S. Pharmacokinetics, pharmacodynamics, and tolerance of single- 
and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Clin 
Pharmacol Ther 1998;64:612-21. 
Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT. Effect of voriconazole 
on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. 
Clin Pharmacol Ther 2006;79:362-70. 
Sadée W, Dai Z. Pharmacogenetics/genomics and personalized medicine. Hum Mol Genet 
2005;14 Spec No. 2:R207-14. 
Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, Morita Y, 
Tamura T, Aoyama N, Hirai M, Kasuga M, Okumura K. MDR1 genotype-related 
pharmacokinetics of digoxin after single oral administration in healthy Japanese 
subjects. Pharm Res 2001;18:1400-4. 
Sanofi-Aventis. Allegra Prescribing Information. Available at http://products.sanofi-
aventis.us/allegra/allegra.html (last accessed 22 December 2010). 2007. 
Satlin LM, Amin V, Wolkoff AW. Organic anion transporting polypeptide mediates organic 
anion/HCO3- exchange. J Biol Chem 1997;272:26340-5. 
Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, Sawada Y. 
Citrus juices inhibit the function of human organic anion-transporting polypeptide 
OATP-B. Drug Metab Dispos 2005;33:518-23. 
Schaub TP, Kartenbeck J, König J, Spring H, Dörsam J, Staehler G, Störkel S, Thon WF, 
Keppler D. Expression of the MRP2 gene-encoded conjugate export pump in human 
kidney proximal tubules and in renal cell carcinoma. J Am Soc Nephrol 1999;10:1159-
69. 
Scheffer GL, Kool M, Heijn M, de Haas M, Pijnenborg AC, Wijnholds J, van Helvoort A, 
de Jong MC, Hooijberg JH, Mol CA, van der Linden M, de Vree JM, van der Valk 
P, Elferink RP, Borst P, Scheper RJ. Specific detection of multidrug resistance 
proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of 
monoclonal antibodies. Cancer Res 2000;60:5269-77. 
Schieber A, Keller P, Carle R. Determination of phenolic acids and flavonoids of apple and 
pear by high-performance liquid chromatography. J Chromatogr A 2001;910:265-73. 
Schiffer R, Neis M, Höller D, Rodríguez F, Geier A, Gartung C, Lammert F, Dreuw A, 
Zwadlo-Klarwasser G, Merk H, Jugert F, Baron JM. Active influx transport is 
mediated by members of the organic anion transporting polypeptide family in human 
epidermal keratinocytes. J Invest Dermatol 2003;120:285-91. 
Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette 
(ABC) family: an overview. Adv Drug Deliv Rev 2003;55:3-29. 
 115 
Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, 
Voordouw AC, Spits H, van Tellingen O, Zijlmans JM, Fibbe WE, Borst P. Normal 
viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-
glycoproteins. Proc Natl Acad Sci U S A 1997;94:4028-33. 
Schinkel AH, Roelofs EM, Borst P. Characterization of the human MDR3 P-glycoprotein and 
its recognition by P-glycoprotein-specific monoclonal antibodies. Cancer Res 
1991;51:2628-35. 
Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Smith B, Weissbach N, Maboudian 
M, Botha J, van Ingen H. Long-term antihypertensive efficacy and safety of the oral 
direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial 
with hydrochlorothiazide. Circulation 2009;119:417-25. 
Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, Rahman 
A, Thummel KE, Fisher JM, Hollenberg PF, Watkins PB. Mechanisms of enhanced 
oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte 
CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug 
Metab Dispos 1997;25:1228-33. 
Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, 
Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Boländer J, Strick R, 
Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab 
M, Brauch H. Association between CYP2D6 polymorphisms and outcomes among 
women with early stage breast cancer treated with tamoxifen. JAMA 2009;302:1429-36. 
Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and 
cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma 
cells. Mol Pharmacol 1996;49:311-8. 
Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A, Fridland 
A. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral 
drugs. Nat Med 1999;5:1048-51. 
Schwarz UI, Seemann D, Oertel R, Miehlke S, Kuhlisch E, Fromm MF, Kim RB, Bailey 
DG, Kirch W. Grapefruit juice ingestion significantly reduces talinolol bioavailability. 
Clin Pharmacol Ther 2005;77:291-301. 
Seki S, Kobayashi M, Itagaki S, Hirano T, Iseki K. Contribution of organic anion 
transporting polypeptide OATP2B1 to amiodarone accumulation in lung epithelial cells. 
Biochim Biophys Acta 2009;1788:911-7. 
Sendra JM, Navarro JL, Izquierdo L. C18 solid-phase isolation and high-performance liquid 
chromatography/ultraviolet diode array determination of fully methoxylated flavones in 
citrus juices. J Chromatogr Sci 1988;26:443-8. 
Senior AE, Gadsby DC. ATP hydrolysis cycles and mechanism in P-glycoprotein and CFTR. 
Semin Cancer Biol 1997;8:143-50. 
Sensi P. History of the development of rifampin. Rev Infect Dis 1983;5 Suppl 3:S402-6. 
Shimizu M, Fuse K, Okudaira K, Nishigaki R, Maeda K, Kusuhara H, Sugiyama Y. 
Contribution of OATP (organic anion-transporting polypeptide) family transporters to 
the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 2005;33:1477-81. 
Shimizu M, Uno T, Sugawara K, Tateishi T. Effects of itraconazole and diltiazem on the 
pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol 
2006;61:538-44. 
 116 
Shirasaka Y, Kuraoka E, Spahn-Langguth H, Nakanishi T, Langguth P, Tamai I. Species 
difference in the effect of grapefruit juice on intestinal absorption of talinolol between 
human and rat. J Pharmacol Exp Ther 2010;332:181-9. 
Shoaf SE, Mallikaarjun S, Bricmont P. Effect of grapefruit juice on the pharmacokinetics of 
tolvaptan, a non-peptide arginine vasopressin antagonist, in healthy subjects. Eur J Clin 
Pharmacol 2012;68:207-11. 
Shon JH, Yoon YR, Hong WS, Nguyen PM, Lee SS, Choi YG, Cha IJ, Shin JG. Effect of 
itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in 
relation to the MDR1 genetic polymorphism. Clin Pharmacol Ther 2005;78:191-201. 
Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, Sheardown SA, Yue L, Burchard 
EG, Brett CM, Giacomini KM. Effect of genetic variation in the organic cation 
transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 
2008;83:273-80. 
Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, 
Lo JC, Burchard EG, Brett CM, Giacomini KM. Effect of genetic variation in the 
organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007;117:1422-
31. 
Shugarts S, Benet LZ. The role of transporters in the pharmacokinetics of orally administered 
drugs. Pharm Res 2009;26:2039-54. 
Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg 
M. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant 
for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol 
Ther 2006;79:103-13. 
Skeggs LT, Jr., Kahn JR, Lentz K, Shumway NP. The preparation, purification, and amino 
acid sequence of a polypeptide renin substrate. J Exp Med 1957;106:439-53. 
Smith AJ, van Helvoort A, van Meer G, Szabó K, Welker E, Szakács G, Váradi A, Sarkadi 
B, Borst P. MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several 
cytotoxic drugs and directly interacts with drugs as judged by interference with 
nucleotide trapping. J Biol Chem 2000;275:23530-9. 
Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A. Identification of OATP1B3 as a 
high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 2005;4:815-8. 
Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. Reduction of metformin renal tubular 
secretion by cimetidine in man. Br J Clin Pharmacol 1987;23:545-51. 
Song IS, Shin HJ, Shim EJ, Jung IS, Kim WY, Shon JH, Shin JG. Genetic variants of the 
organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol 
Ther 2008;84:559-62. 
Sonoda J, Xie W, Rosenfeld JM, Barwick JL, Guzelian PS, Evans RM. Regulation of a 
xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR). Proc Natl Acad 
Sci U S A 2002;99:13801-6. 
Soons PA, Vogels BA, Roosemalen MC, Schoemaker HC, Uchida E, Edgar B, Lundahl J, 
Cohen AF, Breimer DD. Grapefruit juice and cimetidine inhibit stereoselective 
metabolism of nitrendipine in humans. Clin Pharmacol Ther 1991;50:394-403. 
Spahn-Langguth H, Baktir G, Radschuweit A, Okyar A, Terhaag B, Ader P, Hanafy A, 
Langguth P. P-glycoprotein transporters and the gastrointestinal tract: evaluation of the 
potential in vivo relevance of in vitro data employing talinolol as model compound. Int 
J Clin Pharmacol Ther 1998;36:16-24. 
 117 
Sparreboom A, Loos WJ, Burger H, Sissung TM, Verweij J, Figg WD, Nooter K, 
Gelderblom H. Effect of ABCG2 genotype on the oral bioavailability of topotecan. 
Cancer Biol Ther 2005;4:650-8. 
St-Pierre MV, Hagenbuch B, Ugele B, Meier PJ, Stallmach T. Characterization of an 
organic anion-transporting polypeptide (OATP-B) in human placenta. J Clin Endocrinol 
Metab 2002;87:1856-63. 
St-Pierre MV, Serrano MA, Macias RI, Dubs U, Hoechli M, Lauper U, Meier PJ, Marin 
JJ. Expression of members of the multidrug resistance protein family in human term 
placenta. Am J Physiol Regul Integr Comp Physiol 2000;279:R1495-503. 
Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential 
hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003;42:1137-43. 
Steckelbroeck S, Nassen A, Ugele B, Ludwig M, Watzka M, Reissinger A, Clusmann H, 
Lütjohann D, Siekmann L, Klingmüller D, Hans VH. Steroid sulfatase (STS) 
expression in the human temporal lobe: enzyme activity, mRNA expression and 
immunohistochemistry study. J Neurochem 2004;89:403-17. 
Stieger B. Role of the bile salt export pump, BSEP, in acquired forms of cholestasis. Drug 
Metab Rev 2010;42:437-45. 
Sueyoshi T, Kawamoto T, Zelko I, Honkakoski P, Negishi M. The repressed nuclear receptor 
CAR responds to phenobarbital in activating the human CYP2B6 gene. J Biol Chem 
1999;274:6043-6. 
Takanaga H, Ohnishi A, Matsuo H, Sawada Y. Inhibition of vinblastine efflux mediated by 
P-glycoprotein by grapefruit juice components in caco-2 cells. Biol Pharm Bull 
1998;21:1062-6. 
Takanaga H, Ohnishi A, Murakami H, Matsuo H, Higuchi S, Urae A, Irie S, Furuie H, 
Matsukuma K, Kimura M, Kawano K, Orii Y, Tanaka T, Sawada Y. Relationship 
between time after intake of grapefruit juice and the effect on pharmacokinetics and 
pharmacodynamics of nisoldipine in healthy subjects. Clin Pharmacol Ther 
2000;67:201-14. 
Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, 
Endou H. Characterization of methotrexate transport and its drug interactions with 
human organic anion transporters. J Pharmacol Exp Ther 2002;302:666-71. 
Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, 
Ranganath V, Kumanduri V, McLaren W, Holm L, Lindh J, Rane A, Wadelius M, 
Deloukas P. A genome-wide association study confirms VKORC1, CYP2C9, and 
CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 
2009;5:e1000433. 
Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, Tsuji A. Molecular identification and 
characterization of novel members of the human organic anion transporter (OATP) 
family. Biochem Biophys Res Commun 2000;273:251-60. 
Tanaka E. In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin 
Pharm Ther 1998;23:247-55. 
Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O, Inui K. Substrate specificity of 
MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation 
antiporters. Biochem Pharmacol 2007;74:359-71. 
 118 
Templeton IE, Thummel KE, Kharasch ED, Kunze KL, Hoffer C, Nelson WL, 
Isoherranen N. Contribution of itraconazole metabolites to inhibition of CYP3A4 in 
vivo. Clin Pharmacol Ther 2008;83:77-85. 
Terada T, Inui K. Physiological and pharmacokinetic roles of H+/organic cation antiporters 
(MATE/SLC47A). Biochem Pharmacol 2008;75:1689-96. 
Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular 
localization of the multidrug-resistance gene product P-glycoprotein in normal human 
tissues. Proc Natl Acad Sci U S A 1987;84:7735-8. 
Tigerstedt R, Bergman P. Niere und Kreislauf. Skand Arch Physiol 1898;8:223-71. 
Tomás-Barberán FA, Clifford MN. Flavanones, chalcones and dihydrochalcones - nature, 
occurrence and dietary burden. J Sci Food Agric 2000;80:1073-1080. 
Tsujii H, König J, Rost D, Stöckel B, Leuschner U, Keppler D. Exon-intron organization of 
the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin-Johnson 
syndrome. Gastroenterology 1999;117:653-60. 
Tucker RM, Denning DW, Hanson LH, Rinaldi MG, Graybill JR, Sharkey PK, 
Pappagianis D, Stevens DA. Interaction of azoles with rifampin, phenytoin, and 
carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992;14:165-74. 
Turnidge J, Grayson ML. Optimum treatment of staphylococcal infections. Drugs 
1993;45:353-66. 
Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D, Sabolic I, Koepsell 
H, Brockmöller J. The effects of genetic polymorphisms in the organic cation 
transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin 
Pharmacol Ther 2009;86:299-306. 
Uchiumi T, Hinoshita E, Haga S, Nakamura T, Tanaka T, Toh S, Furukawa M, Kawabe 
T, Wada M, Kagotani K, Okumura K, Kohno K, Akiyama S, Kuwano M. Isolation 
of a novel human canalicular multispecific organic anion transporter, cMOAT2/MRP3, 
and its expression in cisplatin-resistant cancer cells with decreased ATP-dependent drug 
transport. Biochem Biophys Res Commun 1998;252:103-10. 
Uno T, Ohkubo T, Sugawara K, Higashiyama A, Motomura S, Ishizaki T. Effects of 
grapefruit juice on the stereoselective disposition of nicardipine in humans: evidence for 
dominant presystemic elimination at the gut site. Eur J Clin Pharmacol 2000;56:643-9. 
Urakami Y, Okuda M, Masuda S, Saito H, Inui KI. Functional characteristics and membrane 
localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating 
tubular secretion of cationic drugs. J Pharmacol Exp Ther 1998;287:800-5. 
Urquhart BL, Ware JA, Tirona RG, Ho RH, Leake BF, Schwarz UI, Zaher H, Palandra J, 
Gregor JC, Dresser GK, Kim RB. Breast cancer resistance protein (ABCG2) and drug 
disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. 
Pharmacogenet Genomics 2008;18:439-48. 
Uwai Y, Ida H, Tsuji Y, Katsura T, Inui K. Renal transport of adefovir, cidofovir, and 
tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res 
2007;24:811-5. 
Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of 
cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in 
cancer chemotherapy. Mol Carcinog 1995;13:129-34. 
 119 
Vaidyanathan S, Bartlett M, Dieterich HA, Yeh CM, Antunes A, Howard D, Dole WP. 
Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and 
extended-release isosorbide-5-mononitrate in healthy subjects. Cardiovasc Ther 
2008a;26:238-46. 
Vaidyanathan S, Bigler H, Yeh C, Bizot MN, Dieterich HA, Howard D, Dole WP. 
Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination 
with irbesartan in renal impairment. Clin Pharmacokinet 2007a;46:661-75. 
Vaidyanathan S, Camenisch G, Schuetz H, Reynolds C, Yeh CM, Bizot MN, Dieterich HA, 
Howard D, Dole WP. Pharmacokinetics of the oral direct renin inhibitor aliskiren in 
combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of 
P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol 2008b;48:1323-38. 
Vaidyanathan S, Jarugula V, Dieterich HA, Howard D, Dole WP. Clinical pharmacokinetics 
and pharmacodynamics of aliskiren. Clin Pharmacokinet 2008c;47:515-31. 
Vaidyanathan S, Jermany J, Yeh C, Bizot MN, Camisasca R. Aliskiren, a novel orally 
effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in 
Japanese and Caucasian subjects. Br J Clin Pharmacol 2006a;62:690-8. 
Vaidyanathan S, Maboudian M, Warren V, Yeh CM, Dieterich HA, Howard D, Dole WP. 
A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with 
metformin, pioglitazone and fenofibrate in healthy subjects. Curr Med Res Opin 
2008d;24:2313-26. 
Vaidyanathan S, Reynolds C, Yeh CM, Bizot MN, Dieterich HA, Howard D, Dole WP. 
Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor 
aliskiren in elderly healthy subjects. J Clin Pharmacol 2007b;47:453-60. 
Vaidyanathan S, Valencia J, Kemp C, Zhao C, Yeh CM, Bizot MN, Denouel J, Dieterich 
HA, Dole WP. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin 
inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, 
valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin 
Pract 2006b;60:1343-56. 
Waldmeier F, Glaenzel U, Wirz B, Oberer L, Schmid D, Seiberling M, Valencia J, Riviere 
GJ, End P, Vaidyanathan S. Absorption, distribution, metabolism, and elimination of 
the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos 
2007;35:1418-28. 
Walle T. Absorption and metabolism of flavonoids. Free Radic Biol Med 2004;36:829-37. 
Walle T, Browning AM, Steed LL, Reed SG, Walle UK. Flavonoid glucosides are 
hydrolyzed and thus activated in the oral cavity in humans. J Nutr 2005;135:48-52. 
van Aubel RA, Smeets PH, Peters JG, Bindels RJ, Russel FG. The MRP4/ABCC4 gene 
encodes a novel apical organic anion transporter in human kidney proximal tubules: 
putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 2002;13:595-
603. 
Van Cutsem J, Van Gerven F, Van de Ven MA, Borgers M, Janssen PA. Itraconazole, a 
new triazole that is orally active in aspergillosis. Antimicrob Agents Chemother 
1984;26:527-34. 
Van der Bliek AM, Baas F, Ten Houte de Lange T, Kooiman PM, Van der Velde-Koerts 
T, Borst P. The human mdr3 gene encodes a novel P-glycoprotein homologue and 
gives rise to alternatively spliced mRNAs in liver. EMBO J 1987;6:3325-31. 
 120 
van Helvoort A, Smith AJ, Sprong H, Fritzsche I, Schinkel AH, Borst P, van Meer G. 
MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-
glycoprotein specifically translocates phosphatidylcholine. Cell 1996;87:507-17. 
Van Peer A, Woestenborghs R, Heykants J, Gasparini R, Gauwenbergh G. The effects of 
food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J 
Clin Pharmacol 1989;36:423-6. 
Vanamala J, Reddivari L, Yoo KS, Pike LM, Patil BS. Variation in the content of bioactive 
flavonoids in different brands of orange and grapefruit juices. J Food Comp Anal 
2006;19:157-166. 
Wang D, Johnson AD, Papp AC, Kroetz DL, Sadée W. Multidrug resistance polypeptide 1 
(MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 
2005;15:693-704. 
Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW. Interaction of common azole 
antifungals with P glycoprotein. Antimicrob Agents Chemother 2002;46:160-5. 
Wang PP, Beaune P, Kaminsky LS, Dannan GA, Kadlubar FF, Larrey D, Guengerich FP. 
Purification and characterization of six cytochrome P-450 isozymes from human liver 
microsomes. Biochemistry 1983;22:5375-83. 
Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St John's 
wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol 
Ther 2001;70:317-26. 
Wang ZJ, Yin OQ, Tomlinson B, Chow MS. OCT2 polymorphisms and in-vivo renal 
functional consequence: studies with metformin and cimetidine. Pharmacogenet 
Genomics 2008;18:637-45. 
Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients 
receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 
1994;56:601-7. 
Varis T, Kaukonen KM, Kivistö KT, Neuvonen PJ. Plasma concentrations and effects of oral 
methylprednisolone are considerably increased by itraconazole. Clin Pharmacol Ther 
1998;64:363-8. 
Varis T, Kivistö KT, Neuvonen PJ. Grapefruit juice can increase the plasma concentrations of 
oral methylprednisolone. Eur J Clin Pharmacol 2000;56:489-93. 
Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug 
Deliv Rev 1997;27:161-170. 
Watkins PB, Wrighton SA, Maurel P, Schuetz EG, Mendez-Picon G, Parker GA, Guzelian 
PS. Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl 
Acad Sci U S A 1985;82:6310-4. 
Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV 
and rifampicin with organic anion uptake systems of human liver. Hepatology 
2002;36:164-72. 
Waxman DJ. P450 gene induction by structurally diverse xenochemicals: central role of 
nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys 1999;369:11-23. 
Weir MR, Bush C, Anderson DR, Zhang J, Keefe D, Satlin A. Antihypertensive efficacy, 
safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with 
hypertension: a pooled analysis. J Am Soc Hypertens 2007;1:264-77. 
 121 
Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, Haefeli WE. Inhibition of 
MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and 
non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos 2007;35:340-4. 
Vella S, Floridia M. Saquinavir. Clinical pharmacology and efficacy. Clin Pharmacokinet 
1998;34:189-201. 
Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on 
oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000;38:111-80. 
Veronese ML, Gillen LP, Burke JP, Dorval EP, Hauck WW, Pequignot E, Waldman SA, 
Greenberg HE. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in 
vivo by grapefruit juice. J Clin Pharmacol 2003;43:831-9. 
Verstuyft C, Schwab M, Schaeffeler E, Kerb R, Brinkmann U, Jaillon P, Funck-Brentano 
C, Becquemont L. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur 
J Clin Pharmacol 2003;58:809-12. 
Westlind A, Malmebo S, Johansson I, Otter C, Andersson TB, Ingelman-Sundberg M, 
Oscarson M. Cloning and tissue distribution of a novel human cytochrome p450 of the 
CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun 2001;281:1349-55. 
Wetterich U, Spahn-Langguth H, Mutschler E, Terhaag B, Rösch W, Langguth P. 
Evidence for intestinal secretion as an additional clearance pathway of talinolol 
enantiomers: concentration- and dose-dependent absorption in vitro and in vivo. Pharm 
Res 1996;13:514-22. 
White DL, Dang P, Engler J, Frede A, Zrim S, Osborn M, Saunders VA, Manley PW, 
Hughes TP. Functional activity of the OCT-1 protein is predictive of long-term 
outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. 
J Clin Oncol 2010;28:2761-7. 
White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S, Zannettino A, Lynch K, 
Manley PW, Hughes T. Most CML patients who have a suboptimal response to 
imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative 
impact of low OCT-1 activity. Blood 2007;110:4064-72. 
White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC, Quinn SR, 
Manley PW, Hughes TP. OCT-1-mediated influx is a key determinant of the 
intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is 
the cause of low in vitro sensitivity to imatinib. Blood 2006;108:697-704. 
Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J 
Med 2005;352:2211-21. 
Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, Vonrhein C, Tickle 
IJ, Jhoti H. Crystal structures of human cytochrome P450 3A4 bound to metyrapone 
and progesterone. Science 2004;305:683-6. 
von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Wright CE, Shader RI. Inhibition 
of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin 
reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. J 
Clin Psychopharmacol 1996a;16:104-12. 
von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, Shader 
RI. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by 
fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 
1996b;36:783-91. 
 122 
Wood JM, Maibaum J, Rahuel J, Grütter MG, Cohen NC, Rasetti V, Rüger H, Göschke 
R, Stutz S, Fuhrer W, Schilling W, Rigollier P, Yamaguchi Y, Cumin F, Baum HP, 
Schnell CR, Herold P, Mah R, Jensen C, O'Brien E, Stanton A, Bedigian MP. 
Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem 
Biophys Res Commun 2003;308:698-705. 
Wrighton SA, Schuetz EG, Thummel KE, Shen DD, Korzekwa KR, Watkins PB. The 
human CYP3A subfamily: practical considerations. Drug Metab Rev 2000;32:339-61. 
Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug 
metabolism. Crit Rev Toxicol 1992;22:1-21. 
Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM. Postmarketing 
reports of QT prolongation and ventricular arrhythmia in association with cisapride and 
Food and Drug Administration regulatory actions. Am J Gastroenterol 2001;96:1698-
703. 
Xia CQ, Liu N, Miwa GT, Gan LS. Interactions of cyclosporin a with breast cancer resistance 
protein. Drug Metab Dispos 2007;35:576-82. 
Yamakawa Y, Hamada A, Shuto T, Yuki M, Uchida T, Kai H, Kawaguchi T, Saito H. 
Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in 
patients with chronic myeloid leukemia. Clin Pharmacol Ther 2011;90:157-63. 
Yamasaki Y, Ieiri I, Kusuhara H, Sasaki T, Kimura M, Tabuchi H, Ando Y, Irie S, Ware 
J, Nakai Y, Higuchi S, Sugiyama Y. Pharmacogenetic characterization of 
sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in 
humans. Clin Pharmacol Ther 2008;84:95-103. 
Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, Johnson EF. The structure of 
human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-
A resolution. J Biol Chem 2004;279:38091-4. 
Yee GC, Stanley DL, Pessa LJ, Dalla Costa T, Beltz SE, Ruiz J, Lowenthal DT. Effect of 
grapefruit juice on blood cyclosporin concentration. Lancet 1995;345:955-6. 
Yin OQ, Gallagher N, Li A, Zhou W, Harrell R, Schran H. Effect of grapefruit juice on the 
pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol 2010;50:188-
94. 
Young JF, Nielsen SE, Haraldsdóttir J, Daneshvar B, Lauridsen ST, Knuthsen P, Crozier 
A, Sandström B, Dragsted LO. Effect of fruit juice intake on urinary quercetin 
excretion and biomarkers of antioxidative status. Am J Clin Nutr 1999;69:87-94. 
Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of 
human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 
2008;392:1093-108. 
Zhao P, Ragueneau-Majlessi I, Zhang L, Strong JM, Reynolds KS, Levy RH, Thummel 
KE, Huang SM. Quantitative evaluation of pharmacokinetic inhibition of CYP3A 
substrates by ketoconazole: a simulation study. J Clin Pharmacol 2009;49:351-9. 
Ziegler TR, Fernández-Estívariz C, Gu LH, Bazargan N, Umeakunne K, Wallace TM, 
Diaz EE, Rosado KE, Pascal RR, Galloway JR, Wilcox JN, Leader LM. 
Distribution of the H+/peptide transporter PepT1 in human intestine: up-regulated 
expression in the colonic mucosa of patients with short-bowel syndrome. Am J Clin 
Nutr 2002;75:922-30. 
Zolk O, Fromm MF. Transporter-mediated drug uptake and efflux: important determinants of 
adverse drug reactions. Clin Pharmacol Ther 2011;89:798-805. 
 123 
Zolk O, Solbach TF, König J, Fromm MF. Structural determinants of inhibitor interaction 
with the human organic cation transporter OCT2 (SLC22A2). Naunyn Schmiedebergs 
Arch Pharmacol 2009;379:337-48. 
 
 
